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Abstract
Despite the amazing biological diversity exhibited by viruses, their very existence relies
upon their ability to overcome a set of common barriers. The nature of these barriers
reflects the nature of viruses themselves. During their extracellular phase, viruses are
metabolically inert obligate parasites. Upon encountering a host cell, productive infection
necessitates that the virus successfully enter the cell, regulate the expression of its genes,
and after assembling new progeny particles, egress such that the cycle of infection can
continue. These three basic processes are not only attractive candidates for therapeutic
intervention, but also reveal much about virus biology in the most basic sense. That is
why these processes are the focus of the studies described herein. We have identified
vimentin, an intermediate filament protein expressed primarily in cells of mesenchymal
origin, as a cellular factor required for the efficient onset of human cytomegalovirus
(CMV) infection in fibroblasts. We observed that an endotheliotropic (EC-tropic) strain
of CMV relies more heavily on vimentin than the fibroblast-adapted strain, possibly
reflecting different modes of entry utilized by these two strains. We have also performed
the first functional study of the 55R E1A protein encoded by human adenovirus (HAdV).
This protein was expressed at late times post-infection and was able to both transactivate
expression of viral genes, and promote productive replication of HAdV in the absence of
all other E1A isoforms. Finally, our focus returns to CMV where we describe a novel
protein that we have dubbed ' nuclear rim-associated cytomegaloviral protein'
(RASCAL). RASCAL is expressed with early-late kinetics and localizes to the nuclear
rim, in deep intranuclear invaginations, and in unusual lamin B-positive vesicular
structures at late times post-infection. RASCAL could be immunoprecipitated with
pUL50, a member of the CMV nuclear egress complex (NEC) and pUL50 was sufficient
to recruit RASCAL to the nuclear rim. These studies have illuminated novel processes
through which two important human viruses enter cells, regulate viral gene expression
and ultimately egress. Considered together, they have also expanded our understanding of
three central aspects of virus biology upon which further studies can build.
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Chapter 1 INTRODUCTION
1.1 Preface
"The aim of science is to seek the simplest explanation of complex facts. We are apt to
fall into the error of thinking that the facts are simple because simplicity is the goal of our
quest. The guiding motto in the life of every natural philosopher should be "Seek
simplicity and distrust it.""-Alfred North Whitehead (1861-1947) English Mathematician
and Philosopher-from Concepts of Nature
The above quote by Alfred North Whitehead should not only serve as an important
reminder to all those seeking to unravel nature's complexities, but should resonate with
particular strength amongst virologists. At a glance, the focus of our studies would seem
exceedingly simple: biological particles composed of small strands of nucleic acids with
limited coding potential encased within a proteinaceous shell, some of which are
surrounded by lipid envelopes, others which are not. In isolation, these particles are
metabolically inert - unable to perform even the most basic functions associated with life,
including self-replication. However, in the context of a host cell, an organism or indeed,
an entire ecosystem, these seemingly simple particles perform a dazzlingly diverse array
of functions, many of which have shaped, and continue to shape every aspect of life on
this planet.
Herein, the author shall focus his attention on three essential processes common
amongst all viruses: entry, gene regulation and egress. The first and last processes were
investigated in the context of human cytomegalovirus infection, whereas gene regulation
was studied in the context of human adenovirus infection. In each case, the author sought
to arrive at the simplest explanation which rectifies a series of complex observations. It is
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the sincere hope of the author that during the course of these studies, areas that were
previously poorly understood have become illuminated, and that once completed, we will
find many more questions to ask, and perhaps even arrive at a few answers.

1.2 Human Cytomegalovirus
1.2.1

General Characteristics

CMV, also known as Human Herpesvirus 5 (HHV-5) belongs to the family
herpesviridae, and is a member of the betaherpesvirus subfamily. These viruses exhibit
strict species specificity and productively infect many differentiated cell types, including
fibroblasts, endothelial cells (EC), epithelial cells, macrophages and dendritic cells (DC)
(48, 67, 88, 129, 134, 199, 228). In fact, it is easier to mention the few cell types that do
not seem to support productive CMV infection; these include lymphocytes and
polymorphonuclear leukocytes (80, 200-201). CMV has been shown to use many
different entry receptors (98) and permissiveness to infection seems to be determined at a
post-penetration step (199, 202). Serial passaging of clinical isolates on human foreskin
fibroblasts (HF) has resulted in the accumulation of mutations which improves growth of
these strains on HF, while concomitantly decreasing their tropism for other cell types,
such as EC and DC (31, 50, 135, 142-143). These strains are now called 'laboratoryadapted,' and many were intially passaged on HF with the hope that they would become
attenuated and could then be used for the generation of a vaccine (73). Unfortunately, this
strategy was largely unsuccessful. However, new vaccine strategies have been developed
over the past several years and are currently the focus of active investigation (191).
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Infection by CMV is ubiquitious in the adult population, though frequency of infection is
higher in less-developed countries. Primary infection usually occurs early in life and is
especially prevalent in childcare settings. In immunocompetent individuals, primary
infection is generally asymptomatic. However, severe disease often develops during
reactivation of CMV in immunocompromised individuals, especially transplant recipients
undergoing immunosuppressive drug regimes. This generally occurs because like other
herpesviruses, CMV is able to establish latency within the host following primary
infection, and periodically reactivates throughout the rest of the host's life. In addition,
CMV is somewhat unique among herpesviruses in that transplacental transmission occurs
naturally. This type of transmission is much more common in women who experience
primary infection during pregnancy, as opposed to those who experience a reactivation
from latency (62, 123, 136).

1.2.2

Virion Structure

Like all herpesviruses, the CMV virion is composed of a double-stranded DNA genome
enclosed within a proteinaceous, icosohedral capsid. The capsid itself is surrounded by
another, less structured proteinaceous layer called the tegument (or matrix). The
tegument consists of approximately 30 virus-encoded proteins, most of which are
phosphorylated, as well as some other cellular proteins and various RNAs. While many
proteins are found in the tegument, the most abundant are pp65 (encoded by UL83), pp71
(encoded by UL82) and pp150 (encoded by UL32) at 15%, 9% and 9% abundance by
mass, respectively (225). These tegument proteins serve two primary functions. The first
is to assist in the structural assembly and disassembly of the virion during entry and
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egress. The second is to subvert the cell's normal response to infection, thereby creating
an environment which is conductive to viral replication (136).
In addition to making contacts with the capsid, tegument proteins also interact with the
viral envelope and the proteins embedded therein. The mature virion envelope is
ultimately derived from the endoplasmic reticulum (ER)/ER golgi intermediate complex
(ERGIC). In terms of facilitating viral entry, the most essential envelope proteins
encoded by CMV share significant homology with those encoded by other herpesviruses.
These proteins form distinct complexes on the viral envelope commonly termed
glycoprotein (g)B, gH:gL and gM:gN (27, 39). gB is expressed on the envelope as a
disulfide-linked homodimer. It is responsible for the initial interaction between the virion
and heparan sulfate proteoglycans present on the surface of target cells, as well as cell-tocell transmission and fusion of infected cells (136). It is also the major target of the
neutralizing antibody response and has thus received attention as a vaccination candidate
(69, 108). Together, these components generate a virion of approximately 200-300 nm in
diameter (136).

1.2.3

Genome

The CMV genome is composed of a unique long (UL) and a unique short (US) sequence
flanked by internal and terminal repeats. This arrangement of repeats promotes
isomerization of the genome, leaving four possible combinations of infectious genomes
(Fig. 1-1). These genomes range in size from 196-241 kbps, depending on the particular
strain in question. The termini of the genome contain conserved packaging signals (pac-1
and pac-2) which are recognized during encapsidation and determine the site of
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concatamer cleavage (136). There is also a large origin of replication (oriLyt) located
between genes UL57 and UL69 which is necessary for lytic replication of the viral
genome (6, 23, 122). CMV is estimated to contain about 140 genes, approximately 80 of
which are necessary for replication in fibroblasts (53, 245). The rest of the genes are
thought to be involved in processes including cell-type specific tropism, temperance or
immune modulation. Currently recognized ORFs have been characterized by a set of
arbitrary criteria, most notably an insistence on undisrupted coding regions and for the
coding of polypeptides greater than 100 amino acids in size. Recent studies have reexamined the historical annotation of CMV genomes and have resulted in the
identification of a number of putative open reading frames (ORFs) that were previously
unrecognized. Several of these ORFs are conserved among multiple clinical isolate and
have thus been dubbed 'conserved ORFs (c-ORFs) (47, 50, 142).

1.2.4
1.2.4.1

Entry and Tropism
Factors associated with viral tropism

Herein, we shall define 'entry' as all processes from the time of initial viral binding to the
expression of immediate early genes. The process of CMV entry into a host cell begins
with binding of gB to surface heparin sulfate proteoglycans (HSPGs) (39). Depending on
the cell type being studied, gH:gL:gO or gH:gL:UL128-131 complexes are then required
to promote higher affinity binding with one of the many known CMV receptors and/or
downstream fusion of the viral envelope with the cellular membrane (98). In fact, the
UL128-131 locus has been mapped as a major viral determinant of CMV tropism. The
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gH:gL:UL128-131A complex is required for endocytic uptake of CMV virions into EC
and epithelial cells, and in some cases this is followed by pH-dependent fusion of the
viral envelope with the endocytic vesicle, which facilitates capsid release into the
cytoplasm (159, 183-184). Interestingly, HF-adapted CMV strains are often found to
have acquired large deletions or mutations in this region which inevitably result in loss of
tropism breadth. For example, the common laboratory adapted strain, AD169, harbours a
frameshift mutation in UL131A which results in the production of a truncated protein and
subsequent loss of EC tropism (1, 3, 81, 230). While the specific mutations acquired by
other laboratory-adapted strains differ subtly, the restricted tropism that results is
common.
Numerous cellular factors also contribute to CMV tropism, though they have not yet been
fully described. Strikingly though, penetration into the cell does not seem to be a major
barrier. A myriad of cell surface receptors which facilitate CMV entry have been
described throughout the years, though none appear to be absolutely required in all
settings. These include various integrin family heterodimers: α2β1, α6β1 and αvβ3 (58,
98, 230), platlet-derived growth factor-α receptor (205) and epidermal growth factor
receptor, whose characterization as a bona-fide entry receptor has been controversial (97,
233).
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FIG. 1-1. Diagrammatic representation of the possible isomeric arrangements of the
CMV genome. The unique long segment of the CMV genome contains the vast majority
of CMV ORFs. It is flanked by a terminal repeat long (b) and an inverted repeat long (b').
The unique short region contains fewer ORFs, many of which encode proteins involved
in immune evasion. The unique short region is flanked by an inverted repeat short (c')
and a terminal repeat short (c). This genetic architecture allows for four possible isomeric
arrangements of the CMV genome. The directionality of the UL and US segments in each
isoform are denoted by arrows.
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1.2.4.2

Penetration of CMV virions in different cell types

Cytoplasmic release of AD169 capsids into HF occurs mainly through direct fusion of the
viral envelope with the plasmalemma, although some studies have reported observing
AD169 in phagolysosome-like structures within HF (40, 204). This may be explained by
the fact that AD169 capsids express only the gH:gL:gO glycoprotein complex, and lack
the gH:gL:UL128-131A complex which is known to be required for endocytic uptake of
CMV in epithelial cells and EC (159, 183-184). The mechanism used by the EC-tropic
strain TB40/E to enter fibroblasts has not been formally investigated, although it was
assumed to be similar to AD169 despite the fact that TB40/E is able to express both
gH:gL:gO and gH:gL:UL128-131A complexes (199). Recently, it has become clear that
the cell type in which a viral strain is grown plays a major role in determining the tropism
and spread of progeny virus. In fibroblast cultures, virus spread is mainly supernatantdriven, whereas in EC cells, spread is mainly focal. Closer inspections of the viruses
released from these cells revealed that HF infected with an EC-tropic strain of CMV
release virus capable of infecting both EC and HF. In contrast, EC infected with the same
EC-tropic strain of CMV released virus that could readily infect HF, but was much
poorer at infecting EC. This phenotype correlated with the amount of gH:gL:UL128131A incorporated into the virions of virus found in the supernatant, with virions from
HF-derived supernatants carrying significantly more of this complex. Further
experiments demonstrated that all of these observations resulted from retention of ECtropic virus expressing gH:gL:UL128-131A on/in EC cells (192).
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1.2.4.3

The cytoskeleton and its role during CMV entry

The cellular cytoskeleton is composed of three major networks: microtubules,
microfilaments and intermediate filaments. The basic units of microtubules are α- and βtubulin heterodimers. These dimers assemble in a head-to-tail orientation to form
protofilaments, 13 of which create a hollow microtubule with an outer diameter of 25 nm.
These structures exhibit a defined polarity whereby the 'plus' end of microtubules is
extremely dynamic and the 'minus' end is quite stable and is tethered to the microtubule
organizing centre (MTOC) (102). Two classes of motor proteins facilitate transport along
these 'cellular roadways.' Plus-ended motor proteins are called kinesins and this
superfamily includes at least 45 members in mammalian cells. These proteins move cargo
towards the cell periphery. They are composed of two heavy chains and two light chains
(130). Minus-end transport (ie. toward the cell centre) is accomplished by dynein. The
structure of dynein is complex, as each motor consists of two heavy chains, two
intermediate chains and multiple intermediate light/light chains (168). Its processivity is
stablized by a large protein complex called dynactin which interacts with specific cargo
(223).
Microfilaments are the smallest of the cytoskeletal elements and their basic units consist
of α-, β- and γ-actin. α-actin is found most commonly in the contractile elements of
muscle tissue, whereas β- and γ-actin co-exist in most other cell types to generate
microfilaments. Like microtubules, actin microfilaments have a definite polarity. ATPbound actin monomers (G-actin) assemble into protofilaments (F-actin), two of which
wind around one another to form a microfilament of 5-9 nm in diameter. The polarity of
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these filaments can be detected by decoration microfilaments with myosin S1 fragments
which create 'barbed' (+) and 'pointed' (-) ends. The actin motor proteins myosin V and
myosin VI are largely responsible for the transport of cargo along microfilaments.
Myosin V is a plus-end-directed motor protein that transports cargo to the cell surface,
while mysoin VI carries endocytic vesicles inward (4).
As their name suggests, intermediate filaments (IF) have a diameter of about 10 nm,
intermediate in relation to microfilaments and microtubules. The major role of IF proteins
is to provide mechanical support for the cell, as there are no known motor proteins which
transport cargo on them. All IF proteins have the same basic structure, globular N- and Cterminal domains surrounding an alpha-helical central rod. Individual IF proteins first
dimerize in the rod domain to form a coiled coil. These dimers then polymerize in an
antiparallel orientation, meaning that unlike microtubules and microfilaments, they do not
exhibit polarity. There are approximately 70 IF genes which are subdivided into six types
of IFs, whose characterization is based on protein structure and amino acid similarity.
Acidic and basic keratins comprise the type I and II IFs, respectively. Type III IFs can
form either homo- or heteropolymers; desmin, glial fibrillary acidic protein (GFAP),
peripherin and vimentin belong to this group. Type IV IFs include α-internexin, synemin,
syncoilin and the neurofilaments. The lamins (A, B and C), which provide structural
support in the nucleus, comprise the type V IFs. Nestin is an example of a type VI IF and
is expressed in many cell types during development, but generally does not persist into
adulthood (56, 64).
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The profile of IFs expressed by different cells vary. Some cells express only one type of
IF, while others express several. This property has been exploited by scientists and
medical practitioners such that certain IFs can now be used as biomarkers to monitor
disease states. For example, vimentin is expressed specifically in mesenchymal cells, but
not in epithelial cells. Thus, vimentin expression can be used to monitor mesenchymal to
epithelial transition and epithelial to mesenchymal transition, which is a common process
during the metastasis of many cancers (104).
Many viruses utilize and alter the cytoskeleton during infection. In certain cases,
cytoskeletal elements must be depolymerized in order for large capsids to be transported
through the cell body. In other cases, cytoskeletal elements are stabilized and exploited,
along with their motor proteins, for capsid transport (49, 117). In the case of CMV, deenveloped capsids associate with the microtubule network following capsid release into
the cytoplasm. Microtubules then facilitate their transport toward the MTOC. Treatment
of cells with microtubule depolymerizing agents nocodazole and colchicine severely
hinders CMV infection, but also results in the structural collapse of vimentin, an
important IF protein. Therefore, one must be cautious in the interpretation of such
experiments (103, 154). At around the same time, depolymerization of the actin
microfilament network is observed and may be necessary for efficient transport of
capsids through the actin microfilament-dense cytosol (11, 101, 116). The role of the IF
network during CMV entry has not been assessed.
The method by which capsids are transported from the MTOC to the nucleus is poorly
understood, but eventually capsids are thought to dock at nuclear pores through which

12

they deposit their genomes. Though this has not been studied carefully in the context of
CMV, elegant atomic force microscopy studies have been able to visualize Herpes
Simplex Type I (HSV-1) capsids docked at the nuclear pore complex (NPC) depositing
densely compacted rod-like structures (thought to be the HSV-1 genome) into the nucleus
(196).

1.2.5

CMV Gene Expression

Following nuclear deposition of the viral genome, immediate-early (IE) gene expression
is initiated. IE1 and IE2 proteins are the first to be expressed and are the major viral
transactivating factors. In addition to the roles these proteins play in activating
downstream viral genes, IE1 blocks signal transducers and activators of transcription
(STAT) signaling in order to prevent interferon (IFN) activation while IE2 induces cellcycle arrest and apoptosis (14, 160, 240-241). At approximately 6 hours post infection
(hpi) IE proteins activate transcription of delayed-early (DE) genes. DE genes are
expressed until 18-24 hpi, and many play important roles in initiation of viral DNA
replication and modulation of the host cell environment to create a milieu which is
conducive to viral replication (7, 237). Late (L) gene regulation is not well-studied in the
context of CMV, but in general, L genes are characterized as those whose expression
begins later than 24 hpi and/or are sensitive to inhibition of viral DNA synthesis (136).
Most genes that belong to this class are involved in encapsidation, virion assembly and
egress (164).
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1.2.6
1.2.6.1

Encapsidation and Egress
Nucleocapsid assembly

Encapsidation takes place in the nucleus adjacent to CMV DNA replication
compartments. The process is initiated by a set of conserved herpesvirus proteins: MCP,
TRI1, TRI2, SCP and PORT, that together form a procapsid around the UL80.5 gene
product, precursor of the assembly protein (pAP). Another protein, precursor of the
maturational protease (pPR), is also required for DNA encapsidation and procapsid
maturation to nucleocapsid. pPR is self-cleaved by the maturational protease (PR, also
called assemblin) which is initially within the same peptide. PR is also responsible for
cleavage of pAP to its various intermediate forms and its mature form, assembly protein
(AP). PR, AP and intermediate pAP isoforms are all removed from nucleocapsids after
packaging of viral DNA (68).

1.2.6.2

The nucleus as a barrier during CMV egress

After successful assembly of the nucleocapsid, a complex egress pathway ensues which
eventually results in the envelopment of capsids and their release from the cell. Before
reaching the cytoplasm, capsids must first traverse the nuclear envelope. This barrier
consists of an inner and outer nuclear membrane, separated by a perinuclear space.
Within the perinuclear space are several proteinaceous structures which link the two
membranes and provide the nucleus with structural support. The NPC consists of a
network of proteins called nucleoporins, which form channels linking the cytoplasm with
the nucleoplasm. These complexes associate with other proteins and are tightly regulated
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as they largely control the transport of materials into and out of the nucleus (52).
However, viral capsids are too large to pass through these complexes. The perinuclear
space is also rich in a rigid network of lamins which link the periphery of NPCs to
chromatin. Together, these structures represent a formidable barrier through which the
virus must escape.

1.2.6.3

The nuclear lamina

The nuclear lamins are type V IF proteins and include lamins A, B1, B2 and C. Lamin
B1 and B2 are encoded by distinct genes, whereas lamins A and C result from differential
splicing of the product encoded by the lmnA gene. Lamin B is mainly associated with the
inner nuclear membrane (INM) and plays a critical role in maintenance of nuclear shape.
Lamin A associates more specifically with the nucleoplasm, performing specialized roles
and contributing to nuclear stiffness (28, 95, 109).
Lamins have the same conserved structural features as other members of the IF family.
They are composed of a central alpha-helical rod domain flanked by globular head and
tail regions. The rod domains of two individual lamin molecules dimerize in a parallel
manner, and these dimers interact with one another to form longer lamin filaments and
regular cross-connections (175). In addition to providing the nucleus with structural
support, the lamina also serves as a scaffold for proteins which span the nuclear envelope,
interact with chromatin or with structures present in the cytosol including lamin B
receptor (LBR) and emerin, chromatin-modifying enzymes and transcription factors, as
well as cytoskeleton-interacting proteins (137, 171).
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Despite its role in mediating nuclear rigidity, the nuclear lamina is a dynamic structure
and must reorganize at various stages throughout the cell cycle. The assembly and
disassembly of the nuclear lamina is regulated by site-specific phosphorylation events by
various kinases, including the cAMP-dependant kinases protein kinase A (PKA), protein
kinase C (PKC) and cdc2/cyclin dependent kinase 1 (CDK1) (149). Lamin A/C is
phosphorylated by CDK1 at Ser-22, Ser-390 and Ser-392 while lamin B is
phosphorylated by CDK1 only at Ser-22 to promote disassembly of the nuclear lamina
during mitosis (87, 149, 167). This strategy is also exploited by the viral NEC in order to
facilitate capsid escape from the nucleus.

1.2.6.4

The CMV nuclear egress complex

The first stage of CMV egress is primary envelopment which occurs at the inner nuclear
membrane. Following successful assembly of viral nucleocapsids and their accumulation
proximal to the INM, the viral pUL97 kinase is recruited to the nuclear envelope by
cellular p32, and also interacts with LBR (120). At this location, pUL97 phosphorylates
lamins at CDK1 sites, leading to their local disruption (84). Lamin phosphorylation by
UL97 generates a binding site for the cellular peptidyl-prolyl cis/trans-isomerase, Pin1.
During CMV infection Pin1 relocalizes to viral replication centres and to the nuclear
lamina (133). Disassembly of the nuclear lamina seems to promote the accumulation of
viral proteins pUL53 and pUL50 (homologs of herpes simplex virus (HSV) proteins
pUL31 and pUL34 and epstein-barr virus (EBV) proteins BFLF2 and BFLF1) to the
nuclear membrane. These proteins interact with phosphorylated p32, lamin A/C and LBR
to form the basic NEC (30, 131-132, 185). pUL50 is a type II integral membrane protein
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that accumulates in the INM. It is required for the proper localization of pUL53 proximal
to the INM and unlike its HSV homolog pUL34, it is sufficient to recruit PKC to the
NEC. Recruitment of PKC aids in further disruption of the nuclear lamina in order to
allow passage of primary enveloped capsids through the perinuclear space (131, 141).
Disassembly of the nuclear lamina results in marked morphological changes within the
nucleus itself. In particular, large infoldings of the INM have been observed proximal to
nucleocapsids and these areas seem to be where primary envelopment takes place (29, 43,
70, 194). Enveloped particles then enter the perinuclear space and are then thought to
fuse with the outer nuclear membrane (ONM) resulting in de-envelopment (Fig. 1-2). It is
likely that other viral and cellular factors contribute to the nuclear egress of CMV, but
have yet to be identified. These factors may also aid in remodeling of the nucleus and/or
the assembly, trafficking and maturation of virions.
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FIG. 1-2. Process of CMV nuclear egress. 1. The process of nuclear egress begins with
assembly of the CMV NEC. This complex mediates disassembly of the nuclear lamina,
which subsequently results in deep invaginations of the INM to regions of the nucleus
containing viral nucleocapsids. 2. Nucleocapsids acquire their primary envelope by
budding through in INM into the perinuclear space. 3. Viral particles containing primary
envelopes move through the perinuclear space towards the ONM. 4. Particles that have
undergone primary envelopment fuse with the ONM to facilitate nucleocapsid release
into the cytoplasm. 5. De-enveloped nucleocapsids are transported through the cytoplasm
and eventually acquire their secondary and final envelope, before being released at the
plasma membrane.
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1.2.6.5

Secondary envelopment and release

The vast majority of tegument proteins are thought to associate with the capsid during the
cytoplasmic stage of egress. While the tegument is often considered to be amorphous,
recent studies suggest that those proteins that associate most closely with the capsid may
actually exhibit an icosohedral symmetry (128). Assembly of the capsid-proximal layers
of the tegument seem to be mediated by a complex series of protein-protein interactions
that exhibit a high degree of redundancy. This process may be nucleated by the UL48
gene product, a homolog of HSV-1 UL36 (or large tegument protein) which interacts
with capsid pentons (124, 128). The UL32 gene product pp150 is another major tegument
protein that plays a crucial role in virion maturation. pp150 associates with capsids in the
nucleus and continues to accumulate at the cytoplasmic inclusion and locations of
secondary envelopment and final maturation (48, 186, 188). Together with UL99encoded pp28, these proteins form the basis of a transport complex which ultimately
results in the secondary envelopment of nucleocapsids at cytoplasmic assembly
compartments located adjacent to the nucleus. This compartment consists of a series of
concentric rings that surround the MTOC, with trans-golgi network and endosomederived rings located most centrally and golgi/ER-derived rings forming the periphery
(45, 188, 198). This rearrangement causes the characteristic 'kidney bean' nuclear
morphology observed at late times post-infection, and the 'owl's eye' cellular morphology
typical of CMV infection. Once secondary envelopment has been completed, vesicles
containing mature virions are transported to the cell membrane where the virus is
released (136).
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1.3
1.3.1

Human Adenovirus
General Characteristics

Adenoviruses were first discovered in 1952 as the etiological agents responsible for acute
respiratory infections (89, 179). However, these infections are responsible for only a
minority of childhood respiratory illnesses, which themselves are generally self-limiting.
The most striking early observation involving adenovirus infections came in 1962, when
Trentin and colleagues showed that HAdV-12 caused malignant tumors upon infection of
newborn hamsters (220). This was the first example of an oncogenic human virus,
although HAdV has never been shown to cause cancer in humans. Nevertheless, this
observation sparked an explosion of interest in the field which led to the use of HAdV as
a tool to understand many critical cellular processes and pathways including: mRNA
splicing, regulation of gene expression, DNA replication and cell cycle control.
There are currently approximately 50 types (formerly serotypes) of HAdV, which are
divided into 6 species (formerly subgroups) based on their ability to agglutinate red blood
cells (178). Recently, the accuracy and utility of naming and characterizing HAdVs
according to the traditional methods of serology and agglutination has come into
question. This has sparked a debate in the field as to the design of a new naming
convention for HAdVs that will serve both the clinical and basic science communities,
and more accurately group viruses based on parameters which reflect the relationships
among the viruses themselves (9, 96, 193).
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1.3.2

Virion Structure

Unlike herpesviruses, HAdV particles are non-enveloped. The capsids are icosohedral in
shape and approximately 90 nm in diameter, with fibers projecting from the vertices
(181-182). 240 hexon (trimer of polypeptide II) capsomers and 12 penton capsomers
constitute the major structural components of the virion (71). Fibers project from the
penton base (hexamers of polypeptide III) and play an important role in receptor binding
and entry (251). The minor capsid protein VI is important for endosomal escape (242).
Recent cryo-electron microscopy and crystallography studies have greatly enhanced
understanding of HAdV capsid structure and assembly (115, 173). Protein IIIa is
responsible for coordinating the penton base with its five surrounding hexon units
through an interaction with the vertices of these subunits that together form group-of-six
tiles. Protein IX acts as a network of 'ropes' linking hexons together to form group-ofnine tiles. These ropes also link group-of-nine tiles to one another, further contributing to
capsid stability. Yet another underlying network, coordinated by protein IIIa and VIII,
bind each group-of-six tile to five surrounding group-of-nine tiles (115, 173).
The viral DNA is condensed within the core by three basic, arginine-rich proteins:
polypeptides V, VII and µ (8, 91, 180). Terminal protein is covalently bound to the 5'ends of viral DNA by a phosphodiester bond between the β-hydroxyl group of serine 562
and the 5' hydroxyl of the terminal deoxycytosine (174, 203). Polypeptide VII is the most
predominant core protein, with over 800 copies per virion (181, 187). The core also
contains approximately 10 copies of the viral cysteine protease p23, which is responsible
for cleavage of several virion precursor proteins during assembly and maturation (236).
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Polypeptide V appears to link the virion core to the capsid via an interaction bridging the
penton base and polypeptide VI (57).

1.3.3

Genome

The HAdV genome is approximately 36 kbp in size and is flanked by inverted terminal
repeats which function as origins of replication during asymmetric synthesis of viral
DNA (46, 177). The viral genome packaging sequence is composed of a series of repeats
located between the left terminal inverted repeats and early region 1A (E1A) (75, 85).
HAdV-2 was the first HAdV to have its genome sequenced completely (177), although
subsequently many more complete sequences have been compiled for both HAdV and
AdVs from other species.
The HAdV genome contains five early transcription units (E1A, early region 1B (E1B),
E2, E3, and E4), three delayed-early units (IX, IVa2 and E2 late) and one late
transcription unit (major late) which encode L1-L5. By convention, the map of the HAdV
genome is depicted with E1A at the left end. While the sequence of most structural
proteins is highly conserved, more variability is evident in early regions 1, 3, 4 and in the
small virus-associated RNA (VA RNA), which is transcribed by RNA polyermase III
(46). Genes are transcribed from both strands of viral DNA, with E1A, E1B, IX, major
late, VA RNA and E3 transcribed from the rightward reading strand, while the leftward
reading strand encodes E4, E2 and IVa2 (18).
All mRNAs transcribed by RNA polymerase II give rise to multiple species through
alternative splicing and/or use of alternative poly(A) sites. The lack of a consistent
terminology for naming of HAdV proteins has led to a confusing nomenclature whereby
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some proteins are named according to the sedimentation coefficients of the mRNAs
which encode them or the particular number of amino acids residues present in the
protein (ie. E1A), others are named according to the molecular weight of the proteins
themselves (ie. E1B and E3), the ORF from which they arise (ie. E4) or descriptively,
according to their function (ie. E2) (18). For the sake of clarity herein, E1A isoforms
shall be referred to according to the number of residues composing each isoform (ie.
289R, 243R, etc... in the case of HAdV-2/5).

1.3.4

Viral Entry and Egress

Most detailed studies of the HAdV infection cycle have been completed using HAdV-2.
Thus, the following observations apply directly to HAdV-2 and more generally to other
HAdVs. Initial HAdV attachment to cells is mediated by interaction of the fiber protein
with coxsackie B virus and adenovirus receptor (CAR) (17). The penton base then binds
integrin family members (specifically, αvβ3 and αvβ5 which are present on most epithelial
cells) via an RGD motif (239). The penton-integrin interaction results in release of the
fibers and endocytosis of the fiber-less virion (144). As endosomes mature and acidify,
partial disassembly of the virion is initiated and continued as virions are released into the
cytosol (22, 170). The reducing environment inside of the cell activates the virionassociated viral protease, which cleaves protein VI, releasing the capsid from the viral
core (79).
Following endosomal escape, viral particles are transported towards the nucleus on
microtubules by dynein motor proteins (44, 77, 111, 118, 215). Viral particles then dock
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at NPCs where disassembly is completed and viral genomes are deposited into the
nucleus (78).
Expression of E1A begins almost immediately upon nuclear deposition of the viral
genome (147). Transcription of E1A is initially controlled by a constitutive enhancer
element (86) and once expressed, E1A activates the expression of downstream viral
genes, as will be discussed extensively below.
Following extensive replication of the viral genome and production of structural virion
components, virion assembly begins in the nucleus of host cells. Following their
translation, hexon and penton monomers rapidly assembly into capsomers in the
cytoplasm. They are then transported into the nucleus where assembly continues (18).
HAdV DNA is packaged into virions starting at the left end of the genome, where the
packaging signal is located (85). Precursor of the major histone-like protein (pVII)
associates with viral DNA late during infection and may form a complex with core
protein V and precursor of µ (235, 250). Packaging is promoted by viral IVa2, L1 52/55K
and L4 22 kDa proteins (156, 165).
Protein VI, VII, VIII, µ and terminal protein are cleaved by the viral cysteine protease,
which is also packaged in the virion. This completes virion maturation and renders the
particle infectious (217, 234).
Escape and spread of progeny virus is mediated through a variety of cooperating
mechanisms. First, the viral L3 protease is able to cleave the IF protein cytokeratin K18,
weakening the overall structural integrity of the cell (34). The 11.6 kDa E3 protein, also
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known as 'adenovirus death protein' is an integral membrane glycoprotein and is highly
expressed at late times post-infection (218). The protein localizes to the nuclear
membrane, ER and golgi apparatus. It is known to interact with MAD2B, a regulator of
the anaphase-promoting complex, though how this interaction results in cell death
remains poorly understood (244). Finally, released, free fiber proteins bind to and prevent
oligomerization of CAR at tight junctions. This is likely to promote viral spread and
mediate access to the airway during respiratory infection (229).

1.3.5
1.3.5.1

E1A
General properties

For the sake of clarity, the following sections will focus on E1A of HAdV-2/5 unless
otherwise specified. E1A is located at the left end of the HAdV genome and is the first
transcription unit to be expressed after infection. The primary E1A transcript is
alternatively spliced to generate 5 mRNA species which encode proteins of 289, 243,
217, 171 and 55 residues (R). Splicing maintains the reading frame of each isoform
except 55R. Sequence comparison of the largest E1A isoform across multiple AdV
serotypes revealed four regions of high conservation which have been dubbed 'conserved
regions (CR) 1-4'. While 289R E1A possesses each of these regions, the smaller E1A
isoforms may lack one or more CRs. 55R E1A is the only E1A isoform that lacks all four
conserved regions (Fig. 1-3) (161).
E1A is essential for efficient infection of human cells, which reflects the diverse and
complex functions it performs (99). In addition to activating viral gene expression, E1A
also reprograms host cells, forcing them out of quiescence and into the cell cycle (15, 19,

25

61, 66). Since E1A does not exhibit DNA binding activity, it is able to perform these
functions by binding to and subverting the normal function of over 50 cellular proteins.
This has led to the description of E1A as a 'viral hub protein' (161).
Interactions between E1A and its many cellular partners occur mainly through molecular
recognition features (MoRFs) or linear motifs. These are short segments of the primary
amino acid sequence that exhibit a high degree of structural plasticity. Indeed, with the
exception of CR3, E1A is thought to be intrinsically unstructured (60). Such flexibility
allows E1A to adopt one of many possible conformations subsequent to binding of
particular targets. Many of these MoRFs can also be found in the endogenous, cellular
binding partners of E1A targets. Amazingly, these MoRFs often overlap in E1A, making
for extremely dense regions of protein binding. Intuitively, only certain combinations of
concurrent binding of E1A to its cellular targets is possible due to steric hindrance, and
this property may be important in determining the novel complexes nucleated by E1A
(161).
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FIG. 1-3.
3. Comparison of the 55R E1A isoform with CRs present in 289R and 243R E1A.
The 55R E1A protein shares only the first 26 amino acids encoded by exon 1 with the
larger E1A isoforms. Splicing of the 9S mRNA causes a frameshift in exon 2 of 55R E1A
that results in a novel C-terminal
terminal amino acid sequence relative to the other E1A isoforms.
289R E1A, the largest E1A isoform, contains all 4 CRs. The 243R E1A isoform is
different from 289R E1A only in that it lacks CR3.
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1.3.5.2

E1A-induced cell cycle progression

The cells of the respiratory epithelium normally infected by HAdV are terminally
differentiated, quiescent cells. Thus, they lack an abundance of many substrates required
by HAdV during the replication cycle. To overcome this difficulty, the virus has evolved
a variety of mechanisms which together force the host to re-enter the cell cycle, making it
more conducive to viral replication. E1A plays a central role in this process by targeting
cellular proteins that are key regulators of growth and cell cycle pathways, including
retinoblastoma (Rb)-family proteins, p300/CREB-binding protein (CBP) and C-terminal
binding protein (CtBP).
243R E1A, which lacks CR3 (a strong transcriptional activation domain), is sufficient to
induce S-phase induction and cell cycle progression of contact-inhibited primary cells
(26, 207, 248). Expressed alone, CR1 or CR2 is sufficient to induce S-phase, but both are
required for progression into mitosis and for transformation in cooperation with E1B or
activated RAS (93, 209). CR2 was shown to bind Rb and Rb family members p107 and
p130 (13, 38, 55, 238). These proteins regulate the E2F family of transcription factors,
many of which control cellular genes required for S-phase entry (including CDK2,
cyclins A and E, and c-MYC) (54, 63, 146, 148, 221). E1A CR2 contains an LxCxE motif
which binds with high affinity to the same pocket domain on Rb family proteins that is
bound by E2Fs (148). Binding of E1A to Rb family proteins results in the release of E2Fs
from Rb-mediated inhibition, resulting in constitutive activation of E2F-responsive
promoters (21). In a normal context, Rb inhibition is relieved by phophorylation mediated
by cyclin-dependant kinase (CDK)-cyclin complexes whose activity is stimulated by
mitogens in G1. Expression of CDK inhibitors which prevent Rb phosphorylation are
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partially responsible for senescence, which is also detrimental to virus replication (16,
190, 210). Through bypassing these cellular pathways, CR2 ensures efficient S-phase
entry, although other functions of E1A are required to push cells through the complete
cell cycle (92).
While initiating relief of Rb-mediated E2F repression provides a solid mechanistic
explanation for the ability of CR2 to induce S-phase progression, the way in which CR1
causes this same phenomenon is much less clear. One important contribution is likely the
association of CR1 with the histone acetyltransferases (HAT) p300 and CBP (10, 13, 211,
232). In normal settings, p300/CBP are recruited to specific promoters via their
interaction with various transcription factors where they activate transcription by
acetylating histone tails or specific lysines present in other transcription factors (74). E1A
binding to p300/CBP is actually tripartite, involving both the non-conserved N-terminus
and CR1 (152, 162). Despite this knowledge, it is unclear how binding of E1A to
p300/CBP contributes to S-phase induction. Binding may inhibit HAT activity, although
even this point remains controversial (2, 32, 83). Interestingly, inhibition of p300 has
been shown to markedly increase expression of MYC, which is important for G0 to S
transition (74). Effects such as this, although elusive, will be important to study more
directly in order to better understand CR1-mediated S-phase induction and will likely
yield important new knowledge of cell cycle regulation in general.
Many of the cellular factors targeted by E1A are responsible for regulating large
networks of gene expression. This was most elegantly demonstrated in series of recent
reports showing that E1A is able to reprogram the expression of virtually every gene
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within the cell over the course of an infection (59, 90). The N-terminus of E1A contains a
CoRNR box motif also found in nuclear receptor (NR) corepressors, which mediates
interaction with NRs. This motif is responsible for the interaction of E1A with
unliganded, but not liganded thyroid hormone receptor (TR) (125). Strikingly, despite
binding in the corepressor mode, E1A is able to activate transcription from thyroid
hormone response elements, effectively ensuring constitutive activation of TR-responsive
genes in the presence and absence of hormone (94, 125-126, 189, 227).
Recently, 289R E1A was shown to activate E2F-responsive gene expression
independently of binding Rb-family proteins. This is accomplished through targeting of
E2F/DP-1 via a direct interaction with DP-1. 289R E1A appears to be recruited to E2Fresponsive promoters by DP-1/E2F heterodimers, stimulating their activity. Interestingly,
this effect seems to be most profound in the context of E2F4 and E2F5, both considered
'repressive' E2Fs (163). E1A is also able to eliminate p130-E2F4 and histone deacetylase
(HDAC)1/2-mSin3B repressive complexes from the promoters of E2F-regulated genes in
quiescent cells. This dramatically decreases H3K9 methylation of these promoters and
correspondingly increases H3K9/14 acetylation, which ultimately results in increased
transcription from E2F-regulated genes (161, 195). This may be yet another example of
redundant targeting of a critical cellular pathway, and the ability of E1A to stimulate
activation of genes that are normally repressed in quiescent cells.
The N-terminus and CR1 also bind a series of other chromatin remodeling complexes,
including p400, Tip60, Gcn5, PCAF and TRAAP (65, 107, 150, 212). How interaction
with these proteins and their associated complexes contributes to S-phase progression is
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equally mysterious. A final set of less mysterious CR1 targets include the CDK inhibitors
p21 and p27 (5, 33, 151). Binding of these inhibitors abrogates their association and
inhibition of CDK-cyclin complexes, thereby promoting cell cycle progression.
The major target of CR4, found near the C-terminus of E1A, is CtBP (35). This protein
acts as a transcriptional corepressor, and upon homodimerization and recruitment to a
promoter by sequence-specific transcription factors, forms a silencing complex (36).
Binding of E1A to CtBP derepresses target promoters and may result in recruitment of
activating complexes, though this has not been tested directly (161). The only other
factors that have currently been identified which bind CR4 are the dual specificity
tyrosine phophorylation-regulated kinase 1A (Dyrk1A) and Dyrk1B. These kinases are
involved in regulating proliferation, differentiation and cell survival (127). Their binding
site on E1A overlaps that of CtBP, suggesting that binding of these two factors may be
mutually exclusive. While the global effects of E1A-Dyrk binding have yet to be
elucidated, E1A has been shown to stimulate Dyrk kinase activity in vitro (249).
Interestingly, CR4 is required for E1A-mediated transformation of rodent cells in
cooperation with E1B. However, it also suppresses oncogenic transformation in
cooperation with activated ras (24, 51, 213-214). Delineating the molecular basis of these
paradoxical phenotypes will provide important insights regarding the mechanism of E1Ainduced transformation.

1.3.5.3

E1A-induced transcription of viral genes

The CR3 region of E1A functions as a strong activation domain when fused to the Gal4
DNA-binding domain and recruited to a Gal4 responsive promoter (113, 121). This
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region is also important in stimulating transcription from the four early HAdV promoters,
as mutations in CR3 substantially reduce the abundance of early viral transcripts (20, 99).
243R E1A (which lacks CR3) can stimulate a low level of early gene transcription,
whereas 289R alone activates transcription of early promoters to the same level as
wildtype (140, 243). Since E1A does not possess DNA binding activity itself, it
associates with cellular transcription factors (through the C-terminal end of CR3) which
bind HAdV early promoters (114). Each early promoter contains binding sites for cellular
transcriptional activators upstream of the TATA-box (100).
Unlike most of E1A, CR3 appears to exhibit distinct structural features and forms a zinc
finger domain (42). One of the major contributors to CR3-mediated transcriptional
activation is MED23. MED23 is a subunit of the mediator complex, which is composed
of approximately 30 total subunits. Mediator plays a key role in transcriptional activation
and functions by bridging DNA-bound activators with the general transcriptional
machinery, in particular, RNA polymerase II. This nucleates assembly of the preinitiation
complex (112). CR3 binds MED23 both in vitro and in vivo, thereby recruiting the
mediator complex to specific viral and cellular promoters and greatly enhancing
transcriptional activity at these promoters (25, 72, 231).
243R E1A specifically activates the E2 early promoter (12, 169). This promoter contains
two inverted E2F binding sites which are activated by E2Fs following E1A-mediated
relief of Rb repression (12, 105-106, 169, 246). Free E2Fs interact with dimers of
E4orf6/7, which greatly increases their affinity for the E2F binding sites found within the
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viral E2 early promoter (41, 121, 153). As E2 products accumulate, viral DNA
replication begins to occur and the late stage of viral gene expression begins.
Expression of most late HAdV transcripts is controlled by the major late promoter
(MLP). This promoter exhibits low levels of activity during the early stages of infection
and is activated several hundred fold at late times (197). Although activation of the MLP
is understood to be mediated by binding of E1A to Sp1 and MAZ transcription factors
(the MLP contains binding sites for both of these proteins), this does not account for the
delayed kinetics of transcription from the MLP (158). Studies to date suggest that both
cis- and trans-acting factors regulate these kinetics.
The cis-acting factor appears to rely on DNA replication, although the precise mechanism
for regulation of kinetics remains poorly understood (216). It has been suggested that
DNA replication may facilitate removal of protein VII, the basic protein that is associated
with viral DNA that is translocated through the NPC, thereby allowing transcription
factors access to the MLP (18). The fact that the transcription factor USF (also called
MLTF) can only bind the MLP after onset of DNA replication provides further support
for a cis-acting change in viral chromatin that is required for binding of factors that drive
transcription from MLP (219).
The HAdV IVa2 protein has been implicated as a transactivator of the MLP. It binds in
the +85 to +120 region upstream of the transcriptional initiation site and cooperates with
USF/MLTF to enhance MLP activity (110, 119, 138-139, 157). IVa2 itself is expressed
with delayed early kinetics and together with MLP, functions as an elegant molecular
timer to control the kinetics of viral gene expression. The second viral transactivator of

33

the MLP appears to arise from an internally spliced mRNA arising from L4, although the
mechanism underlying this action awaits further study (18, 155).

1.3.5.4

E1A interaction with the proteasome

Both 289R and 243R E1A have been shown to interact with, and affect the function of
the proteasome. This was first demonstrated in 1999, when Grand and colleagues showed
that E1A binds to hSug1 (S8), a component of the 19S regulatory subunit of the 26S
proteasome. Surprisingly, HAdV-12 E1A was shown to inhibit activity of the 20S
proteasome in vitro, but had little or no effect on the function of the 26S proteasome (76).
Later studies would reveal that E1A could also interact with S4, another member of the
19S regulatory subunit of the 26S proteasome. S4 possesses ATPase activity and binding
of E1A significantly reduced this activity. This reduction correlated with an increase in
the half-life of p53 in the presence of the human papillomavirus (HPV) E6 protein. E6 is
normally responsible for targeting p53 for proteasomal degradation during HPV
infection. E1A-26S proteasome complexes could be found in both the nucleus and the
cytoplasm, suggesting the E1A might alter proteasome function in both locations. The
binding region for S4 and S8 was mapped to residues 4-25 on E1A. Strikingly, despite
the fact that E1A was found to be a substrate for proteasomal degradation, binding to S4
or S8 was not required for this degradation to occur. In addition, degradation of E1A was
found to be mediated by a C-terminal PEST domain and did not depend on ubiquitylation
(222).
S8 also possesses ATPase activity and in addition to binding the E1A N-terminus, it can
also interact specifically with CR3. Recruitment of S8 (and the 26S proteasome) to early
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viral promoters by CR3 enhances its ability to stimulate transcription of early HAdV
genes. The 20S proteasome can also be recruited by CR3, independent of S8 and the 26S
proteasome. E1A, S8 and the 20S proteasome can all be found on HAdV early gene
promoters and sequences. In fact, inhibition of proteasome function diminishes the ability
of E1A to transactivate viral genes (172). Active proteasomal function is required for
efficient transactivation by many cellular factors as well, including nuclear receptors and
coactivators. Presumably, turnover of promoter-bound factors and dissociation of
transcriptional complexes on certain genes must occur before transcriptional re-initiation
can take place (145). Taken together, these observations suggest that efficient
transactivation by E1A also requires proteasomal activity, and that E1A-mediated
recruitment of the proteasome to viral promoters enhances transactivation of early viral
genes.

1.3.5.5

55R E1A

The 55R isoform of E1A is generated from the 9S mRNA species, described over 30
years ago (20). It is the smallest E1A species and contrary to 289R and 243R E1A, it
accumulates at late times of infection (166). While it is not entirely clear what causes the
shift in splice site preference to generate 55R E1A at late times of infection, it appears to
require replication of viral DNA. Interestingly, the 9S E1A mRNA species is not
produced in 293 cells, which harbor an integrated copy of the left end (E1A and E1B) of
the HAdV genome (206). 55R E1A is the only E1A species that does not contain any of
the CRs. In addition, reconstitution of its splice junction results in a frame shift relative to
all other E1A isoforms. As a result, 55R E1A shares its first 26 amino acids encoded in
exon 1 with all other E1A isoforms. The remaining 29 amino acids encoded after the
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splice junction linking exon 1 and exon 2 are read from a different reading frame and are
therefore unique to the 55R E1A protein (176, 224, 226).
Despite historical knowledge of the 9S mRNA species and its kinetics of expression, the
55R E1A protein has never been studied directly. Therefore, almost nothing is known
about its function. This is due, in large part, to the fact that none of the existing E1A
antibodies (of which there are many), seem to recognize the 55R isoform. Early studies
using 55R cDNA plasmids or mutant virus that could only express 55R E1A indicated
that unlike the 289R and 243R isoforms, 55R E1A could not transform primary BRK
cells when expressed in combination with activated ras (82, 247). Neither could it induce
DNA synthesis in growth-arrested NIH 3T3 cells (208). This is not entirely surprising
given the subsequent knowledge that 55R lacks all of the regions known to be required
for E1A-induced transformation. 55R E1A also fails to stabilize p53 and induce apoptosis
(37). Nevertheless, 55R E1A does share its first 28 amino acids (the first 26 encoded by
exon 1, plus a V and L which are regenerated from sequences encoded by exon 2 as a
consequence of the frameshift caused by splicing) with its larger E1A counterparts.
Several proteins are known to bind (at least partially) in this region, including thyroid
hormone receptor, TRRAP, S4 and S8 (161). 55R E1A may maintain interaction with
these known targets of the larger E1A isoforms to either produce similar functional
outcomes, or perhaps more interestingly, to cause novel outcomes. Finally, the Cterminal region of 55R E1A remains completely unexplored territory and is itself likely
to interact with novel cellular targets that will expand our knowledge of HAdV biology
and may also provide novel insights into biology of the cell.
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1.4 Thesis Overview
Here, we explore three essential processes in the life of any virus: entry, gene regulation
and egress. Entry is explored in the context of CMV infection. We have identified the IF
vimentin as a host factor required for the efficient onset of CMV replication in HF. Our
results demonstrate that the EC-tropic strain TB40/E is more negatively affected by
disruption or absence of vimentin than the HF-adapted strain, AD169. In vimentin null
cells, viral particles were observed to remain in the cytoplasm longer than in their
wildtype counterparts. These findings suggest that vimentin may function during viral
entry to facilitate viral trafficking and/or docking of viral particles to the NPC. In
addition, our results suggest that more broadly tropic CMV strains, such as TB40/E,
exhibit a higher degree of reliance on the vimentin cytoskeleton which may reflect
fundamental differences in the process of entry of these strains.
In examining viral gene regulation, we turned our attention to HAdV. We have developed
a novel antibody which allows for the direct study of the smallest E1A isoform, 55R
E1A. We show that 55R E1A is able to stimulate viral replication relative to E1A null
virus. Using a co-infection system, we found that in the context of 289R E1A, the effect
of 55R E1A on viral replication was not dose-dependent. However, in the presence of
243R E1A, 55R E1A improved virus replication in a dose-dependent manner. This is due,
at least in part, to the ability of 55R to stimulate viral gene expression. Interestingly, the
profile of viral gene transactivation by 55R E1A is distinct from that of wildtype E1A.
Finally, we show that 55R interacts with the S8 component of ATPase proteins
independent of 20S (APIS), but not S4. Knockdown of S8 had a deleterious effect on the
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growth of a virus expressing only 55R E1A. This is the first study to functionally
characterize the 55R E1A protein, describe its effect on virus growth and identify a novel
interaction between it and a cellular target. We are confident that this represents an
exciting new field in the study of adenoviruses and that elucidating additional functions
and cellular targets of 55R will yield important contributions to our understanding of the
functions of E1A and of HAdV biology, in general.
In the final data chapter of this thesis, we turn our attention back to CMV in order to
study the process of viral egress. We identify and describe a novel protein encoded by cORF29 which we have called RASCAL. Two isoforms of RASCAL were found to be
encoded by different CMV strains. The majority of strains encode a 97 amino acid
protein, while an extended 176 amino acid isoform is unique to strains Towne, Toledo,
HAN20 and HAN38. RASCAL localizes to the nuclear rim, in deep intranuclear
invaginations and in cytoplasmic vesicles at late times post-infection. These RASCALcontaining vesicles are positive for lamin B, strongly suggesting that they are derived
from the nuclear membrane. The localization of RASCAL observed during infection was
dependent on a member of the NEC, pUL50. Indeed, RASCAL could be coimmunoprecipitated with UL50, indicating that they are part of the same complex and
strongly suggesting that RASCAL is a novel component of the CMV NEC. The presence
of RASCAL in the Lamin B positive vesicles presents the intriguing possibility that
RASCAL is also involved in steps of virion maturation subsequent to escape of
nucleocapsids from the nucleus.
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Taken together, these studies highlight three crucial stages of virus replication as
exemplified by CMV and HAdV. The insights gained from this work are likely to have
broader implications in our understanding of viral replication and cell biology. Although
the utility of therapeutically targeting the specific proteins/pathways described herein has
not yet been tested directly, any drug capable of interfering with the essential processes
of viral entry, gene regulation or egress could serve as a potent antiviral agent. We hope
that whether in the short or long-term, the knowledge gained from this work will advance
our field and have a positive impact on human health.
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Chapter 2
ONSET OF HUMAN CYTOMEGALOVIRUS REPLICATION
IN FIBROBLASTS REQUIRES THE PRESENCE OF AN
INTACT VIMENTIN CYTOSKELETON
2.1 Introduction
CMV is a ubiquitous herpesvirus that can cause serious disease in immunocompromised
individuals (8, 58). Virtually all cell types, with the exception of lymphocytes and
polymorphonuclear leukocytes, can support CMV replication in vivo (80), and this
remarkably broad tropism is the basis of the numerous clinical manifestations of CMV
infection (8, 58). The range of permissive cells in vitro is more limited, with HF and
endothelial cells being the most widely used for propagation of clinical isolates. Two
extensively studied strains, AD169 and Towne, were generated by serial passage of tissue
isolates in HF for the purpose of vaccine development (22, 68). During this process, both
strains accumulated numerous genomic changes (11) and lost the ability to grow in cell
types other than HF. By contrast, propagation in endothelial cells produced strains with
more intact genomes and tropism, such as TB40/E, VR1814, TR, and PH (59, 80).

The viral determinants of endothelial and epithelial cell tropism have recently been
mapped to the UL128-UL131A genomic locus (32, 92, 93). Each of the products of the
UL128, UL130, and UL131A genes is independently required for tropism and
participates in the formation of a complex at the surface of the virion with the viral
glycoproteins gH and gL (74, 93), which can also independently associate with gO (45).
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The gH/gL/UL128-131A complex appears to be required for entry into endothelial cells
by endocytosis, followed by low-pH-dependent fusion of the virus envelope with
endosomal membranes (73, 74) although some virus strains expressing the UL128UL131A genes do not require endosome acidification for capsid release (66, 79).

HF-adapted strains consistently contain mutations in the UL128-131A genes (32). Loss
of endothelial cell tropism in AD169 has been associated with a frameshift mutation in
the UL131A gene, leading to the production of a truncated protein and to the loss of the
gH/gL/UL128-131A complex, but not the gH/gL/gO complex, from the surface of
AD169 virions (1, 3, 92). Reestablishment of wild-type UL131A expression in AD169 by
repair of the UL131A gene mutation or by cis-complementation yielded viruses with
restored tropism for endothelial cells but with reduced replication capacities in HF (1,
92). Interestingly, the efficiencies of entry of wild-type and repaired or complemented
AD169 viruses were comparable, suggesting that the presence of UL131A did not
interfere with the initial steps of infection in HF but negatively affected virion release (1,
92).

The cellular determinants of CMV tropism are numerous and have not been fully
identified. Virus entry begins with virion attachment to the ubiquitously expressed
heparin sulfate proteoglycans at the cell surface (17), followed by engagement of one or
more receptor(s) including the integrin heterodimers α2β1, α6β1, and αVβ3 (23, 39, 94);
the platelet-derived growth factor-α receptor (84); or the epidermal growth factor
receptor, whose role in CMV entry is still debated (38, 95).
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Subsequent delivery of capsids into the cytoplasm requires fusion of the virus envelope
with cellular membranes. Release of AD169 capsids in HF occurs mainly by fusion at the
plasma membrane at neutral pH although incoming virions have also been found within
phagolysosome-like vacuoles (16, 83). Fusion with the plasmalemma appears to be
mediated by the gH/gL/gO complex as AD169 virions do not contain the gH/gL/UL128131A complex, and infectivity of a gO mutant was severely reduced (37). The
mechanism used by strain TB40/E to penetrate into HF has not been described but was
assumed to be similar to that of AD169 (80) even though TB40/E virions contain both
gH/gL/gO and gH/gL/UL128-131A complexes.

Transport of released, de-enveloped capsids toward the nucleus is mediated by cellular
microtubules, and treatment of Towne-infected HF with microtubule-depolymerizing
agents substantially reduced expression levels of the viral nuclear IE1 (64).
Depolymerization of actin microfilaments was also observed in HF as early as 10 to 20
min post-infection with the Towne strain while stress fiber disappearance was evident at
3 to 5 hpi with AD169 (4, 42, 54), suggesting that microfilament rearrangement may be
required to facilitate capsid transition through the actin-rich cell cortex.

The role of IF in CMV infection not been studied. In vivo, expression of the IF protein
vimentin is specific to cells of mesenchymal origin like HF and endothelial cells (12).
Although the phenotype of vimentin-/- (vim-) mice appears to be mild (15), vimentin-null
cells display numerous defects including fragmentation of the Golgi apparatus (26),
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development of nuclear invaginations in some instances (76), and reduced formation of
lipid droplets, glycolipids, and autophagosomes (29, 52, 87). Vimentin IF interact with
integrins α2β1, α6β4, and αVβ3 at the cell surface and participate in recycling of integrincontaining endocytic vesicles (40, 41). They also accompany endocytic vesicles during
their perinuclear accumulation (34), regulate endosome acidification by binding to the
adaptor complex AP-3 (86), control lysosome distribution into the cytoplasm (87), and
promote directional mobility of cellular vesicles (69). The vimentin cytoskeleton is
tightly associated with the nuclear lamina (10) and was shown to anchor the nucleus
within the cell, to mediate force transfer from the cell periphery to the nucleus, and to
bind to repetitive DNA sequences as well as to supercoiled DNA and histones in the
nuclear matrix (56, 89, 90). Microtubules and vimentin IF form close connections in HF
(30). Drug-induced disassembly of the microtubule network alters IF synthesis and
organization, leading to the collapse of vimentin IF into perinuclear aggregates (2, 25, 30,
70). By contrast, coiling of IF after injection of antivimentin antibodies has no effect on
the structure of microtubules (28, 46, 53), indicating that the interaction between
vimentin IF and microtubules is functionally unidirectional.

In this work, we sought to assess the role of the vimentin cytoskeleton in CMV entry. We
hypothesized that vimentin association with integrins at the cell surface, with endosomes
and microtubules in the cytoplasm, and with the lamina and matrix in the nucleus
facilitates viral binding and penetration, capsid transport toward the nucleus, and nuclear
deposition of the viral genome.
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We found that, akin to microtubules, vimentin IF do not depolymerize during entry of
either AD169 or TB40/E. In comparison to AD169, onset of TB40/E infection in HF was
delayed, and the proportion of infected cells was reduced. Virus entry was negatively
affected by the disruption of vimentin networks after exposure to acrylamide (ACR), by
IF bundling in cells from patients with giant axonal neuropathy (GAN), and by the
absence of vimentin IF in vim- mouse embryo fibroblasts (MEF). In vim- cells, the
efficiency of particles trafficking toward the nucleus appeared significantly lower than in
vimentin+/+ (vim+) cells, and in each instance the negative effects were more pronounced
in TB40/E-infected cells than in AD169-infected cells. These data show that vimentin is
required for efficient entry of CMV into HF and that the EC-tropic strain TB40/E is more
reliant on the presence and integrity of vimentin IF than the HF-adapted strain AD169.

2.2 Materials and Methods
2.2.1

Cells and virus

Primary foreskin HF (a gift from E. S. Mocarski, Atlanta, GA) were propagated in
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal clone serum
III (HyClone), 4 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1
mM sodium pyruvate, and 100 U/ml penicillin and 100 μg/ml streptomycin (all from
Gibco Invitrogen Corp. [completeDMEM]) and were used between passages 17 and 27
postisolation. Normal dermal HF (MCH070 cells) and dermal HF from a patient with
GAN (WG0321cells) were obtained from the Repository for Mutant Human Cell Strains
at Montreal Children’s Hospital and were propagated as described above with the
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addition of 10% fetal bovine serum (HyClone). To induce vimentin IF bundling, cells
were cultured in medium lacking serum for 4 days. Vim+ (MFT-6) and vim- (MFT-16)
immortalized MEF (a gift of R. Evans, Aurora, CO) were propagated as described for
foreskin HF. Human CMV strains AD169varATCC and TB40/E were kind gifts from E.
S. Mocarski and were originally obtained from the ATCC and C. Sinzger (Tübingen,
Germany), respectively. Propagation and purification of both strains were performed as
described previously (35). Virus titers were determined by plaque assay on HF
monolayers in 12-well tissue culture plates. Five different stocks of TB40/E and five of
AD169 were used for the experiments described. The identity of each strain was verified
by PCR amplification of AD169 and TB40/E genomic extracts with primers mapping to
the UL150 gene.

2.2.2

Cell infection

For analysis of microtubules, microfilaments, and vimentin IF structure, HF were plated
at a density of 5 × 104 cells/cm2 in 24-well plates with coverslips 1 day prior to infection
with AD169 or TB40/E at a multiplicity of infection (MOI) of 5. Mock-infected samples
were exposed to culture medium alone. Cells were harvested at 5 and 30 min (min) postinfection and at 1, 2, and 4 hpi. For expression analyses of IE1 and IE2, HF were plated
as above and infected with AD169 or TB40/E at an MOI of 1 or 5 at confluence (3 days
post-seeding). After adsorption for 1 h, cells were washed twice and incubated in fresh
DMEM until 2, 4, 8, 24, 48, 72, and 96 hpi. Endpoint titers of cell-free virus were
determined by plaque assay on confluent HF by serial dilution of supernatants from HF
infected with AD169 or TB40/E at an MOI of 1 and collected at 24, 48, 72, 96, 120, 144,
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and 168 hpi. MCH070 and WG0321 cells were seeded in serum-free DMEM at a density
of 5 × 104 cells/cm2 in 24-well plates with coverslips 4 days prior to infection with
AD169 or TB40/E at an MOI of 1 or 10. After adsorption for 1 h, cells were washed
twice and incubated in fresh DMEM until 4, 8, and 24 hpi. For IE1/IE2 expression
analyses, vim+ and vim- MEF were seeded at a density of 7.7 × 104 cells/well in 24-well
plates with coverslips 1 day prior to infection with AD169 or TB40/E at an MOI of 1 or
10. After adsorption for 1 h, cells were washed twice and incubated in fresh DMEM until
4, 8, and 24 hpi. For pp150 staining analyses, vim+ and vim- MEF were prechilled on ice
for 20 min before exposure to AD169 or TB40/E virions (MOI of 3) for 1 h on ice. Cells
were then transferred to 37°C for 1 h, washed three times with culture medium, and
further incubated for 4 and 8 h.

2.2.3

ACR treatment of HF

Confluent HF cultures were exposed for 2, 4, 6, and 8 h to a 5 mM ACR solution made
by diluting ACR/bis-ACR solution (30% [wt/vol]; Bio-Rad, Hercules, CA) in culture
medium. Uninfected cells were harvested immediately after ACR incubation or after
ACR removal, washing, and incubation in fresh medium for 4 h. For infection with
AD169 or TB40/E at an MOI of 1 or 5, ACR-pretreated cells were washed, exposed to
each virus for 1 h, washed again, and collected at 4 hpi.

2.2.4

Antibodies and immunoflourescence staining analysis

Cells were fixed, permeabilized, and blocked as described previously (36) before
incubation with monoclonal antibodies anti-human vimentin (1:200; V9; Santa Cruz
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Biotechnology, Santa Cruz, CA), anti-α-tubulin (1:100; B-5-1-2; Sigma, St. Louis, MO),
anti-pp150 (1:400; originally from W. Britt, Birmingham, AL), or anti-IE1/IE2 (1:500;
fluorescein isothiocyanate-conjugated MAb810F; Chemicon, Temecula, CA) for 1 h at
room temperature (RT). Samples were then washed in phosphate-buffered saline (PBS)–
0.05% Tween-20 and incubated with Alexa Fluor 594-conjugated anti-mouse
immunoglobulin G (1:100; Molecular Probes, Eugene, OR) for 1 h at RT. For dual
stainings, fixed cells were incubated with a primary antibody and with the Alexa Fluor
594-conjugated goat anti-mouse antibody, blocked with normal mouse immunoglobulin
G (1:100; Caltag, Burlingame, CA), and finally stained for IE1/IE2 with MAb810F.
Microfilaments were stained with a 1:100 dilution in PBS of Alexa Fluor 568-conjugated
phalloidin (Molecular Probes, Eugene, OR), and nuclei were labeled with a 0.2 mg/ml
dilution of Hoechst 33342 (Molecular Probes, Eugene, OR) in PBS for 3 min at RT.
Coverslips were mounted in 90% glycerol–10% PBS containing 2.5 g/liter of 1, 4
diazabicyclo-(2, 2, 2)-octane (DABCO; Alfa Aesar, Pelham, NH) and analyzed on a
Zeiss Axioskop 2 magneto-optical trap fluorescence microscope equipped with a
Qimaging Retiga 1300 coded monochrome 12-bit camera. Images were collected and
pseudo-colored using Northern Eclipse, version 7.0, software. Confocal images were
acquired on a Zeiss LSM 510 META ConfoCor2 laser-scanning confocal microscope
equipped with Zeiss LSM 510 META image processing software.
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2.3
2.3.1

Results
Virus entry does not alter vimentin IF structure

To determine whether the integrity of vimentin IF can impact viral entry, foreskin HF
infected with AD169 or TB40/E were harvested at 5 and 30 min and at 1, 2, and 4 hpi;
cells were stained with anti-vimentin and anti-IE1/IE2 antibodies and analyzed by
fluorescence microscopy (Fig. 2-1 and data not shown). In HF infected with AD169 at an
MOI of 5, nuclear IE1/IE2 staining was observed in about 10% of the cells as early as at
2 hpi (Fig. 2-1R), indicating that, by this time, AD169 entry had been successfully
completed, with the nuclear deposition of the viral genome and the onset of viral gene
synthesis. By contrast, IE1/IE2 expression was not detected in TB40/E-infected cultures
until 4 hpi (data not shown).

In mock-infected cells, vimentin filaments formed a dense, web-like network stretching
in all directions toward the cell periphery and forming a border around the nucleus (Fig.
2-1A to D). Cells infected with AD169 (Fig. 2-1E to X) or TB40/E (data not shown)
exhibited a staining pattern virtually identical to that of mock-infected cells at each of the
times tested, suggesting that vimentin IF did not undergo substantial modifications during
the initial phase of infection. At later times (24, 72, and 96 hpi), infected cells became
rounded and enlarged. Despite these morphological changes, the vimentin perinuclear
border and cytoplasmic network remained intact (data not shown).
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Parallel sets of samples were also stained for α-tubulin and for actin to determine the
effects of viral entry on the structure of microtubules and microfilaments. In AD169 or
TB40/E-infected cells, no microtubule disassembly was observed from 5 min to 4 hpi
(data not shown), consistent with the role of microtubules in facilitating capsid movement
toward the nucleus (64). During infection with AD169, microfilament depolymerisation
and stress fiber disappearance occurred in 2.6% ± 5% and 35% ± 20% of IE1/IE2-
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FIG. 2-1. Organization of the vimentin cytoskeleton during entry of AD169 in HF. Mockinfected (A to D) or AD169-infected (MOI of 5; E to X) HF harvested at 5 or 30 min
post-infection and at 1, 2, or 4 hpi were stained with a monoclonal anti-vimentin antibody
followed by an Alexa Fluor 594-conjugated goat anti-mouse antibody (red) and a
fluorescein isothiocyanate-conjugated anti-IE1/IE2 antibody (green). Nuclear DNA was
stained with Hoechst 33342 (blue). Merged images are shown in panels on the right.
Original magnification was 400× for panels A to D and 100 for panels E to X.
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expressing cells at 2 and 4 hpi, respectively. Interestingly, development of this phenotype
occurred later and to a lower extent in TB40/E-infected HF, with 5% ± 5% and 7.6% ±
5% of IE1/IE2-positive cells displaying loss of stress fibers at 4 and 8 hpi, respectively.
Together, these results indicate that microtubules and vimentin IF remain structurally
intact throughout the initial steps of infection with both strains, suggesting that the
integrity of both networks may be required during virus entry. Moreover, onset of
replication

and

microfilament

disassembly

in

TB40/E-infected

HF

occurred

approximately 2 h later than in AD169-infected cells, indicating a potential delay in the
initiation of TB40/E infection in HF.

2.3.2

AD169 and TB40/E kinetics of infection in HF are different

To directly compare the growth kinetics of AD169 and TB40/E in HF, confluent cell
monolayers were infected in parallel with AD169 or TB40/E at an MOI of 1 or 5. Cells
were harvested at 2, 4, 8, 24, 48, 72, and 96 hpi, and IE1/IE2 expression was monitored
by immunofluorescence staining analysis. Cell supernatants were also collected at 24, 48,
72, 96, 120, 144, and 168 hpi, and the amount of cell-free virus released during infection
was quantified by plaque assay. IE1/IE2 expression was detected in 16% ± 5% (MOI of
1) and in 7.4% ± 3% (MOI of 5) of AD169-infected HF at 2 hpi, with the percentage of
positive cells increasing with time up to 89% ± 8% (MOI of 1) and 97% ± 2% (MOI of 5)
at 96 hpi (Fig. 2-2A and B). By contrast, IE1/IE2 expression was not detected at 2 hpi in
TB40/E-infected HF (Fig. 2-2A and B) while at 4 hpi, approximately 10% of infected
cells
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FIG. 2-2. AD169 and TB40/E infection time course in HF. Cells and supernatants from
cultures infected with AD169 or TB40/E at an MOI of 1 (A and C) or 5 (B) were
collected at the indicated times postinfection. (A and B) Cells were stained for IE1/IE2,
and the percentage of expressing cells was calculated. Means and standard deviations of
the percentage values of IE1/IE2-positive cells scored in five separate fields per sample
in one representative experiment are shown. (C) Amount of cell-free virus released in
supernatants of AD169- and TB40/E-infected HF as quantified by plaque assay.
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displayed nuclear staining at either MOI. From 4 hpi onwards, the percentage of TB40/E
infected cells increased with time at a rate comparable to that of AD169-infected cells, so
that a 1.5- to 2-fold difference in the proportion of AD169- and TB40/E-positive cells
was maintained at each time, irrespective of the MOI used.

Consistent with this difference in the number of infected cells, the amount of cell-free
virus released in the supernatant of TB40/E-infected cultures was about 100-fold lower
than that released by AD169-infected cells at 72 hpi and about fivefold lower at 96 hpi.
At later times, yields became similar, mostly because of the drop in the AD169 virus
production (Fig. 2-2C). These data indicate that the onset of TB40/E infection in HF is
delayed compared to AD169 and that the initial difference in the proportion of infected
cells is maintained with time. Consequently, TB40/E-infected cells also released smaller
amounts of newly formed particles over time.

2.3.3

Pretreatment of HF with ACR inhibits the onset of infection

To determine whether the integrity of the vimentin cytoskeleton is required to facilitate
the onset of viral infection, HF were treated with a 5 mM ACR solution for 2, 4, 6, or 8 h
prior to infection with either AD169 or TB40/E. ACR is a neurotoxin that has been
extensively used to disrupt the organization of IF in neurons and in other cells types (2,
20, 21, 33, 75). ACR treatment of HF induced cell rounding and contraction,
accompanied by the aggregation of vimentin IF in elongated bundles extending into the
cells’ retraction fibers (Fig. 2-3A to E) (2, 20) and by the appearance of invaginations or
folds in the nuclear envelope (Fig. 2-3F). Consistent with literature reports (20, 47), actin
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stress fiber disassembly but no microtubule depolymerisation was detected in ACRtreated cells (data not shown). As the emergence of nuclear folds has been described to
occur in some vimentin null cells, in cells expressing vimentin mutants or containing
thick IF bundles, and in ACR-treated neurons (33, 43, 76, 78), we used the percentage of
cells with nuclear invaginations as an estimate of the extent of IF disruption. As expected,
an exposure time-dependent increase in percentage values was observed, from 1.5% ±
1% after 2 h to 32% ± 7% after 8 h of continual treatment (Fig. 2-3G). The number of
cells displaying nuclear folding became even larger after replacement of ACR with fresh
medium for 4 h (Fig. 2-3G), while incubation in fresh medium for 24 h led to the
complete reestablishment of the vimentin IF network and to the disappearance of nuclear
invaginations (data not shown), underscoring the reversible nature of ACR-induced
changes (2). ACR treatment also did not trigger widespread cell death, as the proportion
of cells displaying apoptotic nuclei never increased above 2% (Fig. 2-3H).

HF pretreated with ACR were infected with AD169 at an MOI of 1 or 5, and the
percentage of cells with nuclear invaginations or with apoptotic nuclei at 4 hpi was
determined. The extent of nuclear folding in samples infected at either MOI was similar
to that of uninfected cells treated with ACR and subsequently incubated for 4 h in fresh
medium (Fig. 2-3, compare panels I and G), suggesting that infection had no effect on the
formation of nuclear invaginations. By contrast, a slightly higher fraction of dead cells
was found after infection of ACR-treated cells, with the highest value (4.2% ± 3%)
observed after 8 h of pretreatment and infection at an MOI of 5 (Fig. 2-3J).
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The proportion of AD169-infected, untreated cells expressing IE1/IE2 was 28% ± 8% at
an MOI of 1 and 57% ± 14% at an MOI of 5 (Fig. 2-4A). ACR pretreatment led to a
marked decline in the proportion of IE1/IE2-positive cells. The extent of this decline was
dependent on the length of the pretreatment period, with a maximum reduction, relative
to untreated samples, of 12-fold (MOI of 1) and 14-fold (MOI of 5) in cells pretreated for
8 h.

The percentage of untreated HF expressing IE1/IE2 after infection with TB40/E was 11%
± 2% at an MOI of 1 and 13% ± 0.2% at an MOI of 5. In cells pretreated with ACR for 6
h, the proportion of IE1/IE2-positive cells had dropped to 0.6% ± 0.9% (19-fold
reduction; MOI of 1) and 1.2% ± 1.1% (11-fold reduction; MOI of 5) while in cells
pretreated with ACR for 8 h, no IE1/IE2 expression was detected (Fig. 2-4B). Thus,
pretreatment of HF with ACR significantly inhibited the onset of both AD169 and
TB40/E replication.

To assess the reversibility of inhibition, HF were either left untreated or were pretreated
with ACR for 4 h prior to ACR removal and exposure to AD169 or TB40/E at an MOI of
1. Removal of the virus inoculum was followed by extensive washing of cells to remove
unbound particles and by incubation in fresh medium for 4, 18, and 24 hpi. At 4 hpi, the
percentage of IE1/IE2- expressing cells in the pretreated samples was approximately 5fold (AD169) and 3.5-fold (TB40/E) lower than that of untreated cells at the same time
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FIG. 2-3. Effects of ACR pretreatment and AD169 infection on IF organization and
nuclear morphology in HF. (A to F) Fluorescence microscopy analysis of vimentin IF
organization in untreated HF (A) and in HF exposed to a 5 mM solution of ACR for 2
(B), 4 (C), 6 (D), or 8 h (E) prior to staining with antivimentin antibodies. (F) Confocal
microscopy image of lamin B-stained cell nuclei after 6 h of ACR pretreatment. (G and
H) Percentage of cells with nuclear invaginations (G) or with nuclear outlines consistent
with apoptosis (H) in HF monolayers harvested immediately after ACR treatment for the
indicated times (white bars) or harvested after ACR removal and incubation of cells in
fresh medium for 4 h (black bars). (I and J) Percentage of cells with nuclear invaginations
(I) or with apoptotic nuclei (J) in HF monolayers harvested after ACR treatment for the
indicated times and AD169 infection at an MOI of 1 (white bars) or 5 (black bars) for 4
h. Mean and standard deviation values from three independent experiments are shown.
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FIG. 2-4. Impact of ACR pretreatment on AD169 and TB40/E infection efficiency. (A
and B) Percentage of IE1/IE2-expressing HF either untreated (No ACR) or after exposure
to a 5 mM solution of ACR for 2, 4, 6, or 8 h prior to infection with AD169 or TB40/E at
an MOI of 1 or 5 for 4 h. (C and D) Percentage of IE1/IE2-expressing HF left untreated
(white bars) or treated with a 5 mM solution of ACR for 4 h (black bars) prior to
infection with AD169 or TB40/E at an MOI of 1. Mean and standard deviation values
from three (A and C) and two (B and D) independent experiments are shown.
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point (Fig. 2-4C and D). This result was expected, as the vimentin cytoskeleton remains
largely disorganized at 4 h after ACR removal (Fig. 2-3G). However, at 18 and 24 hpi the
proportion of IE1/IE2-positive nuclei in ACR-pretreated cells was similar or greater than
that of their untreated counterparts, indicating that the block in progression of the
infection was removed after the reestablishment of a normal vimentin cytoskeleton.

2.3.4

Vimentin bundling in HF from GAN patients reduces the
efficiency of infection

In addition to IF aggregation, ACR treatment of HF also caused stress fiber disassembly
(data not shown) and the development of nuclear invaginations (Fig. 2-3F) and was
reported to inhibit protein synthesis (2). Each of these effects might contribute to the
observed decrease in the percentage of infected cells. To assess the effects of vimentin IF
disruption on viral entry using a different system, we compared the efficiency of onset of
AD169 and TB40/E infection in dermal HF harvested from patients with GAN (WG0321
cells) and from healthy control subjects (MCH070 cells).

GAN is a neurodegenerative disorder characterized by bundling of IF in neurons and in
other cell types, including HF (67, 96). This phenotype can be conditionally induced in
vitro by exposing HF from GAN patients to low-serum conditions (48, 51). Serum
starvation for a period of 4 days induced vimentin bundling in 88.8% ± 2.9% of WG0321
cells but did not affect the IF network of MCH070 cells (Fig. 2-5A to F). IF alteration in
WG0321 cells was phenotypically different from that occurring in ACR-treated HF, with
the appearance of dense, spherical bundles of vimentin IF in specific areas of the cell and
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with peripheral filaments and nuclear contacts remaining unperturbed in the majority of
the cells. In addition, retraction fibers, nuclear invaginations, and microfilament or
microtubule depolymerisation were not observed (Fig. 2-5D to F and data not shown).
Serum-starved WG0321 and MCH070 cells were infected with either AD169 or TB40/E
at an MOI of 1 or 10, and the percentage of IE1/IE2-positive cells at 4, 8, and 24 hpi was
determined. At 4 hpi, 55% ± 16% (MOI of 1) and 78% ± 12% (MOI of 10) of AD169infected MCH070 cells showed IE1/IE2 expression (Fig. 2-5G, H, I, and K). These
percentages were slightly higher than those observed at 4 hpi in HF, likely on account of
the greater degree of quiescence reached by MCH070 cells after serum starvation. At the
same time point, a 3-fold (MOI of 1) and a 1.2-fold (MOI of 10) reduction in the
percentage of IE1/IE2-positive nuclei was observed in WG0321 cells (Fig. 2-5I and K).
By contrast, at 8 and 24 hpi, WG0321 and MCH070 cell populations contained equal
proportions of IE1/IE2-expressing cells at each MOI. These data suggest that vimentin
bundling in WG0321 cells may be detrimental to the onset of AD169 replication and that
this effect is both MOI and time dependent: smaller differences are observed between the
two cell populations after infection at an MOI of 10, and no differences are observed at
later time points postinfection.

No IE1/IE2-positive nuclei were detected at 4 hpi in TB40/E-infected WG0321 or
MCH070 cells at either MOI (Fig. 2-5J and L). At 8 and 24 hpi, however, both WG0321
and MCH070 cells expressed IE1/IE2, indicating that initiation of TB40/E replication
was delayed but not abrogated. Similar to the situation in HF (Fig. 2-2A and B), infection
of MCH070 with TB40/E yielded approximately 30 to 40% fewer IE1/IE2-positive cells
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than infection with AD169 at 8 and 24 hpi and at both MOIs, indicating that efficient
initiation of TB40/E infection is impaired in HF, regardless of their origin (foreskin or
dermis) and of the presence (HF) or absence (MCH070) of serum in the culture medium.
A 1.8-fold reduction in the proportion of IE1/IE2-positive nuclei was observed at 8 h
after TB40/E infection of WG0321 cells compared to MCH070 cells, irrespective of the
MOI used (Fig. 2-5J and L). At 24 hpi, the extent of this reduction appeared to decrease
slightly to 1.65-fold (MOI of 1) and 1.5-fold (MOI of 10), but was not eliminated as it
was for AD169-infected WG0321 cells.
Combined, these data indicate that the presence of vimentin bundles can directly or
indirectly impair the efficient onset of both AD169 and TB40/E replication. In contrast to
infection with AD169, the degree of impairment of TB40/E infection was MOI
independent, and the defect could not be corrected with time.
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FIG. 2-5. Structure of vimentin IF and expression of viral IE1/IE2 proteins in WG0321
and WG0321 dermal fibroblasts. (A to F) Serum-starved dermal fibroblasts from healthy
donors (MCH070) and from patients with GAN (WG0321) were stained for vimentin and
with Hoechst 33342. Merged images are shown as indicated. (G and H) Serum-starved
MCH070 (G) and WG0321 (H) dermal fibroblasts were infected with AD169 at an MOI
of 10 for 4 h prior to staining for vimentin (green) and for IE1/IE2 (red). (I to L)
Percentage of serum-starved MCH070 (white bars) and WG0321 (black bars) cells
expressing IE1/IE2 after infection with AD169 (I and K) or TB40/E (J and L) at an MOI
of 1 or 10. Mean and standard deviation values from three (I, K, and L) and two (J)
independent
experiments
are
shown.
ND,
not
detected.

84

85

2.3.5

Absence of vimentin impairs the onset of infection

To further investigate the role of vimentin on virus entry, immortalized vim+ and vimMEF were infected with AD169 or TB40/E at an MOI of 1 or 10, and the proportion of
IE1/IE2-positive cells at 4, 8, and 24 hpi was determined. MEF do not support human
CMV replication but allow normal entry events to proceed (49, 50), with the block in
infection occurring after IE gene expression. Consistent with literature data, IE1/IE2
expression was observed in MEF infected with either strain (Fig. 2-6), but the
percentages of IE1/IE2-positive cells were lower than those found in HF or MCH070 cell
populations, possibly as a result of the reduced degree of quiescence reached by
immortalized cells compared to primary HF. While the proportion of AD169-infected
vim+ MEF remained unchanged over time, a sudden increase in the number of TB40/Einfected vim+ MEF was observed between 8 and 24 hpi at each MOI.

At all times tested and at both MOIs, the percentage of IE1/IE2-expressing vim- MEF
infected with AD169 was markedly lower than that observed in vim+ MEF (Fig. 2-6 A
and C). The largest differences were recorded during infection at an MOI of 1, with
fivefold, fourfold, and threefold reductions at 4, 8, and 24 hpi, respectively. At an MOI of
10, differences appeared to be slightly reduced, to an average of 2.3-fold. Interestingly,
while the proportion of IE1/IE2-positive, vim+ cells remained fairly constant (Fig. 2-6A
and C,), the percentage of IE1/IE2-positive, vim- cells appeared to slowly increase with
time at both MOIs (Fig. 2-6A and C), suggesting that the onset of AD169 infection in
vim- cells was delayed but not abrogated.
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FIG. 2-6. Viral IE1/IE2 gene expression in vim+ and vim- MEF. Percentage of vim+
(white bars) and vim- (black bars) MEF expressing IE1/IE2 after infection with AD169
(A and C) or TB40/E (B and D) at an MOI of 1 or 10. Mean and standard deviation
values from two independent experiments are shown.
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Similar to what was observed in HF, the proportion of TB40/E-infected vim+ cells at
either MOI was about three- to fourfold lower than that of AD169-infected vim- cells
(Fig. 2-6, compare A to B and C to D). In addition, the absence of vimentin appeared to
have a larger impact on the onset of TB40/E infection, with 7- to 9-fold and 3- to 17-fold
reductions in the percentages of IE1/IE2-positive vim- cells observed at an MOI of 1 and
10, respectively (Fig. 2-6B and D). Finally, and contrary to infection with AD169, the
percentages of IE1/IE2-positive vim- cells appeared to steadily decrease with time during
TB40/E infection at both MOIs, an indication of abortive infection.

Together, these data show that the presence of vimentin is required for the efficient start
of both AD169 and TB40/E replication. While onset of AD169 infection in vim- cells is
initially delayed, it appears to recover with time. By contrast, TB40/E infection becomes
abortive, suggesting a larger degree of reliance on vimentin for the initial stages of
TB40/E infection.

2.3.6

Vimentin is required for proper viral particle trafficking

To assess whether vimentin affected intracellular capsid transport, virion localization was
tracked by staining AD169- or TB40/E-infected vim+ and vim- MEF for pp150, a
tegument phosphoprotein that remains strongly associated with capsids during entry and
that has been used as capsid marker in other studies (64, 81). At 1 hpi with AD169, the
pp150 signal was found predominantly at the cell surface and within the cytoplasm of
vim+ and vim- cells (Fig. 2-7A and B), and no obvious differences were found between
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cell types in the total numbers of particles per cell at 1 and 4 hpi. By 8 hpi, only few vim+
cells still contained particles while the pp150 signal was clearly evident in the cytoplasm
of several vim- cells (Fig. 2-7C and D). The number of pp150-positive, vim+ cells seemed
to decline with time much more rapidly than the number of pp150-positive, vim- cells,
suggesting that capsid disassembly and concomitant loss of the pp150 signal might occur
more rapidly in the presence of vimentin. To quantify this result, the percentage of
pp150-positive vim+ and vim- MEF was determined after infection with AD169 or
TB40/E at an MOI of 3 in synchronized infections. After virus adsorption at 4°C for 1 h,
cultures were shifted at 37°C for 1 h to allow for penetration to occur, then washed, and
further incubated for 4 and 8 h. The proportions of pp150-positive cells after virus
adsorption and penetration were virtually identical in all samples (Fig. 2-7E), indicating
that the absence of vimentin did not affect binding of either strain. After 4 h at 37°C,
however, the percentage of pp150-positive vim+ cells infected with AD169 was
dramatically lower than that of vim- cells (Fig. 2-7E). By 8 h, a slight additional decrease
in the percentage of particle-containing cells was observed in vim- cells (Fig. 2-7E). In
TB40/E-infected cultures, the proportions of virion-containing vim+ and vim- cells after 1
h at 37°C were almost identical, and no decrease relative to the percentage of pp150positive cells after virus adsorption for 1 h at 4°C was observed (Fig. 7E). This situation
remained unchanged in vim- MEF until the 8-h time point, when a decrease in the
percentage of cells with particles was registered. By contrast, vim+ cultures were
characterized by a more gradual decrease in pp150-positive cells over time. Thus, the rate
of pp150 signal loss in AD169-infected, vim+ cells was significantly faster than that in
TB40/E-infected, vim+ cells, suggesting that AD169 virions may be reaching the nucleus
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more rapidly than TB40/E virions. To assess if this was indeed the case, the proportion of
pp150-positive virions localizing at the cell surface, in the cytoplasm, or in close
proximity to the nucleus of infected cells at 1 h posttransfer at 37°C was calculated. In
vim+ cells infected with AD169, particles were equally distributed between the cytoplasm
and the nucleus while in vim- cells, virions accumulated in the cytoplasm (Fig. 2-7F). The
majority of virus particles were also found in the cytoplasm of vim+ and vim- cells
infected with TB40/E, supporting the hypothesis of a slower rate of intracellular
movement of TB40/E virions than of AD169 virions. In vim- cells, a slightly higher
proportion of TB40/E particles were also observed at the cell periphery, suggesting that
penetration of TB40/E capsids may also be delayed by the absence of vimentin.

2.4 Discussion
During entry, all viruses interact with components of the cellular cytoskeleton to reach
their appropriate intracellular sites of replication (71). The role of microfilaments and
microtubules in mediating transport of viral particles has been well established for several
viruses, including other herpesviruses (31, 55, 71). Although vimentin IF lack polarity
and do not directly participate in intracellular cargo movements, they are dynamically
integrated with microfilaments and microtubules and are important for infection with a
variety of viruses. Expression of vimentin at the cell surface allows for binding and
internalization of porcine reproductive and respiratory syndrome virus (44) while its
association with capsid components of the human immunodeficiency virus type 1 (88),
Theiler’s murine encephalomyelitis virus (62), and adenovirus type 2 (5) assists with
virus entry. Vimentin was shown to promote assembly of African swine fever virus, frog
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virus 3, and vaccinia virus by forming protective cage-like structures around the sites of
virion production (61, 72, 85), to enhance egress of bluetongue virus particles via
interactions with the outer capsid protein VP2 (18), and to be required for Junin virus
replication at a stage subsequent to entry but preceding viral protein synthesis (7). A
specific role for vimentin in entry of herpesviruses has not been described. Here, we
show that vimentin IF are likely to play a role during entry of two CMV strains with
different tropisms and that their degree of dependency on an intact vimentin cytoskeleton
correlates with the extent of tropism, possibly as a result of different entry mechanisms.
Like all herpesviruses, CMV replicates in the nucleus and requires virions to be actively
transferred from the cell membrane to the nuclear envelope at the start of infection. Entry
can occur by direct penetration across the plasma membrane or by macropinocytosis,
depending on the cell type and the virus strain (16, 79, 83). Both mechanisms require
fusion of the virus envelope with cellular lipid bilayers, and the subsequent transport of
capsids along cellular microtubules, whose structural integrity is maintained during entry.
Consistent with data from Arcangeletti et al. (4), our results show that the vimentin
cytoskeleton is not disassembled during the initial steps of CMV infection, suggesting
that maintenance of an intact IF network may be necessary for entry. Vimentin disruption
and reorganization are induced early during infection with a variety of viruses including
reovirus (77), respiratory syncytial virus (27), frog virus 3 (60), Thelier’s murine
encephalomyelitis virus (62), vaccinia virus (24), and adenovirus types 2, 5, 4, and 9 (6).
By contrast, IF connections are preserved in cells infected with herpes simplex virus type
1 (HSV-1) (63), equine herpes virus type 1 (91) and adenovirus types 3, 7, and 12, whose
particles are predominantly found within phagosomes (6), indicating that the requirement
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FIG. 2-7. Detection of virus particles in vim+ and vim- MEF. (A to D) Confocal
immunofluorescence images of AD169-infected MEF stained for pp150 at 1 and 8 hpi.
The pp150 signal is depicted in red while the green signal emanates from cellular
autofluorescence. (E) Percentage of AD169- and TB40/E-infected vim+ and vim- MEF
containing pp150-positive particles immediately after adsorption (black bars) and at three
different times postpenetration (dark gray, light gray, and white bars; times are indicated
at the top of the panel). A minimum of 110 cells were counted for each sample. Mean and
standard deviation values from separate cell fields in one representative experiment (out
of three) are shown. (F) Proportion of pp150-positive particles localizing at the cell
surface, in the cytoplasm, or at the nucleus in vim+ and vim- MEF infected with AD169
or TB40/E at 1 h postpenetration. Mean and standard deviation of values from eight
different cells per sample are shown. AD, AD169; TB, TB40/E.
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for an intact IF cytoskeleton may be shared among different herpesviruses and may be
relevant for entry via intracellular vesicles.

In contrast to IF, microfilament disassembly was evident by 2 hpi with AD169 and by 4
hpi with TB40/E. Binding of some herpesviruses to the cell surface triggers rapid
reorganization of the actin cytoskeleton (55), and actin depolymerization close to viral
particles was observed upon fusion of the Towne envelope with the plasma membrane
(42). Microfilament disassembly appeared to be beneficial for the onset of Towne and
AD169 infection (4, 42) as it likely facilitated virion transit across the actin-rich cell
cortex. By contrast, treatment with actin depolymerizing drugs inhibited uptake of HSV-1
particles in cells where entry by phagocytosis dominated over fusion at the plasma
membrane (14), pointing at a possible requirement for intact microfilaments to support
myosin VI-mediated transport of endocytic vesicles toward the cell center (9). Thus, the
difference we observed between AD169 and TB40/E in the timing of microfilament
depolymerization may potentially reflect two different mechanisms of entry of each strain
into HF, with fusion at the plasma membrane followed by immediate actin disassembly
being predominant for AD169 and endocytosis accompanied by delayed microfilament
reorganization being more common for TB40/E. AD169 virions contain the gH/gL/gO
complex, which mediates entry by fusion with the plasma membrane, but lack the
gH/gL/UL128-131A complex, which is required for entry by endocytosis (73, 74). By
contrast, TB40/E virions contain both gH/gL/gO and gH/gL/UL128-131A complexes
endowing TB40/E virions with the potential to enter HF either by fusion at the cell
surface, by endocytosis, or by a combination of both mechanisms.
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Onset of TB40/E infection was delayed by approximately 2 h relative to infection with
AD169, and this resulted in a similar delay throughout the time course of infection, with
the proportion of IE1/IE2-positive cells in TB40/E-infected monolayers remaining lower
than that in AD169- infected cells at each time and irrespective of the MOI used (Fig. 22A and B). These differences are likely to be due to slower and less efficient transport of
TB40/E particles, especially if TB40/E entry mechanisms require the generation and
intracellular movement of vesicles. Fusion of AD169 virions at the plasma membrane
may allow capsids to associate with microtubules in a rapid and efficient manner while
escape of TB40/E capsids from endosomes may require longer times. Although the
intracellular content of AD169 and TB40/E DNA in HF was reported to be
similar at 1.5 hpi (81), HF internalization of radiolabeled AD169 particles was found to
be more efficient than that of the clinical strain TR (73). The delay in TB40/E infection
onset was also reflected by the lower levels of cell-free virus produced by infected cells
at 72, 96, and 120 hpi although by 144 and 168 hpi AD169 and TB40/E yields had
equalized (Fig. 2-2C). To our knowledge, this is the first report directly comparing
growth of AD169 and TB40/E in HF. A 10-fold reduction in cell-free virus yields relative
to AD169 has been described for another clinical strain, VR1814 (1), while repair or
complementation of the UL131A gene mutation in AD169 reduced virus production in
HF (1, 92). It is thus conceivable that expression of UL131A might be detrimental for
efficient TB40/E production in HF, and additional functions encoded by genes mutated
during the process of AD169 adaptation to growth in HF may also contribute to the
phenotype we observed.
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Previous studies have shown that drug-mediated disassembly of microtubules inhibits
onset of infection by CMV (64), HSV-1 (63), and other viruses (31, 57, 71).
Microtubules and IF are closely connected; hence, chemical disruption of microtubule
networks also invariably leads to changes in the organization of IF, complicating the
separation of each system’s contribution. To dissect the role of vimentin IF during CMV
entry, we determined the efficiency of onset of AD169 and TB40/E infection in
fibroblasts with disrupted or absent IF.

ACR has been widely used to selectively and reversibly disrupt vimentin IF without
altering microtubule structures (2, 65, 75) and has been employed in studies addressing
the role of IF in Junin, bluetongue, and dengue virus replication (7, 13, 18). Treatment of
HF with ACR prior to infection with AD169 or TB40/E resulted in an exposure timedependent decrease in the percentage of infected cells (Fig. 2-4A and B), suggesting that
the integrity of vimentin IF is required for CMV entry. Changes in cell and nuclear
morphology and ACR-induced inhibition of protein synthesis may also have contributed
to reduce infection rates while the concomitant disassembly of actin stress fibers may
have affected the onset of TB40/E, but not of AD169 infection, as microfilament
disassembly facilitates entry of AD169 virions (4). By contrast, cell death was not
considered to be a significant factor as the percentage of cells with apoptotic nuclei
remained consistently low (Fig. 2-3H and J), and removal of ACR allowed for
resumption of infection (Fig. 2-4C and D). Intriguingly, infection recovery after ACR
removal suggests that viral particles are still capable of entering cells with disrupted
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vimentin IF. Perhaps in the absence of an extended vimentin cytoskeleton, virions remain
trapped in the cytoplasm or become unable to deposit the viral genome in nuclei with
membrane invaginations. Restoration of a proper IF cytoskeleton accompanied by the
disappearance of nuclear folding may then allow for viral particle trafficking and nuclear
genome deposition to resume.

To establish the role of vimentin IF during CMV infection in a setting that did not
involve exposure to pharmacological agents, IF bundling was induced in fibroblasts from
GAN patients by serum starvation. The phenotype of IF in GAN HF cultures was less
uniform than that in ACR-treated cultures, with some cells showing more prominent
bundling than others and with bundles localizing in distinct areas of each cell, leaving the
rest of the IF network fairly intact (Fig. 2-5F). Inhibition of AD169 infection in this
system appeared to be temporary and MOI dependent, which suggests that particles could
circumvent the obstacle represented by accumulated IF when given enough time or when
present in large amounts. By contrast, TB40/E infection was severely impacted, and the
percentage of infected cells did not substantially increase with time or at higher MOIs.
These results point again at possible differences in AD169 and TB40/E entry
mechanisms. As retrograde transport of endocytic vesicles is severely impaired in
neurons from GAN-null mice (19), it is tempting to speculate that transport of CMV
particles toward the nucleus may be preferentially delayed in GAN HF if capsids are
contained within endosomes rather than free in the cytoplasm following penetration at the
cell surface. A block in the endocytic route of infection is also less likely to be overcome
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by raising the MOI as the speed and direction of vesicle movements would still remain
the limiting factors even in the presence of numerous particles.

Both AD169 and TB40/E were able to infect MEF cells (Fig. 2-6), but as was observed
with HF cultures, the efficiency of onset of TB40/E infection in MEF was lower than that
of AD169, pointing at a possible conservation of entry mechanisms between human and
mouse HF. While the proportion of AD169- infected vim+ MEF remained stable from 4
to 24 hpi, an increase in the percentage of TB40/E-infected cells was observed at 24 hpi
at both MOIs. Intriguingly, the number of vim+ MEF containing AD169 particles
decreased very rapidly after penetration and remained stable at later times while the
reduction in the number of TB40/E-positive cells occurred much more gradually (Fig. 27). Combined, these results suggest that entry of AD169 is more rapid and efficient than
that of TB40/E, with prompt capsid trafficking and nuclear genome translocation
occurring in the majority of AD169-infected cells. By contrast, cytoplasmic movement of
TB40/E virions is lengthier, and, perhaps as a result of this delay, the percentage of cells
expressing IE1/IE2 increases only at later times in infection. Initiation of infection with
both strains in vim- MEF is dramatically hampered, particularly at low MOIs,
demonstrating that this protein is required for infection. Intriguingly, although the
absence of vimentin seemed to only reduce the speed of AD169 particle translocation, it
effectively blocked progression of TB40/E virions. Consequently, the proportion of
AD169-infected vim- cells still increased over time while TB40/E infection became
abortive, perhaps as a result of virion degradation in the cytoplasm. Viral DNA was

98

indeed reported to be eliminated from the cytoplasm of endothelial cells as a consequence
of failures in particle transport toward the nucleus and in nuclear genome deposition (82).

In summary, the efficiency of onset of CMV infection depends on the presence and
integrity of the vimentin cytoskeleton, which may facilitate virus entry at different steps.
As the proportions of vim+ and vim- pp150-positive cells were similar, a role for vimentin
as a CMV receptor at the cell surface is unlikely (Fig. 2-8, step a). Likewise, participation
of IF in uncoating of clathrin from endocytic vesicles (86) is not expected to impact
CMV entry (Fig. 2-8, step b), as clathrin-coated endosomes are too small to
accommodate CMV virions (79). By contrast, vimentin could promote capsid binding to
microtubules after entry at the plasma membrane (Fig. 2-8, step c), enhance
internalization of endocytic vesicles carrying virions bound to integrins (Fig. 2-8, step d),
or allow for rapid AP-3-mediated acidification of endosomes and concomitant
intracytoplasmic release of endocytosed virions (Fig. 2-8, step e). Finally, vimentin
interactions with the nuclear lamina (10) and with cellular DNA (89, 90) may increase
the speed of viral genome translocation across the nuclear envelope and of IE gene
transcription (Fig. 2-8, step f). Additional work will be needed to pinpoint the exact steps
during viral entry that require vimentin assistance. Based on the differences we observed
between AD169 and TB40/E, these will likely depend on the mechanisms of virus entry
and will require the engagement of different virion components encoded by each strain.
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FIG. 2-8. Hypothetical steps during CMV entry requiring vimentin assistance for
efficient completion. Vimentin IF and microtubules are shown as three parallel thin lines
and as thick gray lines, respectively. Black hexagons enclosed in a circle depict
enveloped virions while isolated black hexagons represent virus capsids. Steps are as
follows: (a) vimentin IF acting as receptors for CMV virions at the surface, (b) AP-3mediated involvement of vimentin IF in internalization of clathrin-coated endosomes, (c)
enhancement of capsid attachment and movement along microtubules via vimentin IF, (d)
internalization of integrin-bound virions under the control of vimentin IF, (e) AP-3mediated involvement of vimentin IF in endosome acidification and cytoplasmic release
of capsids, and (f) facilitation of nuclear genome deposition and of gene transcription
onset by nuclear lamina- and matrix-associated vimentin. MTOC, microtubule organizing
center.
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Chapter 3
CHARACTERIZATION OF THE 55 RESIDUE E1A PROTEIN
ENCODED BY SPECIES C HUMAN ADENOVIRUS
3.1 Introduction
HAdV belong to the family Adenoviridae. These viruses have been isolated from
vertebrates ranging from fish to humans. The first human adenoviruses were isolated in
1953 by independent groups searching for etiological agents responsible for acute
respiratory infections (19, 48). However, it was not until 1962, when Trentin and
colleagues discovered that HAdV-12 could cause tumors when injected into newborn
hamsters, that interest in the field exploded (56). This was the first demonstration of a
human virus that could cause cancer. Subsequent to that seminal observation, HAdV has
been used extensively to study fundamental biological processes ranging from regulation
of the cell cycle to mRNA splicing.
Later studies would reveal that genes encoded at the leftmost end of the HAdV genome
were responsible for its oncogenic capacity. E1A of HAdV type 2/5 encodes 5 proteins of
289, 243, 217, 171 and 55 R (Fig. 3-1A). These proteins are generated by differential
splicing of a single mRNA species. At the earliest stages of infection, E1A transcription
is controlled by a constitutive enhancer and expression of the largest two isoforms
dominates, with the smaller three isoforms accumulating later (42, 55). While the largest
two proteins have been studied extensively, no specific functions have been assigned to
the smallest three isoforms. The 289R and 243R E1A products are extensively
phosphorylated and these modifications are important for regulation of E1A function (11,

110

29, 62). E1A is sufficient to immortalize primary rodent cells when expressed alone (20),
and can transform these cells in cooperation with a second oncogene, such as E1B (14) or
activated Ras (49). During infection, the major functions of E1A include inducing the
host cell to enter S-phase and activating the transcription of downstream viral genes (4).
These functions of E1A are essential for efficient replication of HAdV (23, 52).
E1A does not exhibit DNA binding activity, and its ability to activate transcription is
mediated by its interaction with variety of cellular transcription factors and regulatory
proteins (39). 289R E1A activates transcription from early viral promoters as well as
wild-type, although 243R can also perform this function to a lesser degree (33-35, 46,
67). This difference in the ability to activate expression of viral genes is largely attributed
to CR3 which is present in 289R E1A, but absent in 243R E1A. By itself, CR3 functions
as a potent activation domain when fused to a Gal4 DNA-binding domain (31). Its ability
to activate transcription is dependent upon its association with the mediator complex via
direct interaction with MED23 (1, 7, 13, 30, 60). Interactions of CR3 with other cellular
proteins, including TATA box-binding protein (TBP) (27), the proteosome component S8
(45) and the acetyltransferase p300/CBP (40-41) also play an important role in CR3mediated transcriptional activation. Transcription from the E2 early promoter represents a
special case as it is induced in a specific, and indirect manner via 243R E1A-mediated
activation of the E2F family of transcription factors. The 243R E1A protein binds pRb,
thereby facilitating the release of E2Fs. Free E2Fs then bind to inverted sites located
within the E2 promoter to activate transcription (3, 25-26, 43, 71). The major late
promoter, which controls expression of the viral structural proteins, is active at a low
level at early times post-infection and expression increases several hundred fold at late
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times (51). Binding of E1A to Sp1 and MAZ transcription factors contributes to this
activation, but does not account for the delayed kinetics of expression from this promoter
(38).
Recruitment of APIS to early viral promoters by E1A enhances transcription of early
viral genes (45). The HAdV-5 289R and 243R E1A proteins and the HAdV-12 266R and
235R proteins can be immunoprecipitated with proteasomes (15). Amino acids 4-25
mediate binding of E1A to members of the 19S regulatory components of the
proteasome, human hSug1 (S8) and S4. Binding inhibits the ATPase activity of this
subunit which correlates with decreased proteasome activity (57). S8 is also recruited by
CR3 to enhance transcription of early viral genes. Interestingly, the 20S proteasome is
also recruited to CR3 independently of APIS and the 26S proteasome. E1A, S8 and the
20S proteasome are found on early gene promoters and sequences during infection and
thus, may be important in transcriptional initiation and elongation. In addition, inhibition
of proteasome activity represses E1A-dependent transcriptional activation, further
supporting the importance of this interaction during infection (45).
Despite the fact that no specific functions have been assigned to the smallest three E1A
proteins, the 55R isoform constitutes a particularly interesting case. Its function has
remained elusive despite the initial discovery of its mRNA species over 30 years ago (5).
This may be attributed, at least in part, to the fact that no existing E1A Abs are able to
recognize the 55R product. While 55R shares the first 26 amino acids encoded by exon 1
with the other E1A proteins, reconstitution of the splice junction linking exon 1 and exon
2 results in a frameshift relative to the other isoforms which results in a unique C-
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terminal amino acid sequence (10, 47, 59). The 55R mRNA species accumulates
preferentially at late times post-infection and seems to require replication of the viral
genome, since 55R mRNA species are only detected in HAdV-infected human HEK293,
and not in mock infected cells despite the integration of genomic E1A and constitutive
expression of 289R and 243R E1A in this cell line (8, 53-54, 59, 66). These properties
suggest that in addition to possibly binding targets which are known to interact with the
extreme N-terminus of the larger E1A isoforms, 55R E1A may also interact with unique
targets via its novel C-terminus region. Due to the late kinetics of 55R E1A expression,
these interactions may play important roles during the latest stages of HAdV infection.
Here, we characterize an antibody which specifically recognizes the 55R E1A protein
encoded by HAdV-2. This antibody can be used for detection of HAdV-2 55R E1A by
western blot, indirect immunofluorescence and immunoprecipitation. We report for the
first time a series of phenotypic and functional properties associated with 55R E1A. It is
primarily localized to the nucleus and is sufficient to promote virus growth in growtharrested IMR-90 fibroblasts. This may be due, in part, to the ability of 55R E1A to
activate transcription of viral genes with kinetics and magnitudes that are unique in
comparison to genomic E1A. Finally, we demonstrate that 55R E1A interacts with S8, a
member of the APIS complex, but not with S4. This is the first reported cellular target of
55R E1A. Knockdown of S8 was detrimental to virus replication, suggesting that this
interaction is functionally important during infection.

3.2 Materials and Methods
3.2.1 Cells and viruses
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HEK293, HEK293T, HT1080, A549 and IMR-90 cells were originally obtained from the
American type culture collection (ATCC). dl309 (expresses all E1A proteins) (23), dl312
(does not express any E1A proteins) (23), dl520 (does not express 289R E1A) (16), dl521
(expresses only 55R E1A) (16), pm975 (does not express 243R E1A) (34) and HAdV-2
have all been described previously. JM17-55R was constructed cloning the 55R E1A
coding sequence into pXC-Myc+ which had been digested with EcoRI and SalI to
remove the myc epitope tag. Recombinant virus was rescued by transfecting 5 µg of the
new plasmid, pXC-55R HAdV-2 E1A, into HEK293 cells along with 10 µg of pJM17
using a 1:14 DNA-to-Superfect (Qiagen) ratio. Virus was then plaque purified and
screened by sequencing of viral DNA. All cells were propagated in DMEM (Wisent)
supplemented with 10 % heat-inactivated FBS, 100U/ml penicillin and 100 µg/ml
streptomycin (all from Gibco). All viruses were grown on either HEK293 or A549 and
were purified using cesium chloride gradient, as described previously (68).

3.2.2 Cell transfections and infections
To analyze the kinetics of 55R E1A mRNA and protein expression, A549 cells were
infected with HAdV-2 at an MOI of 1. Samples were collected at 24, 48, 72, 96 and 120
hpi to analyze the kinetics of E1A mRNA expression. For analysis of protein expression,
samples were collected at 6, 24, 48 and 72 hpi.
For virus replication assays, IMR-90 cells were seeded in 6-well dishes and were growth
arrested by contact inhibition for 3 days after reaching confluency. For single-virus
infections, cells were infected with either dl309, pm975, dl520, dl521 or dl312 at an MOI
of 5 and were then incubated at 37° C, 5 % CO2 for 1 h to permit adsorption. Cells were
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washed 5 times with PBS and were re-incubated with fresh medium. For growth assays,
supernatants were collected at 4, 48 and 120 hpi and the titre of cell-free virus was
assessed by plaque assay on HEK293 cells. For analysis of viral gene expression, cells
were collected at 24, 48, 72, 96, 120 and 144 hpi. Virus co-infection replication assays
were performed in a similar manner, with growth arrested IMR-90 cells being infected
with either pm975 + dl521, pm975 + dl312, dl520 + dl521 or dl520 + dl312 at an MOI of
5 per virus.
For transfections, HT1080 and HEK293T cells were seeded on glass coverslips at a
density of 5 × 104 cells/cm2 one day prior to transfection with Superfect (Qiagen)
according to manufacturer's guidelines.
siRNA knockdown of S8 was performed in A549 seeded at 5 × 104 cells/cm2 using
siLentFectTM (Bio-Rad) transfection reagent and 10 nM PMSC5 Silencer® Select siRNA
(Ambion). A second set of cells were treated with siRNA Control #2 (Ambion).
Following a 12 h incubation, cells were infected with either dl521 or dl312. Supernatants
were collected at 24 and 96 hpi and virus yield was determined by plaque assay on
HEK293 cells.

3.2.3 mRNA isolation and qRT-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen) and was subjected to first
strand cDNA synthesis using Superscript II reverse transcriptase (Invitrogen) and a
mixture of random hexamers and oligo(dT)20, according to manufacturer's instructions.
qRT-PCR was performed using EXPRESS SYBR GreenER qPCR supermix (Invitrogen)
on a Bio-Rad iQ5 iCycler according to manufacturer's guidelines. E1B 2.2 kb, E3A, E4
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orf6/7 (45), E2 (2) and hexon (24) were amplified using primers described previously.
GAPDH was amplified using the forward primer CCTGGCCAAGGTCATCCATGAC
and the reverse primer TGTCATACCAGGAAATGAGCTTG. Conventional RT-PCR
was performed using PCR-EZ D-PCR Master Mix (Bio Basic Inc.). E1A species were
amplified using the forward primer CCACGGAGGTGTTATTACCG and the reverse
primer TCAGGATAGCAGGCACCAAT. 55R E1A was detected using the forward
primer

AATGAATTCTTGGACCAGCTGATCGAAGAGG

and

reverse

primer

GATCCTTATGGCCTGGGGCGTTTACAGCTCAAG.

3.2.4 Plasmid construction
pLE-9S and pEGFP-N1 were kind gifts of E. Moran and J. Torchia, respectively. All
ligations were performed using T4 Ligase (NEB) according manufacturer's instructions.
To construct pCANmycEGFP-55R, HAdV-2 55R-EGFP was cut out of pEGFP-55R
using NcoI and XbaI. Overhangs were filled in using the Klenow fragment from E. coli
DNA polymerase I (NEB) and the insert was ligated into the BamHI site of pCANmyc
that had also been blunted using the Klenow fragment. pEGFP-N1-9S was constructed by
PCR of HAdV-2 55R E1A from pCANmycEGFP-55R using the forward primer
ATCTCGAGATGAGACATATTAT, which contains a BamHI restriction site and the
reverse primer GTGGATCCTTGGATAGCAGG, which contains an XhoI restriction site.
The insert and vector (pEGFP-N1) were each digested with BamHI and XhoI and were
then ligated together. pCANmyc-55R was constructed by cloning 55R hAdV-2 E1A inframe with the N-terminal myc tag of pCANmyc. GST-55R/53R E1A fusions were made
by cloning the 55R E1A proteins from HAdV-2 and HAdV-5, as well as the 53R E1A
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protein of HAdV-12 into the EcoRI/SalI sites of pGEX 4T1. PCNA4-HA-S8 and
PCNA4-HA-S4 have been described previously (45).

3.2.5 Generation of anti-55R E1A Abs
Polyclonal rabbits Abs were generated against a peptide corresponding to the unique Cterminal region of HAdV-2 55R E1A: KYG-43-NRSLQDLPGVLNWCLLS-55. The
peptide was coupled to keyhole limpet hemocyanin (KLH) using bis-diazobenzidine. 5
mg of peptide was conjugated to 5 mg of KLH. The KLH-peptide conjugate was injected
subcutaneously into female New Zealand White rabbits. Each rabbit was injected at four
sites with 100 ug at each site. Before injecting, the KLH-peptide conjugate was
emulsified with Freund's Complete Adjuvant for the initial inoculation and with Freund's
Incomplete Adjuvant for subsequent injections. The rabbits were injected at three week
intervals and test bleeds were taken 10 days following the preceding injection.
Antibody reacting against the peptide was affinity purified using a peptide column that
was prepared by conjugating 5 mg of peptide to 6 mls bed volume of Affi-gel 10
(BioRad) via hydroxysuccinimide linkage. The serum was diluted two-fold in Trisbuffered saline (TBS) and then passed twice over the affinity column. The column was
washed and then eluted with 100 uM glycine, pH 2.2 and the eluted antibody was
dialysed against TBS. The antibody was initially tested against sequential dilutions of the
peptide spotted onto nitrocellulose. The rabbits underwent a total of eight injections.

3.2.6 Protein purification
pGEX4T1-HAdV-2-55R, pGEX4T1-HAdV-5-55R and pGEX4T1-HAdV-12 53R were
expressed in E. coli RIL (Stratagene) and were purified using standard methods.
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3.2.7 Immunoprecipitation, GST-pulldown and immunoblot analysis
For immunoprecipitation experiments, HEK293T or A549 were lysed in NP-40 lysis
buffer (0.5 % NP-40, 50 mM Tris pH 7.8, 150mM NaCl) supplemented with protease
inhibitor cocktail (Sigma). One microgram of anti-GFP mAb (Clontech) was used for
immunoprecipitation of EGFP-55R in combination with 125 µl of 10 % protein Asepharose resin (Sigma) from 0.5 mg of cell lysate. Samples were agitated for 1 h at 4 °C.
Beads were washed five times with lysis buffer and samples were boiled in 1x lithium
dodecyl sulfate (LDS) sample buffer for 5 min. Samples were separated on a sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and were transferred
onto a polyvinylidene difluoride (PVDF) membrane (GE Healthcare). Membranes were
blocked in 5 % nonfat milk in 1x Tris-buffered saline with 0.1 % Tween-20.
For western blots, cells were lysed in NP-40 lysis buffer and were then boiled in sample
buffer and treated as described above. Membranes were stripped by heating in a 2 M
glycine buffer, pH 2.2 with 0.5 % SDS. Ponceau staining was performed according to
standard protocols.
GST pulldowns were performed using 0.25 µg of GST-55R E1A and 0.5 mg of lysate
from HEK293T or A549 cells that had been transfected with constructs expressing HAS8, HA-S4 or were left untransfected. Samples were agitated for 1 h at 4 °C with 12.5 µl
of glutathione sepharose 50 % slurry and were then treated as described for
immunoprecipitation experiments. HA-S8 and HA-S4 were detected using rat anti-HA
mAb (1:2000, 3F10, Roche). EGFP was detected using anti-GFP mAb (1:2000,
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Clontech). 55R E1A was detected using custom rabbit polyclonal anti-HAdV-2 55R E1A
antibodies (1 µg/ml).
Secondary antibodies used included goat anti-mouse IgG (1:200 000, Jackson Labs), goat
anti-rabbit IgG (1:200 000, Jackson Labs) and goat anti-rat IgG (1:20 000, Pierce); all
were conjugated to horseradish peroxidase. Membranes were incubated with ECL+
substrate (GE Healthcare) for 1 min prior to exposures.

3.2.8 Immunofluorescence microscopy
All cells were seeded on coverslips in 24-well tissue culture dishes and were fixed in 3.7
% paraformaldehyde (Fisher) for 30 min at room temperature. After washing in PBS,
cells were permeabilized on ice using 0.2 % Triton X-100 (Biobasic) for 20 min.
Coverslips were transferred to humidity chambers and were blocked using 10 % FBS in
PBS (blocking buffer, BB) for 30 min at room temperature. Cells were incubated at room
temperature for 1 h with anti-55R E1A rabbit polyclonal Abs (1:50), anti-E1A mAb M73
hybridoma supernatant (neat) and/or anti-myc (9E10 hybridoma supernatant, neat)
primary Abs. After washing 3x with BB, cells were incubated for another hour at room
temperature with with Alexa Fluor® 546 goat anti-mouse IgG, Alexa Fluor® 594 goat
anti-rabbit IgG and/or Alexa Fluor® 488 goat anti-mouse IgG (all from Molecular
Probes). Finally, cells were washed 3x with PBS and nuclei were labeled with 0.2 mg/ml
Hoechst 33342 (Molecular Probes) for 3 min at room temperature. Cells were washed
three more times and coverslips were then mounted on glass microscope slides using
mounting media consisting of 90 % glycerol (Biobasic), 10 % PBS and 2.5 g/litre 1,4diazabicyclo(2,2,2)octane (DABCO, Alfa Aesar). Imaging was performed using a Zeiss
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Axioskop 2 magneto-optical trap fluorescence microscope equipped with a QImaging
Retiga 1300-coded monochrome 12-bit camera. Images were captured and pseudocolored
using Northern Eclipse version 7.0 software. Confocal images were acquired using a
Zeiss LSM 510 META confocal laser scanning microscope equipped with Zeiss Zen
imaging software for analysis.

3.3 Results
3.3.1 Characterization of anti-55R E1A polyclonal Abs
Despite discovery of the putative 55R E1A product of species C HAdV over 30 years
ago, the protein itself has never been detected or systematically characterized in the
context of infection. This is due, in part, to the fact that none of the existing Abs which
recognize various epitopes of E1A from species C HAdV are able to detect the 55R
isoform. To address this issue, we generated rabbit polyclonal antibodies which
specifically recognize the 55R E1A species of subgroup C HAdV.
A peptide was synthesized corresponding to residues 43-55 of the unique C-terminal
region of HAdV-2 (KYG-43-NRSLQDLPGVLNWCLLS-55). This peptide was coupled
to keyhole limpet hemocyanin and was used to immunize rabbits. Antibodies were
affinity purified from rabbit serum and specificity was demonstrated by dot blot assay
using the immunizing peptide (data not shown). In order to determine the breadth of
specificity of the affinity purified Abs, a western blot was performed against purified
GST-55R E1A from HAdV-2 and HAdV-5, as well as the equivalent 53R E1A isoform
of HAdV-12. Interestingly, the antibody demonstrated exquisite specificity for 55R E1A
from HAdV-2, but was unable to detect the 55R E1A protein from HAdV-5 (Fig. 3-1C),
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a closely related species C HAdV with only 3 non-identical amino acids located in the Cterminus of the protein (Fig. 3-1B). The Abs were also unable to recognize the 53R E1A
protein of HAdV-12, a more divergent species A HAdV, or GST alone (Fig. 3-1C).
We next sought to determine whether the Abs could be used to immunoprecipitate
HAdV-2 55R E1A. To do this, lysates were prepared from HEK293T cells expressing
EGFP-55R E1A, EGFP alone or from mock transfected cells. Lysates were then
incubated with polyclonal anti-55R E1A Abs along with protein A-sepharose beads.
After washing the beads thoroughly and boiling them with LDS sample buffer, proteins
were separated by SDS-PAGE and were transferred to a PDVF membrane. A band
corresponding to the molecular weight (MW) of EGFP-55R E1A appeared only in the
sample from EGFP-55R E1A-expressing cells when the membrane was probed with anti55R E1A polyclonal antibodies or anti-GFP mAb (Fig. 3-1D). Thus, the polyclonal anti55R E1A Abs can likely recognize both native and denatured HAdV-2 55R E1A.
Finally, we aimed to determine whether our anti-55R E1A Abs could be used to study the
subcellular localization of 55R E1A by indirect immunofluorescence. HT1080 cells were
either mock transfected (data not shown) or were transfected with a construct which
expressed myc-55R. 24 h post-transfection, cells were fixed and stained using anti-55R
E1A and anti-myc followed by Alexa Fluor® 594 goat anti-rabbit IgG or Alexa Fluor®
488 goat anti-mouse IgG. Samples were analyzed by confocal microscopy and
colocalization of signal was observed only in cells expressing myc-55R E1A (Fig. 3-1E),
demonstrating that the Ab could also be used for determination of the subcellular
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FIG. 3-1. Characterization of 55R E1A polyclonal antibodies. A) Graphical depiction of
the mRNA species generated by splicing of the primary E1A transcript. B) Amino acid
sequence comparison of the proteins encoded by the 9S mRNA species of HAdV-2,
HAdV-5 and HAdV-12. Amino acids which differ between HAdV-2 and HAdV-5 are
denoted in red. C) Western blot of GST-purified 55R E1A (or 53R E1A, in the case of
HAdV-12) using our custom rabbit polyclonal anti-55R E1A Abs. D) EGFP-55R E1A
was immunoprecipitated from HT1080 cells using custom rabbit polyclonal anti-55R
E1A Abs. e) Indirect immunofluorescence images of HT1080 cell expressing myc-55R
E1A, stained with an anti-myc Ab and anti-55R E1A polyclonal Abs. Nuclei were stained
with Hoechst 33342.

122

localization of 55R E1A. 55R E1A could be found in both the nucleus and cytoplasm of
these cells, similar to what has been described for the larger E1A isoforms (12, 28).

3.3.2 55R E1A is Expressed at Late Times Post-Infection and is
Localized Mainly to the Nucleus
Although several studies have reported the kinetics of 55R E1A expression at the mRNA
level, the expression kinetics of the protein itself have never been investigated (8, 53-54,
58-59, 66). Indeed, prior to this study, the 55R E1A protein has never been detected in
the context of infection. To examine the relationship between 55R E1A mRNA
expression and expression of the 55R E1A protein, A549 cells were infected with HAdV2 at an MOI of 1. Kinetics of E1A mRNA expression were first examined by RT-PCR in
order to verify the results of earlier studies under our specific experimental conditions.
Expression of 13S and 12S mRNA could be detected at 24 hpi and increased from 48 to
96 hpi. Expression of 11S and 10S mRNA was detectable from 48 to 120 hpi, with
maximal expression at 96 hpi. The 9S E1A mRNA species could also be detected from
48-120 hpi, with maximal expression occurring at 96 hpi (Fig. 3-2A). The reduced
abundance of all mRNA species at 120 hpi is likely due to both cell death (which was
observed at this stage of infection) as well as the end of one round of viral replication and
the beginning of a second round of infection in previously uninfected cells. These results
closely matched those found in previously published reports (58-59).
Next, we analyzed samples prepared in parallel for expression of E1A proteins by
immunofluorescence microscopy. Using the M73 antibody, which recognizes the Cterminal region encoded by exon 2 of all E1A products except 55R E1A, expression of
E1A protein could begin to be detected as early as 6 hpi. This increased up to 24 hpi and
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then stayed relatively consistent. Conversely, expression of 55R E1A could be detected
only faintly and in very few cells starting at 24 hpi, with expression increasing up to 72
hpi (Fig. 3-2B). These results are consistent with 55R E1A expression occurring
primarily at late times post-infection, as suggested by the kinetics of 9S mRNA species.
Importantly, this is the first time that 55R E1A has been detected in the context of viral
infection. Interestingly, 55R E1A seems to be localized mainly in the nucleus, similar to
the larger E1A isoforms, despite the fact that it lacks the nuclear localization signal
present in these proteins (Fig. 3-2B). These results show for the first time that like the 9S
E1A mRNA, 55R E1A protein is expressed preferentially at late times post-infection and
appears to be present mainly in the nucleus of infected cells.

3.3.3 55R E1A activates expression of viral genes
Given the kinetics of 55R E1A expression and its localization in the nucleus, we sought
to assess whether, akin to the largest E1A isoforms, 55R E1A could transactivate viral
genes. To accomplish this, we performed a qRT-PCR assay on growth-arrested IMR-90
cells infected with dl309, JM17-55R, dl521 and dl312 using primers which recognize
transcripts expressed from selected viral promoters (2, 24, 45). RNA was extracted from
contact inhibited IMR-90 fibroblasts which had been infected with the viruses mentioned
above for 24, 48, 72, 96,
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FIG. 3-2. Determination of 55R E1A mRNA and protein expression kinetics in A549
cells. A549 cells were infected with HAdV-2 at an MOI of 1. A) Cells were collected at
24, 48, 72, 96 or 120 hpi for RT-PCR analysis of each E1A mRNA species. GAPDH was
also analyzed as a loading control. B) Cells were grown on coverslips and were collected
and fixed at 6, 24, 48 and 72 hpi. The larger E1A isoforms were labeled with the
monoclonal E1A Ab M73, while 55R E1A was labeled with custom rabbit polyclonal
anti-55R E1A Abs. Nuclei were stained with Hoechst 33342.
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120 or 144 hpi. All samples were normalized internally to GAPDH and viral gene
expression was compared to that observed for dl312-infected samples.
dl309, which expresses all E1A isoforms, induced expression of E1B approximately
10,000-fold relative to dl312 at 24 hpi. The level of transactivation induced by dl309
reached a maximum of approximately 317 000-fold by 120 hpi. In comparison, JM1755R, which constitutively expresses only 55R E1A, resulted in only a 52-fold induction
of E1B expression relative to dl312 24 hpi, with no appreciable increase as the infection
progressed. In correlation with the expected expression kinetics of 55R E1A, the levels of
E1B steadily increased during dl521 infection (harbors genomic E1A and splices only
55R E1A) up to a maximum of 165-fold at 72 hpi (Fig. 3-3A). Thus, 55R E1A is able to
induce expression of E1B to a modest extent when compared to wild-type E1A. In
addition, the maximal degree of induction remains consistent whether 55R E1A is
expressed constitutively from cDNA or requires splicing of the primary E1A transcript.
The E2A transcript was induced later and to much lower levels compared to E1B during
dl309 infection. This was expected based on the indirect mode of E2 promoter activation
by E1A (3, 25-26, 43, 71). At 72 hpi, E2A was induced approximately 5-fold compared
to dl312 infection. This level of induction remained relatively consistent until 144 hpi.
During infection with viruses expressing 55R E1A only, E2A levels did not reliably
increase above those observed in dl312 until 144 hpi and even then expression only
reached 2- to 4-fold above background (Fig. 3-3B).
Levels of E3A expression during dl309 infection ranged from approximately 26 000-fold
at 24 hpi to 1.2-million fold at 48 hpi. Induction of E3A expression was much more
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modest during infection with 55R E1A-expressing viruses. At 24 hpi, E3A was induced
only 2- and 10-fold by JM17-55R and dl521, respectively. Maximum E3A induction
reached 4000-fold at 96 hpi during dl521 infection and 2900-fold at 120 hpi during
JM17-55R infection. Again, both the kinetics and magnitude of E3A expression differed
during infection with 55R E1A-expressing viruses when compared to dl309, expressing
wildtype E1A (Fig. 3-3C).
Unlike E3A, which was induced to much higher levels at 24 hpi by wildtype E1A virus
than those expressing only 55R E1A, E4orf6/7 levels were comparable among all three
viruses tested at this time point and were around 50-fold higher than those observed
during dl312 infection. In this case, the kinetics of transcript expression were also similar
among all three viruses and peaked at 120 hpi, although by this point transcript levels in
dl309-infected cells were over three logs higher than those observed in cells infected with
JM17-55R or dl521 (Fig. 3-3D).
Finally, transactivation of the MLP was read out by assessing the levels of hexon mRNA
expression induced by each virus. During dl309 infection, hexon transcript levels
progressively increased from 46-fold above dl312 at 24 hpi to a maximum of 424 000fold above dl312 at 120 hpi. In comparison, hexon was induced only 7-fold by JM17-55R
at 24 hpi, and not at all by dl521. By 96 hpi, dl521 had reached its maximum degree of
hexon expression at 24 000-fold greater than dl312, while induction by JM17-55R
reached a plateau of 800- to 900-fold at 96 and 120 hpi, respectively (Fig. 3-3E).
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FIG. 3-3. Transactivation of viral genes by 55R E1A. A-E) Contact-inhibited primary
IMR-90 fibroblasts were infected with dl309, JM17-55R, dl521 or dl312 at an MOI of 5.
Cells were collected at 24, 48, 72, 96 or 120 hpi. Samples were subjected to qRT-PCR
analysis using primers specific to transcripts controlled by various HAdV promoters
including A) E1B, B) E2A, C) E3A, D) E4orf6/7 or E) Hexon. All samples were
normalized internally to GAPDH and then to the levels of gene expression observed in
dl312-infected cells using the ∆∆CT method.
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Taken together, these results show that 55R E1A is able to transactivate the expression of
viral genes. This was true in the case of both dl521, which contains genomic E1A but
splices only the 9S product, and of JM17-55R, which carries 55R cDNA in an E1Adeleted background. In each case, the levels of viral gene expression observed were
distinct (and usually several log-fold lower at peak expression) from that of virus
harboring wildtype E1A, as were the kinetics of gene expression. The ability of 55R E1A
to transactivate viral genes is particularly interesting in light of the fact that 55R E1A
does not contain any of the CRs present in the larger E1A isoforms. Further elucidation
of the mechanism through which 55R accomplishes this feat will be of great interest.

3.3.4 55R E1A is sufficient to promote replication of HAdV in
Contact-Inhibited IMR-90 fibroblasts
The observation that 55R E1A was able to transactivate expression of viral genes led us
to investigate whether this E1A isoform could also promote virus growth when expressed
alone in an E1A-deleted virus background. Contact-inhibited IMR-90 cells were infected
with dl309, pm975, dl520, JM17-55R, dl521 or dl312 at an MOI of 5. Supernatants were
collected at 4, 48 and 120 hpi and the yield of cell-free virus was assessed by plaque
assay on HEK293 cells. In samples collected at 4 hpi, no more than 40 plaque-forming
units (pfu/ml) were ever present and there was no significant difference between dl312
and the viruses expressing various E1A proteins. Since growth was measured as foldchange relative to dl312 (E1A-deleted virus), this demonstrated that washing of cells 1 h
after adsorption efficiently removed residual virus particles and ensured that virus yield at
later times was due to de novo virus replication (data not shown).
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As expected, dl309 grew best on the contact-inhibited IMR-90 fibroblasts, followed by
pm975. To our surprise, JM17-55R produced approximately 7-fold more virus than dl520
at 48 hpi, while at 120 hpi this trend was reversed, with dl520 producing about 14-fold
more virus than JM17-55R. dl521 grew to titres which closely resembled those reached
by dl520 at both 48 and 120 hpi. Most importantly, viruses expressing only 55R E1A
consistently exhibited a 30- to 2800-fold growth advantage compared to E1A-deleted
virus, demonstrating that on its own, 55R E1A was sufficient to promote replication of
HAdV in contact-inhibited IMR-90 (Fig. 3-4A). Therefore, not only can 55R E1A
transactivate expression of viral genes, it is also sufficient to promote viral replication.
Due to the genetic organization of genomic E1A, it was not possible to construct a virus
that lacks expression of only 55R E1A without inducing mutations in the other E1A
isoforms. Such a strategy runs the serious risk of confounding the interpretation of results
gathered from this type of approach due to the large numbers of proteins with which E1A
interacts. Nevertheless, it was important to evaluate the impact of 55R E1A on virus
growth in the context of the two major E1A isoforms, 289R and 243R. To accomplish
this, we made use of a co-infection model, whereby growth arrested IMR-90 fibroblasts
were infected with either pm975 or dl520, in combination with either dl521 or the E1Adeleted dl312. Cells were infected with each virus at an MOI of 5, for a total MOI of 10.
In combination with a virus expressing 289R E1A (pm975), co-infection with dl521 only
moderately improved virus yield compared to co-infection with dl312. However, coinfection of dl521 with a virus expressing only 243R E1A (dl520) resulted in 1-log
growth increase relative to co-infection with dl312 at 48 hpi. This improved to a 2-log
increase by 120 hpi (Fig. 3-4B). It is important to note that both pm975 and dl520 can, on
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their own, produce 55R E1A. Thus, these results suggest that in combination with 289R
E1A, endogenous levels of 55R E1A are sufficient to maximize virus replication in
contact-inhibited IMR-90. However, in the context of 243R E1A, additional 55R E1A
provided by co-infection with dl521 has a growth-promoting effect which implies a
unique mechanism for the replication-promoting phenotype exhibited by 55R E1A.
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FIG. 3-4. Replication of viruses expressing 55R E1A in contact-inhibited IMR-90 cells.
A) Contact-inhibited primary IMR-90 cells were infected with dl309, pm975, dl520,
JM17-55R, dl521 or dl312 at an MOI of 5. Supernatants were collected at 4, 48 or 120
hpi and cell-free virus titres were determined by serial dilution on HEK293 cells. B)
Contact-inhibited primary IMR-90 fibroblasts were infected with pm975 and dl312,
pm975 and dl521, dl520 and dl312 or dl520 and dl521. Supernatants were collected at 4,
48 and 120 hpi and the titres of cell-free virus were assayed as described in A).
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3.3.5 55R interacts with the S8 component of the 19S regulatory
proteasome
Interaction of the major E1A isoforms with the APIS complex has been demonstrated
previously and is known to be important in the ability of E1A to enhance transcription of
early genes (45). Binding of E1A to the S4 and S8 components of APIS was initially
mapped to amino acids 4-25 on the E1A protein (57). Later studies would show that S8
could also be recruited by CR3 (45). In light of the fact that 55R E1A shares homology to
the larger E1A isoforms in its first 28 amino acids, we sought to determine whether it too
could interact with components of APIS and whether this interaction was important for
its ability to enhance virus replication.
To determine whether 55R E1A could interact with S4 and/or S8, A549 cells were
transfected with a construct expressing either HA-S4, HA-S8 or were mock transfected as
a control. Lysates from these cells were incubated with GST-purified HAdV-2 55R E1A
which was pulled down with glutathione sepharose beads. Quite interestingly, we
observed an interaction of GST-55R E1A with HA-S8, but not with HA-S4 (Fig. 3-5A).
To confirm whether this interaction occurred in a more natural setting, we also
cotransfected A549 cells with constructs expressing 55R-GFP or GFP alone with
constructs expressing HA-S8. Indeed, 55R-GFP was able to pull down HA-S8, whereas
GFP alone could not (Fig. 3-5B).
To determine whether this interaction had functional consequences in the context of virus
replication, we knocked down endogenous S8 in A549 cells using validated siRNA
directed against S8. We infected cells with either dl312 or dl521 and normalized dl521
growth to that observed using dl312 in cells treated with siRNA directed against S8
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(siS8) or a scrambled siRNA control. This allowed us to control for any non-specific
effects of S8 knockdown on virus growth. Interestingly, at 48 hpi dl521 growth in cells
treated with siS8 was reduced 2-fold compared to cells treated with control siRNA (Fig.
3-5C). This led us to conclude that the interaction of 55R E1A with S8 is functionally
important in the ability of 55R E1A to promote virus replication. While the specific
mechanism for the replication-promoting phenotype of the 55R E1A-S8 interaction
remains to be elucidated, it is likely that it is important in the ability of 55R E1A to
transactivate viral genes, analogous to the larger E1A isoforms.

3.4

Discussion

Despite discovery of the 9S mRNA species over 30 years ago, the protein that it encodes,
as well as the function of that protein has remained completely elusive. Early studies
successfully demonstrated that the 9S mRNA product is processed preferentially at late
times post-infection, and that this shift in splice site preference seems to require viral
DNA replication (8, 53-54, 59, 66). Unfortunately, the kinetics of 55R E1A protein
expression could not be assessed at that time. To our knowledge, none of the abundant
E1A-directed Abs generated since that time have been able to specifically detect the 55R
E1A protein. This limitation has severely hampered efforts to biochemically and
functionally characterize this E1A species.
To address this important issue, we generated polyclonal rabbit Abs against a peptide
corresponding to amino acids 43-55 of the unique C-terminal region of the 55R E1A
protein from HAdV-2. We demonstrated that these Abs specifically recognized GSTpurified 55R E1A from HAdV-2, but not from the closely related HAdV-5 55R E1A or
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FIG. 3-5. Interaction and consequences of 55R E1A interaction with the APIS component
S8. A) Lysates were prepared from A549 cells transiently transfected with constructs
expressing either HA-S8 or HA-S4. Lysates were incubated with GST-purified 55R E1A
and complexes were pulled down using glutathione sepharose beads. Membrane was
probed with anti-HA (3F10). B) Lysates were prepared from A549 cells transiently
transfected with constructs expressing HA-S8 and either 55R-GFP or GFP alone.
Complexes were immunopreciptated using rabbit polyclonal anti-55R Abs and Protein A
sepharose beads. Membrane was probed with anti-HA (3F10). C) A549 cells were treated
with scrambled siRNA or siRNA directed against S8. These cells were infected with
either dl521 or dl312 and supernatants were collected 48 hpi. Virus titres were
determined by serial dilution of supernatants on HEK293cells.
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the equivalent, but more distantly-related 53R E1A protein encoded by HAdV-12 (Fig. 31C). The utility of these Abs was demonstrated in western blot, immunoprecipitation and
indirect immunofluorescence assays (Fig. 3-1C-E). We are convinced that the
development of this extremely valuable tool will aid in the further study of the HAdV-2
55R E1A protein, especially given the breadth of assays for which it is useful.
We next set out to finally reconcile earlier studies which have described the kinetics of
9S mRNA expression with the kinetics of 55R E1A protein expression. In agreement
with earlier studies performed on other cell lines, 9S mRNA expression was observed at
late times post-infection of A549 cells (48-96 hpi, Fig. 3-2A) (58-59). Co-staining of the
larger E1A isoforms and 55R E1A yielded two interesting and important findings. Firstly,
the kinetics of 55R E1A protein expression match nicely with the kinetics of 9S mRNA
expression that we observed in A549 cells. Secondly, 55R E1A was found to localize
primarily to the nucleus, similar to the larger E1A isoforms, despite the fact that it lacks
the NLS present in the larger proteins (Fig. 3-2B). The ability of 55R E1A to enter the
nucleus may be explained by the fact that molecules less than 40 kDa in size are able to
pass relatively freely through the NPC (61). 55R E1A falls well below this limit, with a
predicted MW of approximately 6 kDa. Once in the nucleus, 55R E1A is likely enriched
and retained there by binding to cellular partners also present in the nucleus.
The localization of E1A in the nucleus led us to investigate whether, akin to the larger
E1A isoforms, 55R E1A had any role in transactivation of viral genes. This is one of the
two major functions of E1A, the other of course being the induction of S-phase. Early
studies have yielded some peripheral observations regarding the effects (or lack thereof)

136

of 55R E1A on the host cell, but none have examined the role of 55R E1A on viral
replication directly. For example, dl521 was not able to transform either cloned rat
embryo fibroblasts or baby rat kidney cells (16). This is not surprising given that it lacks
several regions known to be essential for transformation by the larger E1A proteins. In
addition, the 289R and 243R E1A isoforms have long been known to cause the cyt and
deg phenotypes (later recognized to be apoptosis) in the absence of E1B 19K.
Conversely, virus expressing 55R E1A in the absence of E1B 19K failed to produce this
phenotype (64). E1A-induced apoptosis has been attributed to the ability of E1A to bind
p300 and pRb, key regulators of E2F1-induced apoptosis (44). The regions required for
binding of these factors are missing from the 55R E1A isoform. Similar work examining
the role of E1B 19K in regulating early gene expression hinted at some interesting
properties of a virus carrying 9S cDNA in an E1A-deleted background. Namely, while
E1B 19K repressed viral gene expression in HeLa cells infected with 13S and 12S cDNA
viruses, it had a stimulatory effect on early gene expression in cells infected with a 9S
cDNA virus (63-64). While the particular reasons for this phenotype remain unclear, they
led us to wonder whether 55R E1A could also transactivate viral gene expression in
contact-inhibited, primary IMR-90 cells.
Indeed, our studies showed that viruses expressing only 55R E1A were sufficient to
transactivate expression of both early and late viral genes. While the kinetics and
magnitude of this transactivation varied from gene-to-gene, as expected, the maximal
levels of expression induced were consistently lower than virus expressing wildtype E1A
(Fig. 3-3). The transactivating properties of 289R and 243R E1A have been studied quite
extensively. The difference in phenotypes induced by 289R and 243R E1A have been

137

attributed to the presence of CR3 in the 289R protein, which itself serves as a potent
transcriptional activation domain (31). As mentioned earlier, the ability of CR3 to
activate transcription relies heavily on its association with MED23, a component of the
mediator complex (1, 7, 13, 30, 60). CR1, 2 and 4 are then responsible for many of the
properties exhibited by 243R E1A, including those common to 289R E1A, through
mediating interactions with a variety of cellular factors including: pRb (21, 32, 65),
p300/CBP (37, 69), TRRAP (9), BS69 (17, 22), UBC9 (18, 70) and CtBP (6, 50). As 55R
E1A does not contain any of the CRs, the mechanism through which it is able to
transactivate viral genes remains of great interest. This may be mediated in part through
interactions with proteins known to bind within the first 28 amino acids of E1A which are
conserved in 55R. In addition, it is highly probable that 55R E1A interacts with novel
partners through its unique 27 C-terminal amino acids. This region is predicted to be
unstructured and does not contain any easily recognizable domains which would help
predict binding partners or function. An in-depth, systematic characterization of this
region will be the focus of intense future studies.
While the ability of 55R E1A to stimulate expression of viral genes in contact-inhibited
IMR-90 cells was highly interesting, it did not guarantee that the virus could replicate
productively under these conditions. It is known that E1A-deleted viruses can undergo
low level replication in transformed cell lines. However, E1A-null viruses replicate
extremely poorly in primary, growth arrested cells unless infected at extremely high
MOIs (36). Therefore, we assessed the replication of HAdVs expressing various
combinations of E1A proteins in growth-arrested, primary IMR-90 cells infected at an
MOI of 5. In all cases, replication was normalized to that observed during infection with
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dl312 (an E1A-null virus) such that any growth above this level could be attributed to a
replication-promoting role for the respective E1A protein(s) carried by each virus. As
expected, dl309 harboring wildtype genomic E1A replicated to the highest titres at both
48 and 120 hpi. This was followed by pm975, which expresses 289R, but not 243R E1A.
dl520, which expresses 243R E1A, but not 289R E1A, grew approximately 2- to 3-logs
better than dl312-infected virus at 48 and 120 hpi, respectively. Surprisingly, JM17-55R
carrying 9S cDNA in an E1A-deleted background, and dl521 grew to equivalent, and in
some cases, higher titres than dl520 (Fig. 3-4A). Again, this was unexpected given the
lack of CRs present in 55R E1A and coupled with the observation that it does not have
the potent transforming effects on cells of its larger counterparts (16). The differences
observed in the growth of JM17-55R and dl521 likely reflect both the expression level
and kinetics of 55R E1A. While both viruses express 55R E1A under the control of the
E1 promoter, it is expressed constitutively by JM17-55R and must be spliced from
genomic E1A during infection with dl521.
During natural infection, 55R E1A is not expressed alone, but in the context of the other
E1A isoforms. Therefore, it was important for us to examine the effect of 55R E1A on
virus replication in the presence of the larger E1A proteins. Co-infection experiments
revealed that infection of cells with pm975 and dl521 did not enhance virus replication
beyond that observed in cells infected with pm975 and dl312. This suggests that the
endogenous levels of 55R E1A produced by pm975 are sufficient to maximize virus
replication in combination with 289R E1A. However, co-infection of cells with dl520 and
dl521 enhanced virus titres 1- to 2-logs relative to cells infected with dl520 and dl312 at
48 and 120 hpi, respectively. These results indicate that in the context of 243R E1A,
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addition of exogenous 55R E1A can enhance virus replication (Fig. 3-4B). This
observation is especially intriguing given that 243R E1A causes only low levels of viral
gene transactivation on its own, while 289R can by itself activate viral gene expression to
wildtype levels (34, 67). Together, these observations lend even more strength to the
evidence that 55R E1A directly and actively transactivates expression of viral genes,
which promotes productive virus replication.
Finally, we determined that like 289R and 243R E1A, 55R E1A was able to bind S8, a
regulatory component of the 26S proteasome and member of the APIS complex. This is
the first reported cellular binding partner of 55R E1A (Fig. 3-5A, B). The binding site for
S8 was originally mapped to residues 4-25 of E1A (57). These residues are conserved in
the 55R E1A isoform. S4, another member of APIS, was also found to bind residues 4-25
of E1A. Notably, 55R E1A does not appear to bind this APIS subunit (57). The reason
for this selectivity is unclear but may a result of an inhibitory effect exerted by the Cterminus of 55R E1A on the binding of S4. Alternatively, binding to S4 may be promoted
by regions of the larger E1A proteins not present in 55R E1A.
Further studies determined that S8 can also bind to CR3. CR3 could recruit S8 to early
viral promoters which in turn stimulated the transactivation activity of CR3. On the other
hand, inhibition of proteasome function was detrimental to the ability of CR3 to
transactivate viral genes. Unfortunately, the result of proteasome inhibition on virus
growth was not evaluated (45). Despite the fact that 55R E1A does not contain CR3, we
hypothesized that its interaction with S8 might have a similar functional outcome and that
this outcome should impact virus replication if important. Knockdown of S8 reduced
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growth of dl521 2-fold by 48 hpi in A549 cells (Fig. 3-5C). Since growth was normalized
to dl312, this effect could be fully attributed to the effect of S8 knockdown on the
function of 55R E1A. Therefore, in addition to identifying the first binding partner of
55R E1A, we have also determined that this interaction is important for its transactivating
and growth promoting activities.
In summary, we have developed the first Abs capable of specifically recognizing the 55R
E1A isoform of HAdV-2. These antibodies could be used for detection of 55R E1A by
western blot, immunoprecipitation and indirect immunofluorescence. This is the first
report describing the kinetics of 55R E1A protein expression, which was done in parallel
with the expression kinetics of 9S mRNA. We have discovered that like the larger E1A
isoforms, 55R E1A is localized predominantly in the nucleus of host cells, despite the
fact that it lacks the NLS present in the larger E1A proteins. 55R E1A was able to
transactivate viral genes in contact-inhibited IMR-90 cells, and was sufficient to promote
replication of the virus in these same cells. We have identified the first binding partner of
55R E1A in S8, a component of APIS. This interaction is presumed to occur through
amino acids 4-25, also present in the larger E1A proteins. Interestingly, 55R E1A
demonstrates a unique specificity in this regard, and does not bind to S4, which was also
shown to interact with the larger E1A isoforms through amino acids 4-25. Knockdown of
S8 had a detrimental effect of growth of dl521, a virus which expresses only the 55R
E1A isoform. Therefore, this interaction is likely to be important in mediating the
transactivating and replication-promoting properties of 55R E1A. We believe that this
study represents an extremely important contribution to the E1A field and in the
understanding of AdV biology in general. This is the first report to observe and
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functionally characterize 55R E1A since its discovery over 30 years ago. Further studies
focused on unraveling the mechanism of 55R E1A-mediated viral gene transactivation
and of its growth promoting properties will be important in understanding novel
mechanisms controlling viral gene regulation. In addition, identification of putative
binding partners of the unique C-terminal region of 55R E1A is likely to enhance our
understanding of the interactions of HAdV with host cells, and more specifically, the
E1A-mediated events that are important at late times post-infection.
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Chapter 4
RASCAL IS A NEW HUMAN CYTOMEGALOVIRUSENCODED PROTEIN THAT LOCALIZES TO THE
NUCLEAR LAMINA AND IN CYTOPLASMIC VESICLES AT
LATE TIMES POST-INFECTION
4.1 Introduction
CMV is a highly prevalent betaherpesvirus that can cause severe multiorgan disease in
immunocompromised individuals (45). The ability of this virus to infect an exceptionally
wide variety of different cell types substantially contributes to pathogenesis (5, 68). CMV
tropism is largely determined by a finely tuned interplay between cellular and viral
factors, many of which act at the earliest stages of infection (30, 68). We recently showed
that the cellular protein vimentin is required for efficient onset of infection in primary
human foreskin fibroblasts (HF). Interestingly, the degree of reliance on the presence and
integrity of vimentin intermediate filaments is dependent on the virus strain, with the
broadly tropic strain TB40/E being more negatively affected than the HF-adapted,
attenuated strain AD169 (44).
Serial passage of clinical isolates in HF or in EC has produced strains with different
tropisms. The attenuated strains AD169 and Towne were developed as vaccine
candidates by propagation in HF for more than 50 (AD169) and 125 (Towne) serial
passages (19, 53, 61). During this process, both strains, compared to clinical isolates,
accumulated multiple mutations and genomic deletions, resulting in the loss of more than
19 ORFs (8). The number of serial passages in HF of another commonly used strain,
Toledo, has been more moderate (19, 54, 58). This, however, did not prevent the
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emergence of numerous genomic mutations, including the inversion of a 15-kb fragment
(8, 16, 56). As a consequence of these changes, productive infections by AD169, Towne,
and Toledo are largely restricted to HF. In contrast, propagation of clinical isolates in EC
has yielded a series of strains with more-intact genomes and broader tropisms, such as
TB40/E, VHL/E, and FIX (VR1814) (25, 60, 71). These strains retain the ability to grow
in a wider variety of cell types, including EC, epithelial cells, and DC, in addition to HF
(23, 28, 59, 60, 68).
The UL128, UL130, and UL131A gene products were recently identified as essential
mediators of CMV infection of EC and epithelial cells (26, 72, 73) and of virus transfer
from infected EC to monocyte-derived DC (23). Each of these proteins is independently
required for the broader tropisms of EC-propagated CMV isolates (63, 64), and the
presence of mutations affecting their functionality has been directly linked to the inability
of AD169, Towne, and Toledo to initiate productive infections in EC and epithelial cells
(26, 72, 73). We have shown that mature Langerhans-type DC differentiated in vitro from
CD34+ hematopoietic progenitor cells are highly permissive to direct infection with
TB40/E or VHL/E, with 48 to 72% of cells in culture expressing the viral immediateearly genes IE1 and IE2 at 48 hpi (28). In contrast, only 2 to 5% and 0% of mature
Langerhans cells were IE1/IE2 positive after exposure to Towne and Toledo,
respectively. However, productive infection was detected in 12 to 17% of cells infected
with AD169, despite the fact that this strain lacks expression of the UL131A gene as a
consequence of a frameshift mutation (26). These results suggested the existence of
additional viral genes with products involved in mediating tropisms for specific cell
types, such as DC. To identify possible candidates, we compared the amino acid
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sequence of each ORF found in the genome of TB40-BAC4, a sequenced clone of the
TB40/E strain in a bacterial artificial chromosome (BAC) (GenBank accession number
EF999921) (69), to the sequence of each ORF found in AD169 and AD169- BAC
(accession numbers X17403 and AC146999) (10, 49), Towne and Towne-BAC
(accession numbers FJ616285, AC146851, and AY315197) (17, 18, 49), and ToledoBAC (accession number AC146905) (49). The product of a putative ORF, originally
identified by Murphy et al. and named c-ORF29 (49), was considered of particular
interest because the amino acid sequence of the putative protein encoded by Toledo and
Towne was extended by 79 residues compared to the putative protein encoded by TB40/E
and AD169. This led to our speculation that that the extended version might result in a
nonfunctional version of the c-ORF29-encoded protein. We thus focused our studies on
the products of this ORF.
Here, we show for the first time that CMV c-ORF29 encodes a protein expressed at early
to late times postinfection and localizes to the nuclear rim in peculiar invaginations of the
nuclear lamina and in cytoplasmic vesicular structures at late times p.i. Based on this
localization pattern, we named this gene product nuclear rim-associated cytomegaloviral
protein, or RASCAL. Surprisingly, no difference was observed in the distributions of
RASCAL during infection of HF with TB40/E or Towne, suggesting that the intracellular
trafficking of this protein is not affected by the presence of the additional residues at the
C terminus of RASCAL from strain Towne (RASCALTowne). Ectopic expression of
RASCAL in human embryo kidney 293T (HEK293T) cells further revealed that this
protein requires the presence of the NEC member UL50 to reach the nuclear rim, while
coimmunoprecipitation (co-IP) assays provided evidence for the existence of an
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interaction between RASCAL and UL50. These findings suggest that RASCAL may be a
new component of the NEC with possible roles in remodeling the nuclear lamina during
nucleocapsid egress from the nucleus.

4.2 Materials & Methods
4.2.1

In silico analysis

RASCAL amino acid sequences were analyzed using the following programs: ClustalW2
(32), NetPhosK (4), NetNGlyc (http://www.cbs.dtu.dk/services/NetNGlyc/), SignalP3.0
(2),

Kyte-Doolittle

hydropathy

plot

(31),

TMpred

(http://www.ch.embnet.org/software/TMPRED_form.html), TopPred II (11), dense
alignment surface (DAS) (13), ESLpred (3), HSLpred (22), TargetP1.1(20), and SubLoc
v1.0 (29).

4.2.2

Cells and virus

HF and HEK293T cells were gifts of E. S. Mocarski, Emory University, Atlanta, GA,
and were propagated in Dulbecco’s modified Eagle medium supplemented with 10%
fetal clone serum III (HyClone), 100 U/ml penicillin, 100 µg/ml streptomycin, 4 mM
HEPES, and 1 mM sodium pyruvate(all from Gibco Invitrogen Corp.). HF were used
between passages 17 and 27 postisolation. Human CMV strains AD169varATCC and
TB40/E and the green fluorescent protein (GFP)-tagged derivative of TownevarRIT3,
Towne/GFP-IE2 (J. Xu, D. Formankova, and E. S. Mocarski, unpublished), were
originally obtained from the American Type Culture Collection, from C. Sinzger
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(Tübingen, Germany), and from E. S. Mocarski (Emory University, Atlanta, GA),
respectively. Propagation and purification of all strains were performed as previously
described (28).

4.2.3

HF infection and cell transfection

HF were plated at a density of 5 × 104 cells/cm2 3 days prior to exposure to AD169,
TB40/E, or Towne/GFP-IE2 at a multiplicity of infection (MOI) of 3 or 5. Mock-infected
samples were exposed to culture medium alone. After virus adsorption at 37°C in 5%
CO2 for 1 h, the inoculum was removed, and cells were washed three times with medium
prior to incubation in fresh medium until they were harvested at different times p.i. For
phosphonoformic acid (PFA) treatment, HF were exposed to Towne/GFP-IE2 (MOI of 3)
for 1 h at 37°C, washed, and further incubated in fresh culture medium containing 300
µg/ml of PFA (Sigma, St. Louis, MO). HEK293T cell transfection was performed using
PolyFect (Qiagen) as per the manufacturer’s guidelines.

4.2.4

mRNA isolation and RT-PCR

mRNA was isolated from mock-, TB40/E-, or Towne/GFP-IE2-infected HF using the
µMACS mRNA isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Firststrand cDNA synthesis was performed using SuperScript III reverse transcriptase
according to the manufacturer’s guidelines (Gibco Invitrogen Corp.). c-ORF29 TB40/E
was amplified with the forward primer GCGGATCCTAATGGGGGAACGCC (labeled a
> in Fig. 2A,top) and the reverse primer GTGGATCCAGAGATGCGGAAAAGCC
(labeled <b in Fig. 2A, top), c-ORF29 Towne was amplified with the forward primer
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GCGGATCCTAATGGGGGAACGCC (labeled a > in Fig. 2A, top) and the reverse
primer CCTCGAGAAAAGCACGCAAGC (labeled <c in Fig. 2A, top), vimentin was
amplified with the forward primer CGGATCCATGTCCACCAG and the reverse primer
CGAATTCTTCAAGGTCAT,

UL99

was

CGGATCCATGGGTGGCGAACTCT

amplified
and

with
the

the

forward

reverse

primer
primer

GGATATCTGAAAGGACAAGGGGGCG, and β-actin cDNA was amplified with the
forward primer GGTCATCACCATTGGCAATGAGCGG and the reverse primer
GGACTCGTCATACTCCTGCTTGCTG.

4.2.5

Plasmid construction

L-RASCALTB40/E (where the prefix “L” stands for LNCX) was generated by excising
GFP from LNCX-GFP (LGFP) (36) using EcoRI and EcoRV and by replacing it with the
RASCALTB40/E sequence amplified by PCR using a forward primer containing the
EcoRI restriction site (GGAATTCATGGGGGAACGCCGTGTG) and a reverse primer
containing the RASCALTB40/E stop codon and the EcoRV restriction site
(GCGATATCTTAAGATGCGGAAAAGCCA). L-RASCALTB40/E-GFP was generated by
cloning RASCALTB40/E, lacking its stop codon, in frame with the N terminus of GFP
using the EcoRI and BamHI restriction sites present in LGFP. The forward primer used
to make L-RASCALTB40/E-GFP was the same as that used to make L-RASCALTB40/E.
The reverse primer (GTGGATCCAGAGATGCGGAAAAGCC) contained a BamHI
restriction site and was designed to remove the RASCAL stop codon. Hemagglutinintagged LNCX UL50 (LNCX UL50-HA) was generated by amplifying the UL50
sequence from cDNA populations derived from AD169-infected HF using the forward
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primer AGAATTCATGGAGATGAACAAGGTT, containing an EcoRI restriction site,
and

the

reverse

primer

TTTTGTCGACTCAAGCGTAATCTGGAACATCGTATGGGTAGTCGCGGTGTGCG
GAG, containing the HA tag nucleotide sequence. This PCR product was cloned into the
pSC-B vector (Stratagene, La Jolla, CA) and subsequently excised using EcoRI before
being ligated into the EcoRI restriction site of LNCX (43). FLAG- tagged L-UL53 (LUL53-FLAG) was created by amplifying the UL53 sequence from cDNA populations
derived

from

TB40/E-infected

HF

using

the

forward

primer

AGAATTCATGTCTAGCGTGAGCG, containing the EcoRI restriction site, and the
reverse

primer

TTTTGTCGACTCACTTGTCATCGTCGTCCTTGTAGTCAGGCGCACGAATGCTG
TTGA, containing the FLAG tag nucleotide sequence and the SalI restriction site. The
UL53-FLAG PCR product was ligated into the EcoRI and SalI sites of LGFP after
excision of the GFP coding sequence.

4.2.6

Generation of anti-RASCAL Abs

Polyclonal rabbit antibodies (Abs) were raised by ProSci Inc. (Poway, CA) against the
RASCAL peptide YAPFDSHRRHVSELRGHRD conjugated to the keyhole limpet
hemocyanin. Abs were affinity purified and were provided at a final concentration of 1.7
mg/ml.
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4.2.7

Immunoblot analysis

Cell pellets from mock-, TB40/E-, or Towne/GFP-IE2-infected HF and from HEK293T
cells nontransfected or transiently transfected with L-RASCALTB40/E-GFP or with LRASCALTB40/E were resuspended in 3% sodium dodecyl sulfate (SDS) lysis buffer
containing 125 mM Tris-HCl (pH 6.8), 3% SDS, 10 mM dithiothreitol, 0.4 mM
phenylmethylsulfonyl fluoride, and complete EDTA-free protease inhibitor cocktail
(Roche). Cell lysates were boiled at 100°C for 5 min, and cell debris were eliminated by
centrifugation at 16,100 × g for 3 min. Protein concentrations were determined with the
DC protein assay kit (Bio-Rad). Protein extracts were then separated by electrophoresis
on a 15% SDS-polyacrylamide gel and transferred to polyvinylidene difluoride
membranes. Membranes were blocked overnight at 4°C in blocking buffer containing 10
mM Tris-Cl (pH 7.5), 100 mM NaCl, 5% milk powder, 0.1% Tween 20 prior to
incubation with rabbit anti-RASCAL Abs (1:1,000) or with mouse anti-HA Abs (1:1,000)
for 1 h at room temperature (RT). Membranes were rinsed in wash buffer (10 mM Tris-Cl
[pH 8.0], 150 mM NaCl, and 0.05% Tween 20) and were incubated with horseradish
peroxidase-conjugated goat anti-rabbit IgG (1:4,000; Vector Laboratories) or goat antimouse IgG (1:5,000; Vector Laboratories) for 1 h at RT. For reprobing, membranes were
incubated in 62.5 mM Tris-Cl (pH 6.8), 100 mM β-mercaptoethanol, and 2% SDS at
50°C for 30 min, rinsed with phosphate-buffered saline (PBS) containing 0.1% Tween
20, blocked overnight at 4°C, and incubated with preimmune rabbit serum (1:1,000)
followed by horseradish peroxidase-conjugated goat anti-rabbit IgG (1:4,000), both for 1
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h at RT. Signal was developed by enhanced chemiluminescence (ECL plus kit; GE
Healthcare).

4.2.8

Co-immunoprecipitation assays

HEK293T cells were transfected with LNCX (control) or were cotransfected with LRASCALTB40/E and LNCX UL50-HA at a 1:3 molar ratio or with LNCX UL50-HA and
L-UL53-FLAG at a 1:1 molar ratio in T25 flasks. At 24 h posttransfection, cells were
harvested in 500 µl of co-IP buffer containing 50 mM Tris-HCl (pH 8), 100 mM NaCl, 5
mM EDTA, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride, and complete EDTAfree protease inhibitor cocktail (Roche) prior to the addition of 5 µg of mouse monoclonal
anti-HA Abs (Invitrogen) or of polyclonal anti-RASCAL Abs for 2 h at 4°C under
rotation. Extracts were incubated with 100 µl of protein A-Sepharose bead slurry (Sigma)
for 2 h at 4°C, pelleted, washed in lysis buffer containing 200 mM NaCl, and subjected to
immunoblot analysis as described above.

4.2.9

Immunofluorescence staining analysis

Cells were fixed in 3.7% paraformaldehyde (Fisher Chemicals, Fairlawn, NJ) for 30 min
at RT, permeabilized in 0.2% Triton X-100 (USB Corporation, Cleveland, OH) for 20
min on ice, and blocked in 100% horse serum (HS; PML Microbiologicals, Wilsonville,
OR) for 30 min at RT. Cells were then incubated with rabbit polyclonal anti-RASCAL
Abs (1:500) alone or in combination with monoclonal Abs directed against the FLAG tag
(1:1,000; clone M2; Sigma, St. Louis, MO), the HA tag (1:500; Invitrogen), IE1/IE2
(1:500; fluorescein isothiocyanate [FITC]-conjugated MAb810F; Chemicon, Temecula,
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CA), lamin B (1:50; Santa Cruz Biotechnology, Santa Cruz, CA), or lamin A/C (1:50;
Santa Cruz Biotechnology, Santa Cruz, CA). Samples were washed in PBS-0.05% Tween
20 prior to incubation with Alexa Fluor 594-conjugated goat anti-rabbit IgG Abs (1:500;
Molecular Probes, Eugene, OR) alone or in combination with FITC-conjugated goat antimouse IgG Abs (1:100; Invitrogen, Carlsbad, CA). For control stainings, cells were
incubated with preimmune sera diluted 1:500 in 100% HS. For dual staining of cells
expressing UL50-HA and UL53-FLAG, samples were incubated with mouse monoclonal
anti-FLAG Abs and rabbit polyclonal anti-HA Abs (1:500; Zymed), followed by FITCconjugated goat anti-mouse IgG Abs and Alexa Fluor 594-conjugated goat anti-rabbit
IgG Abs. All Abs were diluted in 100% HS and were incubated on samples for 1 h at RT.
Nuclei were labeled with Hoechst 33342 (0.2 mg/ml; Molecular Probes, Eugene, OR) for
3 min at RT and were mounted in 90% glycerol-10% PBS containing 2.5 g/liter of 1,4diazabicyclo(2,2,2)octane (DABCO; Alfa Aesar, Pelham, NH). Samples were analyzed
on a Zeiss Axioskop2 magneto-optical trap fluorescence microscope equipped with a
QImaging Retiga 1300-coded monochrome 12-bit camera. Images were captured and
pseudocolored using Northern Eclipse version 7.0 software. Confocal images were
acquired on a Zeiss LSM 510 META ConfoCor2 confocal laser scanning microscope
equipped with Zeiss LSM 510 META image processing software.
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4.3 Results
4.3.1

Identification of the ORF encoding RASCAL and in silico
analysis of the predicted amino acid sequence

The genomic region of TB40-BAC4 corresponding to nucleotides 9100 to 11200 was
screened for the presence of ORFs with the potential to encode proteins of at least 80
amino acids (aa) and containing a 5’ATG codon. One ORF of 294 nucleotides encoding a
putative protein of 97 aa was found. As described for c-ORF29 (48, 49), the sequence of
this ORF was located on the negative strand of the genome (nucleotides 9855 to 10148 in
TB40-BAC4) and partially overlapped (206 nucleotides) the 5’ end of the US17 gene
(Fig. 1A, left). An ortholog of this ORF was found in the Towne-BAC genome, spanning
nucleotides 199167 to 199697 (in GenBank accession no. AY315197) and overlapping
the 5’ end of the US17 gene by 442 nucleotides (Fig. 4-1A, right). In contrast to what was
previously reported for c-ORF29 (48, 49), however, searches of the nonredundant
nucleotide collection databases using the BLASTN algorithm failed to reveal the
presence of a full-length c-ORF29 ortholog in the genome of chimpanzee CMV. A
ClustalW2 global alignment of the predicted amino acid sequence of c-ORF29 from
strain TB40-BAC4 (RASCALTB40/E) with sequences from 13 other human CMV strains
showed that RASCAL is highly conserved and that not only strains Towne and Toledo,
but also two new CMV strains, HAN20 and HAN38, carry a longer version of this
protein, containing 79 additional amino acids (Fig. 4-1B). No significant homology
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between either isoform of RASCAL and proteins of cellular or viral origin was detected
in extensive searches of multiple amino acid sequence databases.
Two potential phosphorylation sites with scores greater than 80% were identified in
RASCALTB40/E by the NetPhosK software, one of which was specific for protein kinase C
(PKC) at Thr 48 and the other for protein kinase A (PKA) at Ser 65. One additional site
for PKA was found in the longer version of the protein at Ser 103 (Fig. 4-1B). A single
potential N-glycosylation site was detected by the NetNGlyc software at residue Asn 17
(Fig. 4-1B). However, the SignalP3.0 algorithm failed to predict the presence of a signal
sequence at the N terminus of RASCAL, suggesting that this protein may not be
recognized by the glycosylation machinery in vivo.
A Kyte-Doolittle hydropathy plot of RASCALTB40/E revealed the presence of two regions
of at least 17 aa with overall hydrophobicity values greater than 1, one located at the N
terminus (aa 6 to 24) and the other at the C terminus (aa 79 to 97) (Fig. 4-1C, left, shaded
boxes). Both were predicted to contain a transmembrane domain (TMD) by three protein
topology prediction algorithms, TMpred, TopPred II, and DAS. The amino acid
sequences of these putative TMDs are highly conserved in all strains (Fig. 4-1B, black
lines). Although strains Merlin, JP, and HAN13 carry a single amino acid replacement of
Leu 12 with Ile, HAN38 carries a Leu 13-to-Ser substitution, and 3301 carries a Val 6-toMet substitution, none of these changes altered the outcome of the predictions. Two
additional hydrophobic regions consisting of more than 17 aa were detected in
RASCALTowne (Fig. 4-1C, right, boxes with dashed borders), but neither was predicted to
be a TMD by all three software programs.
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4.3.2

RASCAL expression in infected and transfected cells

To determine if c-ORF29 was expressed during infection, we performed reverse
transcriptase-PCR (RT-PCR) analyses of mRNA extracts from mock-, TB40/E-, or
Towne/GFP-IE2-infected HF using the primers schematically depicted in the top panel of
Fig. 4-2A. A single product of approximately 300 nucleotides was detected in extracts
from TB40/E-infected cells amplified with primers a > and < b (Fig. 4-2A, bottom).
Mock-infected samples and control reaction mixtures lacking the cDNA template were
negative (Fig. 4-2A, bottom, and data not shown). Although the sequence of primer < c is
complementary to nucleotides 9621 to 9624 of the TB40/E genome, no product was
obtained when the same extracts were amplified with primers a > and < c (not shown),
suggesting that no transcript spanning the region between these primers was produced in
cells infected with TB40/E. In contrast, a single product of about 550 nucleotides was
observed in extracts from Towne/GFP-IE2-infected cells amplified using primers a > and
< c (not shown). Sequence analysis of this PCR product confirmed the presence of a T-toC mutation at position 292, resulting in the conversion of a TAA stop codon into a CAA
codon coding for the amino acid Gln. RT-PCR analyses of mRNA extracts from HF
infected with TB40/E in the presence of PFA revealed that c-ORF29 expression was
reduced, but not completely abrogated, in the absence of viral DNA replication (Fig. 42B). In contrast, no expression of the true late gene UL99 was detected in PFA-treated
cells (Fig. 4-2B). Together, these data indicate that c-ORF29 is transcribed with early-late
kinetics during infection and confirm that the Towne strain carries a longer version of this
ORF.
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To determine if c-ORF29 did encode a protein, affinity-purified, polyclonal rabbit Abs
were raised against residues 21 to 39 of the predicted RASCALTB40/E amino acid
sequence. The specificities of these Abs were tested using Western blot analyses of
protein extracts from HEK293T cells transiently transfected with expression plasmids
encoding RASCALTB40/E only or RASCALTB40/E fused to the N terminus of the GFP
amino acid sequence (RASCALTB40/E-GFP). Two proteins with expected molecular masses
of approximately 11 kDa (Fig. 4-2C, asterisk) and 38 kDa (Fig. 4-2C, arrowhead) were
detected in extracts from cells transfected with expression plasmids encoding
RASCALTB40/E and RASCALTB40/E-GFP, respectively. These proteins were not recognized
by the anti-RASCAL Abs in extracts from nontransfected cells (Fig. 4-2C) or by the
preimmune serum (not shown). Moreover, the 38-kDa protein was also specifically
detected in membranes reprobed with anti-GFP monoclonal Abs (not shown), indicating
that this polypeptide did contain both the RASCAL and the GFP epitopes. Two additional
bands of 15 and 20 kDa were observed in extracts from both transfected and
nontransfected cells and were considered to be cellular proteins nonspecifically
recognized by the anti-RASCAL Abs. Finally, two products with molecular masses of
less than 15 kDa were observed exclusively in cells expressing RASCALTB40/E-GFP,
suggesting that they might correspond to degradation products of the fusion protein.
To assess if RASCAL was expressed in CMV-infected cells, protein extracts from mock-,
TB40/E-, and Towne/GFP-IE2-infected HF were separated by SDS-polyacrylamide gel
electrophoresis (PAGE). The same membrane was probed with anti-RASCAL Abs and,
after being stripped, with preimmune serum. A single band of approximately 11 kDa was
detected in extracts from TB40/E-infected HF and in extracts from HEK293T cells
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expressing RASCALTB40/E, used as the control (Fig. 4-2D, left, asterisks). This band was
not detected in samples from mock- and Towne/GFP-IE2-infected cells. In addition, two
proteins with molecular masses larger than 15 kDa but smaller than 20 kDa were
observed exclusively in extracts from Towne/GFP-IE2-infected HF (Fig. 4-2D, left).
While the larger protein (Fig. 4-2D, left, square) is likely to correspond to RASCALTowne
(predicted molecular mass, 19.4 kDa), the smaller protein remains uncharacterized. None
of these bands, including the nonspecific protein of approximately 15 kDa recognized by
the anti-RASCAL Abs in HF and HEK293T cell extracts, was detected by the preimmune
serum (Fig. 4-2D, right).

4.3.3 RASCAL localizes at the nuclear envelope and in cytoplasmic
vesicular structures during infection
To establish the subcellular localization of RASCAL during infection, mock-, AD169-,
TB40/E-, and Towne/GFP-IE2-infected HF (MOI of 5) were harvested at 24, 48, 72, 96,
120, and 144 hpi. Cells were stained with the preimmune serum or with the affinitypurified anti-RASCAL Abs and with FITC- conjugated anti-IE1/IE2 Abs. Nuclei were
stained with Hoechst 33342. No signal was observed in mock-infected cells (Fig. 4-3A to
C), indicating that no cellular proteins were recognized nonspecifically by the antiRASCAL Abs in immunofluorescence staining assays. Similarly, staining of infected
cells with the preimmune serum did not yield any specific signal (not shown). At 24 hpi,
RASCAL fluorescence was barely detectable (not shown). By 48 hpi, a prominent
cytoplasmic signal was observed in infected cells, with a punctuate pattern more densely
concentrated around the nucleus (Fig. 4-3D to F). At 72 hpi, RASCAL accumulation in a
perinuclear ring was clearly detectable in a large proportion of cells (Fig. 4-3G to I,
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arrow), and by 96 hpi most of the RASCAL signal emanated from the nuclear rim, with
very little diffuse fluorescence remaining in the cytoplasm (Fig. 4-3J to L). In some cells,
RASCAL appeared to also concentrate in cytoplasmic vesicular compartments distributed
from the nuclear envelope to the cell surface (Fig. 4-3J to L, asterisk). At 96 hpi and,
more prominently, at 120 hpi, RASCAL fluorescence appeared to originate almost
exclusively from peculiar structures likely located on the nuclear envelope and
characterized by a central “knot” with rod-like extensions (Fig. 4-3M to O, arrowheads).
These nuclear envelopes and the cytoplasmic structures became clearly visible at 144 hpi
(Fig. 4-3P to R), at a time when few or no perinuclear rings were still detectable. The
same staining pattern was observed in AD169- and TB40/E-infected cells (not shown),
indicating that the presence of the 79 additional amino acids in RASCALTowne did not
interfere with its localization.
To determine if the RASCAL protein was produced in the absence of viral DNA
replication, HF were infected with Towne/GFP-IE2 (MOI of 3) in the presence or
absence of PFA. Cells were harvested at 24, 48, 72, 96, 120, and 144 hpi and stained for
RASCAL and for IE1/IE2. As expected, intranuclear accumulation of IE1/IE2 at the sites
of viral genome replication (52) was observed exclusively in untreated HF (Fig. 4-4B and
D). In these cells, RASCAL expression was detected starting from 24 hpi, and signal
accumulated at the nuclear rim, on the nuclear envelope, and in cytoplasmic vesicles at
late times p.i. (Fig. 4-4A and C). In contrast, no RASCAL-specific signal was detected in
PFA-treated cells at each time p.i. (Fig. 4-4E and G and data not shown), suggesting that
expression of the RASCAL protein was reduced to levels below detection in the absence
of viral DNA replication.
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FIG. 4-1. Genomic location of the c-ORF29 gene and in silico analysis of the RASCAL
amino acid sequence. (A) Schematic map of the TB40-BAC4 (GenBank accession no.
EF999921) and of the Towne-BAC (accession no. AY315197) genomic regions
corresponding to nucleotides 9200 to 10200 (TB40/E) and 198750 to 199750 (Towne).
The black horizontal line depicts the viral genome, with vertical lines positioned every
500 nucleotides. ORFs are represented by arrows pointing in the direction of
transcription. (B) ClustalW2 alignment of RASCAL amino acid sequences from 14
human CMV strains. Viral genome accession numbers are as follows: TB40-BAC,
EF999921; PH-BAC, AC146904; TR-BAC, AC146906; FIX-BAC, AC146907; 3157,
GQ221974; 3301, GQ466044; HAN13, GQ221973; JP, GQ221975; Merlin, AY44689;
AD169, X17403; HAN38, GQ396662; HAN20, GQ396663; Toledo-BAC, AC146905;
and Towne-BAC, AC146851. Dots and dashes indicate identical and absent amino acids,
respectively. The asterisks mark the specific amino acid predicted to be phosphorylated
by PKA or PKC or to be N glycosylated (N-glyc). The black lines underscore the putative
TMDs. (C) Kyte-Doolittle (K-D) hydropathy plot of RASCALTB40/E and RASCALTowne
amino acid sequences, performed using a window size of 9 aa. The shaded boxes include
the stretch of amino acids corresponding to the putative TMDs, while the boxes with the
dashed borders include the two additional hydrophobic regions of more than 17 aa
detected in RASCALTowne.
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4.3.4

RASCAL and lamin B colocalize at the nuclear lamina and in
cytoplasmic vesicular structures

To establish the subcellular localization of RASCAL during infection, mock-, AD169-,
TB40/E-, and Towne/GFP-IE2-infected HF (MOI of 5) were harvested at 24, 48, 72, 96,
120, and 144 hpi. Cells were stained with the preimmune serum or with the affinitypurified anti-RASCAL Abs and with FITC-conjugated anti-IE1/IE2 Abs. Nuclei were
highlighted with Hoechst 33342. No signal was observed in mock-infected cells (Fig. 43A to C), indicating that no cellular proteins were recognized nonspecifically by the antiRASCAL Abs in immunofluorescence staining assays. Similarly, staining of infected
cells with the preimmune serum did not yield any specific signal (not shown). At 24 hpi,
RASCAL fluorescence was barely detectable (not shown). By 48 hpi, a prominent
cytoplasmic signal was observed in infected cells, with a punctuate pattern more densely
concentrated around the nucleus (Fig. 4-3D to F). At 72 hpi, RASCAL accumulation in a
perinuclear ring was clearly detectable in a large proportion of cells (Fig. 4-3G to I,
arrow), and by 96 hpi most of the RASCAL signal emanated from the nuclear rim, with
very little diffuse fluorescence remaining in the cytoplasm (Fig. 4-3J to L). In some cells,
RASCAL appeared to also concentrate in cytoplasmic vesicular compartments distributed
from the nuclear envelope to the cell surface (Fig. 4-3J to L, asterisk). At 96 hpi and,
more prominently, at 120 hpi, RASCAL fluorescence appeared to originate almost
exclusively from peculiar structures likely located on the nuclear envelope and
characterized by a central “knot” with rod-like extensions (Fig. 4-3M to O, arrowheads).
These nuclear envelopes and the cytoplasmic structures became clearly visible at 144 hpi
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(Fig. 4-3P to R), at a time when few or no perinuclear rings were still detectable. The
same staining pattern was observed in AD169- and TB40/E-infected cells (not shown),
indicating that the presence of the 79 additional amino acids in RASCALTowne did not
interfere with its localization.
To determine if the RASCAL protein was produced in the absence of viral DNA
replication, HF were infected with Towne/GFP-IE2 (MOI of 3) in the presence or
absence of PFA. Cells were harvested at 24, 48, 72, 96, 120, and 144 hpi and stained for
RASCAL and for IE1/IE2. As expected, intranuclear accumulation of IE1/IE2 at the sites
of viral genome replication (52) was observed exclusively in untreated HF (Fig. 4-4B and
D). In these cells, RASCAL expression was detected starting from 24 hpi, and signal
accumulated at the nuclear rim, on the nuclear envelope, and in cytoplasmic vesicles at
late times p.i. (Fig. 4-4A and C). In contrast, no RASCAL-specific signal was detected in
PFA-treated cells at each time p.i. (Fig. 4-4E and G and data not shown), suggesting that
expression of the RASCAL protein was reduced to levels below detection in the absence
of viral DNA replication.

4.3.5 RASCAL interacts with UL50 and requires its presence to
gather at the nuclear lamina
At early times p.i. (48 hpi), RASCAL localizes mainly in a cytoplasmic punctuate pattern
(Fig. 4-3D to F). Relocalization to the nuclear rim occurs only later in infection (72 hpi
[Fig. 4-3G to I]), at a time when both UL50 and UL53 are abundantly expressed and
gathered at the NEC. This suggested that RASCAL might require the presence of other
NEC components to reach the nuclear lamina. To test if, akin to UL53, RASCAL
relocalization to the nuclear lamina was mediated by UL50, three expression plasmids
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were constructed, one containing RASCALTB40/E, one containing a C-terminal FLAGtagged version of UL53 (UL53-FLAG), and one containing a C-terminal HA-tagged
version of UL50 (UL50-HA), as described previously (14, 40). HEK293T cells
transfected with one of these constructs were stained with rabbit anti-RASCAL Abs and
with mouse anti-HA or mouse anti-FLAG Abs. No signal was detected in cells
expressing UL50-HA or UL53-FLAG after being stained with anti-RASCAL Abs (Fig.
4-7B and D), indicating that these Abs did not cross-react with either protein. As
previously shown (7, 41, 42), UL50-HA localized at the nuclear lamina and in
cytoplasmic vesicular structures (Fig. 4-7A), while UL53-FLAG was predominantly
nuclear, with some cytoplasmic dotted staining (Fig. 4-7C). When expressed in the
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FIG. 4-2. RASCAL expression in infected and transfected cells. (A, top) Schematic
depiction of the primers used to amplify c-ORF29 by RT-PCR from TB40/E- or
Towne/GFP-IE2-infected HF. The > and < symbols depict the direction of
polymerization. The sequence of primer a > is complementary to nucleotides 1 to 13 of
c-ORF29TB40/E and of c-ORF29Towne, the sequence of primer < b is complementary to
nucleotides 277 to 291 of c-ORF29TB40/E and of c-ORF29Towne and to nucleotides 189 to
203 of US17, while the sequence of primer < c is complementary to nucleotides 515 to
528 of c-ORF29Towne and nucleotides 427 to 440 of US17. (Bottom) RT-PCR analysis
of c-ORF29 transcription in mock or TB40/E-infected HF at the indicated times p.i.,
using primers a > and < b. Amplification of vimentin’s cDNA was used as the PCR
control. (B) RT-PCR analysis of c-ORF29 and of UL99 transcription in HF infected with
TB40/E in the presence (+) or absence (-) of PFA (300 µg/ml). Amplification of β-actin’s
cDNA was used as the PCR control. (C) Immunoblot analysis results of RASCALTB40/E
expression in protein extracts from HEK293T cells nontransfected or transfected with
expression plasmids encoding RASCALTB40/E-GFP or RASCALTB40/E. The blot was
incubated with an anti-RASCAL polyclonal Ab as described in Materials and Methods.
Expected molecular masses were 10.6 kDa for RASCALTB40/E and 37.6 kDa for
RASCALTB40/E-GFP. Asterisk, RASCALTB40/E; arrowhead, RASCALTB40/E-GFP. (D)
Immunoblot analysis of RASCAL expression in protein extracts from mock-, TB40/E-,
or Towne/GFP-IE2-infected HF and in HEK293T cells expressing RASCALTB40/E. The
same membrane was incubated first with an anti-RASCAL polyclonal Ab (left) and
subsequently with the preimmune serum (right) as described in Materials and Methods.
Expected molecular masses were 10.6 kDa for RASCALTB40/E and 19.4 kDa for
RASCALTowne.

Asterisk,

RASCALTB40/E;

square,

RASCALTowne.
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FIG. 4-3. RASCAL intracellular localization. Mock-infected (A to C) or Towne/GFPIE2-infected HF (MOI of 5) (D to R) were harvested at the indicated times p.i. and were
stained with affinity-purified rabbit anti-RASCAL polyclonal Abs followed by Alexa
Fluor 594-conjugated goat anti-rabbit Abs. The signal emitted from the GFP-IE2 protein
was further amplified with FITC-conjugated anti-IE1/IE2 Abs, and nuclear DNA was
stained with Hoechst 33342. The arrows point at RASCAL accumulation at the nuclear
rim, the arrowheads indicate the peculiar structures observed on the nuclear surface at
late times p.i., and the asterisks mark the locations of the cytoplasmic RASCAL-positive
vesicles. Original magnification, 400×.
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FIG. 4-4. RASCAL expression in the absence of viral DNA synthesis. HF infected with
Towne/GFP-IE2
IE2 (MOI of 3) in the presence or absence of PFA (300 µg/ml) were
harvested at the indicat
indicated times p.i. and stained with affinity-purified
purified rabbit antianti
RASCAL
ASCAL polyclonal Abs followed by Alexa Fluor 594-conjugated
conjugated goat anti-rabbit
anti
Abs
and FITC-conjugated
conjugated anti IE1/IE2 Abs. Original magnification, 400
400×.
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absence of CMV infection, RASCALTB40/E did not accumulate at the nuclear rim but
displayed a punctuate cytoplasmic staining similar, although not completely identical, to
that observed in infected HF at 48 and 72 hpi (compare Fig. 4-7E to Fig. 4-3D and G).
Coexpression of UL50-HA and UL53-FLAG induced the relocalization of UL53-FLAG
to the endoplasmic reticulum and to the nuclear rim (Fig. 4-7F to H), as expected (7, 40).
Expression of RASCALTB40/E in the presence of UL53-FLAG did not modify the
localization of either protein (Fig. 4-7I to K), while coexpression of RASCALTB40/E and
UL50-HA triggered the accumulation of RASCALTB40/E in a UL50-positive, perinuclear
region (Fig. 4-7L to N). These data indicate that the presence of UL50, but not of UL53,
is required to mediate RASCALTB40/E tethering to the nuclear rim and suggest that
RASCALTB40/E may interact with UL50. Expression of RASCALTB40/E in the presence of
both UL50-HA and UL53-FLAG did not change the localization pattern of either
RASCALTB40/E or UL53, and both proteins still accumulated at the nuclear lamina
together with UL50 (not shown), suggesting that UL50 may bind to RASCALTB40/E and
UL53 via two different interaction domains. To investigate if RASCAL did indeed
interact with UL50, protein extracts from HEK293T cells transfected with LNCX or
cotransfected with L-RASCALTB40/E and LNCX UL50-HA were subjected to co-IP using
anti-HA or anti-RASCAL Abs. As a control, extracts from HEK293T cells transfected
with LNCX or cotransfected with LNCX UL50-HA and L-UL53-FLAG were subjected
to co-IP using anti-HA Abs. As expected (7, 40, 41, 65), UL53-FLAG did
coimmunoprecipitate with UL50-HA (Fig. 4-8A, lane 4), while no signal was observed in
immunoprecipitates from control cells (Fig. 4-8A, lane 3). Specific bands of about 44
kDa (UL50-HA) and 10 kDa (RASCAL) were detected in cell lysates (Fig. 4-8B, left,
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FIG. 4-5. RASCAL colocalization with lamin B and with lamin A/C at the nuclear
envelopes of infected cells. Confocal images of TB40/E infected HF (MOI of 5)
harvested at 72 hpi (A to C) or 96 hpi (D to L) and stained with affinity-purified
affinity
rabbit
anti-RASCAL
ASCAL polyclonal Abs followed by Alexa Fluor 594-conjugated
conjugated goat anti-rabbit
anti
Abs (red), with monoclonal anti
anti-lamin B Abs followed by FITC-conjugat
conjugated anti-mouse
Abs (green), or with monoclonal anti
anti-lamin A/C Abs (K-L) followed by FITC-conjugated
FITC
anti-mouse Abs (green). Consecutive confocal planes were images to show the extent of
invaginations through the nucleus (G
(G-I). Bar size, 10 µm.
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FIG. 4-6. RASCAL colocalization with lamin B but not lamin A/C in cytoplasmic
vesicles. Confocal images of TB40/E-infected HF (MOI of 5) harvested at 96 hpi and
stained with affinity-purified rabbit anti-RASCAL polyclonal Abs followed by Alexa
Fluor 594-conjugated goat anti-rabbit Abs (red), with monoclonal anti-lamin B Abs
followed by FITC-conjugated anti-mouse Abs (green) (A to F), or with monoclonal antilamin A/C Abs followed by FITC-conjugated anti-mouse Abs (green) (G to I). The area
magnified in panels D to F is framed by a square box in panels A to C. Arrowheads
indicate the points of close contact between the cytoplasmic vesicles and the nuclear
lamina. Bar size, 5 µm.
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lane 10) and in immunoprecipitates (Fig. 4-8B, left, lane 8, and right, lane 14) from LRASCALTB40/E- and LNCX UL50-HA cotransfected cells, irrespective of whether antiHA or anti- RASCAL Abs were used as immunoprecipitating reagents. No bands were
detected in extracts from control cells (Fig. 4-8B, left, lanes 5, 6, and 9, and right, lanes
11 and 12). Together, these data indicate that RASCAL and UL50 can be found in the
same complex and suggest that RASCAL is likely to be a new NEC member.

4.4 Discussion
In this report, we show that the putative CMV gene c-ORF29 encodes a protein,
RASCAL, displaying a dual localization to the nuclear lamina and to cytoplasmic
vesicles at late times during infection. Accumulation of RASCAL at the nuclear lamina
requires the presence of UL50. The interaction of these two proteins suggests that
RASCAL is likely to be a new component of the NEC. The occurrence of lamin Bpositive vesicular structures in the cytoplasm of infected cells at late times p.i. has been
previously reported (42, 47, 66), but the nature and function of these vesicles has not yet
been determined. The presence of RASCAL and lamin B within these structures suggests
that they may originate from the nuclear envelope. We thus speculate that RASCAL may
play a role in facilitating the transition of nucleocapsids across the nuclear envelope and
may have additional functions in promoting virion maturation and trafficking toward the
plasma membrane.
Akin to all herpesviruses, CMV genome replication and encapsidation occur in the nuclei
of host cells (45). Release of newly assembled nucleocapsids into the cytoplasm
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necessarily entails crossing of the nuclear envelope, in a process presumed to involve an
initial envelopment of nucleocapsids by budding through the INM, followed by a deenvelopment step as virions traverse the outer nuclear membrane (ONM) (34, 37, 38, 50,
67). The INM is structurally supported by the nuclear lamina, a dense fibrillar network
composed of A- and B-type lamins and their partners (57). Localized destabilization of
this structure is required for virions to gain access to the INM and is mediated by
components of the NEC, a multiprotein complex composed of the viral proteins UL50,
UL53, and UL97 and of the cellular proteins p32, LBR, and PKC (41). UL50 is a key
mediator of the NEC formation and directly interacts with UL53, p32, and PKC (41).
Recruitment of UL53 and PKC to the nuclear lamina is strictly dependent on the presence
of UL50, while p32 can reach this location also via interactions with LBR (7, 40, 41).
UL50 also acts to enhance the accumulation at the NEC of the viral kinase UL97,
although UL97 recruitment is largely mediated by binding to p32 (35).
Similar to UL53 and PKC, RASCAL localization to the nuclear rim is dependent on
UL50 (Fig. 4-7L to N). RASCAL and UL50 could also be coimmunoprecipitated (Fig. 48B), indicating the existence of direct or indirect interactions between the two proteins.
Thus, RASCAL may either be a new UL50 binding partner or may be recruited to the
NEC via interactions with PKC and/or p32.
Both RASCAL and UL53 were able to reach the nuclear lamina when coexpressed in the
presence of UL50 (not shown), indicating a lack of competition between these two
proteins for binding to UL50. Thus, if the RASCAL-to-UL50 link is direct, two distinct
binding domains must exist on the surface of UL50, one for RASCAL and one for UL53.
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Although our data do not exclude the possibility of an interaction between RASCAL and
UL53, complete overlap of signals emanating from each of these proteins was not
observed in the cytoplasm of cotransfected cells, and expression of UL53-FLAG did not
result in the relocation of RASCAL to the nucleus (Fig. 4-7I to K). We thus believe that
the formation of RASCAL-UL53 complexes is unlikely to occur.
Quite interestingly, no differences were observed in the intracellular localization of
RASCALTB40/E and RASCALTowne during infection, despite the fact that the RASCAL
version encoded by Towne is substantially longer than that encoded by TB40/E (Fig. 4-1
and 2). As both proteins accumulate at the NEC, the domains required for this
localization must be located within the first 97 aa of RASCAL, while the presence of the
79 additional amino acids in RASCALTowne does not contribute to, or interfere with, the
recruitment process. We thus speculate that the two proteins, although similarly localized,
will prove to be functionally different and that these differences will be dependent on
their ability to interact with specific cellular and/or viral proteins in addition to the
components of the NEC. Studies are currently in progress to identify the exact domains
required for the tethering of RASCALTB40/E and RASCALTowne to the nuclear lamina and
to isolate the potential binding partners of each protein.
Extensive overlap of the RASCAL and lamin B signals was observed at the nuclear rim
and in intranuclear invaginations of the INM in TB40/E-, Towne/GFP-IE2-, or AD169infected HF (Fig. 4-5A to I and data not shown). Substantial infoldings of the INM have
been described in a number of ultrastructural studies of CMV-infected cells, and the
presence of UL50, UL53, and UL97 at these sites was documented by immunoelectron
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and immunofluorescence microscopy (6, 7, 14, 24, 35, 50, 62, 67). These invaginations
were shown to be sites of nucleocapsid budding across the INM and were proposed to
enhance the efficiency of virion egress from the nucleus by increasing the surface area of
the INM and by acting as channels for the unhindered transport of primary enveloped
virions toward the ONM (6). Confocal microscopy imaging of cells stained for RASCAL
and lamin B clearly showed that both these proteins are located at sites found deep within
the nuclear volume (Fig. 4-5D to I). In contrast, lamin A/C colocalization with RASCAL
was less prominently in the nuclear invaginations and more evident at the openings of the
INM channels (Fig. 4-5J to L). Although these staining pattern differences could
potentially be due to some variation in the binding efficiency of each Ab, it is also
conceivable that they might reflect functional differences between the two types of
lamins (57). Together, these results strongly suggest that RASCAL is associated with the
INM and provide further support to the hypothesis that RASCAL is a new component of
the NEC.
Although expression of UL50 and UL53 was reported to be sufficient for the remodeling
of the nuclear lamina and for the formation of INM invaginations in COS7 cells (7), the
presence of nuclear foldings was not observed in HeLa (40) or in HEK293T (Fig. 4-7F to
H) cells coexpressing these proteins. Expression of RASCALTB40/E in the presence of
UL53 (Fig. 4-7I to K), UL50 (Fig. 4-7L to N), or both (not shown) also did not induce the
formation of INM folds, indicating that RASCAL expression on its own, or in
conjunction with UL50 and UL53, is not sufficient to trigger the development of these
structures. These data suggest that the generation of INM invaginations in the absence of
infection may be cell type dependent and may be affected by the intracellular content and
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FIG. 4-7. Localization of UL50-HA, UL53-FLAG, and RASCALTB40/E in transfected
cells. (A to D) Confocal images of HEK293T transiently transfected with expression
plasmids encoding UL50-HA (A and B) or UL53-FLAG (C and D) and stained with
mouse anti-HA Ab (A), mouse anti-FLAG Abs (C), or affinity-purified rabbit antiRASCAL polyclonal Abs (B and D) followed by FITC-conjugated goat anti-mouse Abs
(green) or Alexa Fluor 594-conjugated goat anti-rabbit Abs. (E to M) Confocal images of
HEK293T coexpressing UL50-HA and UL53-FLAG (E to F), UL53-FLAG and
RASCALTB40/E (H to J), or UL50-HA and RASCALTB40/E (K to M). Cells were stained
with rabbit anti-HA and mouse anti-FLAG Abs followed by Alexa Fluor 594 goat antirabbit Abs (green) and FITC-conjugated goat anti-mouse Abs (red) (E to G), with mouse
anti-FLAG and rabbit anti-RASCAL Abs followed by FITC-conjugated goat anti-mouse
Abs (green) and Alexa Fluor 594-conjugated goat anti-rabbit Ab (red) (H to J), or with
mouse anti-HA and rabbit anti-RASCAL Abs followed by FITC-conjugated goat antimouse Abs (green) and Alexa Fluor 594-conjugated goat anti-rabbit Abs (red) (K to M).
Bar size, 10 µm.
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FIG. 4-8. Determination of RASCAL’s interaction with UL50 by co-IP. (A) Immunoblot
analysis of protein extracts from HEK293T cells transiently transfected with LNCX or
cotransfected with L-RASCALTB40/E and LNCX UL50-HA. Proteins were denatured in
3% SDS lysis buffer (lysate) or were subjected to co-IP with anti-HA Abs (left) or with
anti-RASCAL Abs (right) prior to separation on 10% (UL50-HA) or 15%
(RASCALTB40/E) SDS-PAGE gels. An aliquot corresponding to 2% of the original co-IP
buffer volume was loaded onto the gels as the input control (input). Membranes were
probed with anti-HA (1:500) or anti-RASCAL (1:1,000) Abs. (B) Immunoblot analysis
of protein extracts from HEK293T cells transiently transfected with LNCX or
cotransfected with LNCX UL50-HA and L-UL53-FLAG. Proteins were denatured in 3%
SDS lysis buffer (lysate) or were subjected to co-IP with anti-HA Abs, prior to separation
on 10% SDS-PAGE gels. Membranes were probed with anti-HA (1:500) or anti-FLAG
(1:500) Abs. Expected molecular masses were 43.9 kDa for UL50-HA, 10.6 kDa for
RASCALTB40/E, and 43.3 kDa for UL53-FLAG.
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availability of PKC, a kinase whose activity is required to enhance the disassembly of the
nuclear lamina during mitosis (12) and during egress of herpes simplex virus type 1
(HSV-1) and of murine and human CMV (33, 40, 46, 47, 51). In addition to PKC, the
viral kinase UL97 is recruited to the nuclear lamina (35) and substantially contributes to
its phosphorylation-mediated dissolution (27, 35, 41, 42, 55). The presence of these two
kinases at the NEC fostered the speculation that they might phosphorylate specific NEC
components. Although no significant posttranslational modification was detected for
UL53 in infected HF (14), phosphorylation of both UL50 and UL53 was reported to
occur after in vivo labeling of transfected cells with 33P (40), and phosphorylation of
UL50 was shown to be mediated by PKC (40).
We did not observe substantial changes in the SDS-PAGE mobility of RASCALTB40/E
from either infected or transfected cells (Fig. 4-2C and D), despite the predicted presence
of potential phosphorylation sites for both PKC and PKA (Fig. 4-1B). Protein
phosphorylation, however, has been reported to increase, decrease, or leave unaffected
the apparent molecular weights of proteins separated on SDS-PAGE gels. It is thus
conceivable that both RASCALTB40/E and RASCALTowne might indeed be phosphorylated.
The potential presence of this modification might explain the appearance of a fastermigrating band in protein extracts from Towne-infected cells (Fig. 4-2D), particularly
considering that the amino acid sequence of RASCALTowne is predicted to contain two
additional phosphorylation sites compared to that of RASCALTB40/E. Further analyses are
in progress to clarify this issue. While expression of UL53 was reported to occur with late
kinetics (14), c-ORF29 transcription was observed starting from 6 hpi (Fig. 4-2A), and its
protein product was detected at low levels starting from 24 hpi, with signal intensities
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markedly increasing at later times (Fig. 4-3). These data suggest that RASCAL
accumulation in infected cells may begin before synthesis of UL53 and, possibly, of
UL50, while RASCAL gathering at the nuclear rim occurs exclusively at late times p.i.,
when both UL50 and UL53 are present within the NEC. c-ORF29 transcription was
reduced, but not completely abolished, in the absence of viral DNA replication (Fig. 42B), while signal from the protein product of c-ORF29 became completely undetectable
by immunofluorescence staining analysis of PFA-treated cells (Fig. 4-4). These results
suggest that, as with the synthesis of another NEC component, UL97, RASCAL is
expressed with early-late kinetics, requiring viral DNA replication for maximum
expression (39).
As previously mentioned, the c-ORF29 and US17 nucleotide sequences partially overlap.
Although the kinetics of US17 gene expression have not been studied in detail, the
presence of early transcripts hybridizing to the US17 gene region was detected in
microarray studies of viral gene expression in Towne-infected HF (9). Interestingly,
however, synthesis of the US17 protein was observed starting from 72 hpi and was
entirely inhibited by treatment with PFA (15). These data suggest that, although both the
US17 and c-ORF29 genes are located on the negative strand of the genome and have
partially overlapping sequences, their transcription may be controlled by different
promoters.
While expression of both UL50 and UL53 is absolutely necessary for the production of
viral progeny from infected cells (18, 74), growth of two distinct US17 deletion mutant
viruses in HF was not impaired (18, 74). As the c-ORF29 and US17 nucleotide sequences
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extensively overlap, it is likely that deletion of c-ORF29 will also not lead to dramatic
reductions in mutant virus yields, at least in HF. Although the absence of RASCAL
expression might still affect the efficiency of virion egress in HF, we expect that more
dramatic effects may be observed in cell types other than HF.
Substantial overlap of the RASCAL and lamin B, but not lamin A/C, signals was
observed in cytoplasmic vesicles distributed from the nucleus to the cytoplasm of
infected HF at late times p.i. (Fig. 4-3J, M, and P, 4-4A and C, and 4-6A to F). Although
the existence of similar vesicles has been mentioned in previous analyses of human- or
murine-CMV-infected cells stained for lamin B (47, 66), their origin and nature has not
yet been established and is the subject of ongoing investigations. Our confocal
microscopy images indicate that they are likely to originate from the nuclear envelope
(Fig. 4-6), an assumption further reinforced by the fact that they do appear to contain
lamin B. It is currently unclear, however, whether they consist of a single or of a double
membrane and if they are derived from the INM, the ONM, or both. As these structures
have been noticed before in cells expressing exogenous UL50 (7), it is possible that they
may contain additional NEC components and possibly even nucleocapsids. If so, they
may constitute a completely novel, alternative route of virion maturation and transport
from the nucleus to the cell surface. Alternatively, they may represent sites of viral
particle degradation, similar to the nuclear envelope-derived, four-layered structures
described in the cytoplasm of HSV-1-infected HF (1), which were recently shown to be
autophagosomes (21).
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The presence of RASCAL at these sites raises the intriguing possibility that RASCAL
might remain associated with virions during egress, possibly becoming a tegument
component. UL50 was reported to be an envelope glycoprotein in proteomic analyses of
the CMV particles (70), and UL53 was shown by immunoelectron microscopy to be a
tegument protein (14), although this localization was not confirmed by the proteomic
study (70). It is thus conceivable that RASCAL may accompany newly formed
nucleocapsids during their journey from the nucleus to the periphery, perhaps by
triggering the formation of nucleus-derived vesicles. If so, RASCAL may indeed function
as a new determinant of viral tropism by enhancing virion egress from specific cell types
or, if included in the tegument, by promoting entry of viral particles into uninfected cells.
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Chapter 5
GENERAL DISCUSSION
"Every honest researcher I know admits he's just a professional amateur. He's doing
whatever he's doing for the first time. That makes him an amateur. He has the sense to
know that he's going to have a lot of trouble, so that makes him professional."
-Charles Franklin Kettering (1876-1958) U.S. Engineer and Inventor

5.1 Thesis Summary and Significance of Research
Despite their amazing biological diversity, all viruses face at least three common
obstacles: they must enter host cells, express their genes and replicate, and finally, exit
the host cell so that the cycle of infection can continue. While the breadth of strategies
employed by viruses to accomplish each of these feats is striking, so too are the
commonalities exhibited by many viruses that are otherwise quite phylogenetically
distinct. The study of these fundamental processes not only teaches us much about our
virus of particular interest, but also of the basic biological pathways in general.
Herein, I have described studies focusing on each of these three common processes. In
Chapter 2, I have shown that vimentin, an IF protein, is required for the efficient onset of
CMV infection. We found that vimentin remains stable during entry of CMV strains
AD169 and TB40/E (Fig. 2-1). Virus entry was hampered in HF treated with the
vimentin-disrupting agent, ACR (Fig. 2-4), and in cells harvested from patients with
GAN, a genetic disorder which causes vimentin bundling (Fig. 2-5). Finally, virus entry
was also negatively affected during infection of vim- MEFs (Fig. 2-6). In these cells, virus
particle trafficking towards the nucleus appeared much less efficient than in vim+ MEFs
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(Fig. 2-7). In each case, the EC-tropic strain TB40/E exhibited a greater reliance on
vimentin during entry than the fibroblast-adapted strain, AD169. These observations may
indicate that these two strains, which were previously thought to enter HF in a similar
manner, actually employ different modes of entry in this cell type. Further, these studies
highlight a potentially important and previously underappreciated role for IFs during
entry of CMV, and possibly other herpesviruses.
In Chapter 3, I have shifted models and focused on the 55R E1A protein of species C
HAdV. This protein is encoded by the 9S mRNA species and is the smallest of all the
E1A isoforms. While the mRNA encoding this protein was discovered over 30 years ago,
the lack of an Ab which specifically recognizes 55R E1A has precluded more detailed
biochemical and functional characterization to this point. To address this issue, we
generated rabbit polyclonal Abs against the unique C-terminal amino acid sequence of
HAdV-2. I have demonstrated that these Abs can be used to detect HAdV-2 55R E1A by
western blot, immunoprecipitation and by indirect immunofluorescence (Fig. 3-1). I have
confirmed that like 9S mRNA, 55R E1A is expressed at late times post-infection and that
the protein is localized primarily to the nucleus (Fig. 3-2). Using several mutant and
recombinant viruses, I have shown that 55R E1A is capable of transactivating the
expression of viral genes in primary, contact-inhibited IMR-90 cells (Fig. 3-3). This
promoted virus replication, as viruses expressing only the 55R E1A isoform were able to
replicate productively and to titres several log-fold greater than E1A null virus in these
same cells (Fig. 3-4). I have also identified the first binding partner of 55R E1A in S8
(Fig. 3-5A, B). S8 is a component of APIS, a regulatory subunit of the 26S proteasome.
Knockdown of S8 reduced the infectious yield of a virus which expresses only the 55R
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E1A isoform, indicating that this interaction is important for the replication-promoting
properties of 55R E1A (Fig. 3-5C). These studies are the first to detect and functionally
characterize the 55R E1A isoform. The identification of the transactivating and growthpromoting capacities of this protein are intriguing observations that are likely to spawn a
new field of E1A research.
Studies described in Chapter 4 again focus on CMV, and in particular, on a novel CMVencoded protein which we have dubbed RASCAL. RASCAL is encoded by c-ORF29,
which is located within the US segment of the CMV genome. Interestingly, the RASCAL
protein encoded by CMV strains Towne and Toledo is extended by 79 residues, giving
the protein a total size of 177 amino acids, compared to the 98 amino acid protein
encoded by strains TB40/E and AD169 (Fig. 4-1B). However, the phenotypes that we
observed did not seem to be affected by this extension. RASCAL is expressed with earlylate kinetics (Fig. 4-2A, B) and localizes to the nuclear rim and in deep intranuclear
invaginations at late times post-infection (Fig. 4-3, 4-5). This localization was dependent
on the NEC component pUL50 (Fig. 4-7). Co-immunopreciptation experiments revealed
an interaction between RASCAL and pUL50, suggesting that RASCAL is likely a new
viral component of the CMV NEC (Fig. 4-8). Intriguingly, RASCAL was also found in
small membranous, lamin B-positive vesicles that appeared to emanate from the nucleus
at late times post-infection (Fig. 4-6). In the future, it will be interesting to determine
whether these unique structures play an active role in viral egress. It will also be
important to dissect the particular mechanism through which RASCAL may aide in the
egress of CMV.
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Taken together, these studies represent focused investigations of three critical stages in
viral replication: entry, gene regulation and egress. In addition to gaining valuable
knowledge regarding the biology's of CMV and HAdV, these studies have also yielded
insights into more basic and general biological principles. The study of processes so
fundamental to virus replication always provide the enticing opportunity to identify
targets for therapeutic intervention. While it is unclear whether the particular proteins and
pathways described herein represent viable therapeutic targets, contextualization of the
relative contributions of these phenomena to the process of viral replication as a whole
will surely aide in the rational design of compounds that have the potential to improve
human health on a global scale.

5.2 Requirement for an Intact Vimentin IF Network to
Facilitate Efficient Onset of CMV Infection
Although virus entry may seem like a relatively discreet and straightforward matter of
penetrating the cell membrane, it is in fact a complex, multifactorial process that relies on
the exploitation of many cellular pathways. After binding to and penetrating the cell
membrane, CMV capsids associate the microtubule network where they are presumably
transported by dynein motor proteins toward the MTOC (36). While the MTOC is located
in close proximity to the nucleus (generally within 1.5 µm in the case of fibroblasts, and
even larger distances in other cell types, such as neurons), how capsids make their way
from the MTOC to NPCs where nuclear deposition of the viral genome occurs remains
poorly understood (49). These distances are 10-80 fold larger than the diameter of the
capsid itself (19). The size of CMV capsids coupled with the density of the cytoplasmic
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environment make passive diffusion an unlikely explanation for this process (28, 54).
Together, these observations would suggest that the virus has evolved a more efficient
mechanism to facilitate this process. In addition, studies which have investigated the role
of microtubules in CMV transport have used methods that also result in the disruption of
IFs, confounding the interpretation of their results (36).
The impact of microtubules and microfilaments on the entry of herpesviruses has been
appreciated for some time (28). However, the contributions of IFs during this process
have largely been ignored. This is likely due, in large part, to the fact the IFs are unique
among the three classes of cytoskeletal proteins in that they lack polarity and associated
motor proteins (15). Despite this perceived deficiency, they do possess many other
properties that could be considered important in the context of viral infection. IFs are
responsible for providing mechanical support for the cell, maintaining the shape and
positioning of the nucleus, and organelle targeting, among other functions (13). Finally,
the IF network stretches from the plasma membrane (and in some cell types, from the cell
surface) to the nucleus, thereby providing multiple opportunities for exploitation during
viral entry.
Early observations outlining the dynamics of microtubule and microfilament
polymerization during CMV infection led us to first investigate that status of the IF
network from viral penetration to expression of IE genes. We found that, akin to
microtubules, the vimentin IF network remains stable from binding to expression of IE
genes (Fig. 2-1) (36).

Given the differential regulation of the other cytoskeletal

components, we hypothesized that maintenance of vimentin stability might be
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functionally important during CMV entry in HF. We also observed that in comparison to
infection with AD169, onset of TB40/E infection as measured by IE gene expression was
substantially delayed in HF. This delay was maintained throughout virus replication up to
144 hpi, at which time titres of AD169 and TB40/E equalized (Fig. 2-2). AD169 entry in
HF occurs predominantly through direct fusion at the plasma membrane (9, 53). This
seems to be mediated by the gH/gL/gO glycoprotein complex present on AD169 virions
(21). Historically, entry of TB40/E into HF has been assumed to occur through the same
mechanism, despite the fact that in addition to the gH/gL/gO complex expressed by
AD169, TB40/E is also capable of expressing gH/gL/UL128-131A. This complex seems
to be required for endothelial and epithelial cell tropism (17, 60-61). Strains expressing
UL128-131A have been observed to enter endothelial cells by endocytosis, followed by
fusion of the viral envelope with the endosomal membrane, which may or may not
require low pH (39, 46-47, 51). Considered in the context of the delayed kinetics of
TB40/E entry in HF relative to AD169 observed in our study, it is tempting to speculate
that TB40/E may also enter HF by endocytosis, or by a combination of endocytosis and
direct fusion, depending on the viral glycoprotein - cellular receptor complex that is
primarily engaged upon binding. More detailed studies will be necessary to delineate the
precise pathway(s) through which TB40/E enters HF. Understanding these processes in
detail is of great importance, especially considering the attractiveness of targeting entry
in the rational design of anti-viral therapeutics.
To determine if the stability of the vimentin IF network was indeed important during the
onset of CMV infection, we treated HF with ACR, a vimentin IF-disrupting agent, prior
to infection with strains AD169 or TB40/E. ACR treatment induced aggregation of
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vimentin into bundles which were most dense along the cell's retraction fibers. Vimentin
aggregation was accompanied by rounding of the cell and a morphological change of the
nuclei, characterized primarily by folds and invaginations of the nuclear membrane (Fig.
2-3A-F). As reported in the literature, this treatment left the microtubule network intact,
thereby allowing us to assess the role of vimentin IF network directly (2, 37, 48). ACR
treatment had an exposure time-dependent inhibitory effect on infection with either
AD169 or TB40/E. As expected, the overall proportion of cells infected with TB40/E was
lower than that of AD169, consistent with the delay in onset of TB40/E infection of HF
observed earlier (Fig. 2-4A, B). Importantly, the effect of ACR treatment on the onset of
infection could be overcome at later times post-infection (Fig. 2-4C, D). This was
attributed to the reversibility of ACR treatment on the structure of the vimentin
cytoskeleton and also gave us confidence that ACR did not have a direct effect on the
CMV particles themselves.
Given the potentially pleiotropic effects of ACR on the cell, we felt that it was important
to validate our results in other model systems. We were able to exploit fibroblasts from
patients with GAN, a neurodegenerative disorder caused in part, by bundling of IFs (42,
66). In HF, this phenotype could be conditionally induced by growing cells from GAN
patients in low serum conditions (23). Of particular interest to us, the vimentin
abnormalities caused by serum starvation of fibroblasts from GAN patients were distinct
from those caused by ACR treatment. GAN fibroblasts exhibited local regions of
spherical vimentin bundling, while the structure of vimentin IFs in other parts of the cell
remained structurally intact (Fig. 2-5A-H). Infection of these cells with AD169 at an
MOI of 1 delayed onset of infection at 4 hpi, but this delay was overcome at 8 and 24 hpi.
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Infection at an MOI of 10 reduced the impact of vimentin bundling in GAN HF on
AD169 infection.

In comparison, we could not detect IE1/IE2 expression in GAN

fibroblasts or normal dermal fibroblasts infected with TB40/E at 4 hpi. This delay relative
to AD169 infection was thus consistent in fibroblasts regardless of their origin. At 8 and
24 hpi we observed significantly reduced levels at IE1/IE2 expression in fibroblasts from
GAN patients infected with TB40/E at an MOI of 1. This reduction was not appreciably
reduced when cells were infected at an MOI of 10 (Fig. 2-5I-L).
Together with the results gathered during infection of ACR-treated HF, the GAN model
continued to suggest that an intact vimentin cytoskeleton was crucial for the efficient
onset of CMV infection. In the context of AD169 infection, vimentin bundling in GAN
fibroblasts caused a delay in the onset of infection that could be overcome by both time
and MOI. Based on these results, we speculated that vimentin IFs may be important in
the proper trafficking of CMV particles to the nucleus. At low MOIs, particles which
encountered these bundles would be temporarily impeded. However, at higher MOIs the
probability that one or more particles could travel from the cell periphery to the nucleus
in a regions where the structure of vimentin IFs remained intact would be greatly
improved. Additionally, vimentin bundling in GAN fibroblasts did not result in the severe
distortions in nuclear morphology induced by ACR treatment. This reduced the
possibility that widespread nuclear instability simply abrogated the ability of viral
particles to dock at or translocate their genomes through NPCs. TB40/E was more
negatively affected by vimentin bundling than AD169 further suggesteing that these two
strains may enter fibroblasts using different mechanisms.
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As a final validation that the vimentin IF network is important during onset of CMV
infection, we compared the efficiency of infection with AD169 or TB40/E in vim+ or
vim- MEFs. While MEFs do not support productive human CMV infection, the restriction
event occurs after expression of IE genes (24-25). Therefore, these cells represented an
excellent system through which to study the impact of vimentin on CMV entry. VimMEFs displayed a significantly reduced proportion of IE1/IE2-expressing cells than vim+
MEFs infected with AD169 or TB40/E. The proportion of vim+ MEFs infected with
AD169 remained consistent over time and at both tested MOIs. However, the proportion
of vim- MEFs expressing IE1/IE2 moderately increased with time, indicating that the
absence of vimentin delayed onset of infection, rather than inhibiting it altogether (Fig. 26A, C).
Contrary to the steady proportion of vim+ cells observed at all times during AD169
infection, we observed a sharp rise in the proportion of vim+ cells expressing IE1/IE2
during TB40/E infection between 8 and 24 hpi. In contrast, the number of IE1/IE2expressing vim- cells slowly decreased over time. The decrease was not due to the
proliferation of uninfected cells, and thus seems to represent abortive infection (Fig. 26B, D). In agreement with our earlier observations, TB40/E was again more negatively
affected by the absence of vimentin than was AD169. The consistency with which this
phenotype was observed serves as strong evidence that these two strains utilize distinct
entry pathways in fibroblasts.
To identify the stage at which the absence of vimentin impairs the onset of CMV
infection, we tracked individual viral particles stained with an antibody specific for the
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capsid-associated tegument protein pp150 during the early stages of infection of vim+ and
vim- MEFs (Fig. 2-7). This protein is known to remain associated with the capsid until
disassembly following nuclear deposition of the viral genome (36, 52). There was no
difference in the number of pp150+ cells exposed to either strain of virus for 1 h at 4°C.
This indicated that vimentin does not affect binding of either AD169 or TB40/E. After
transfer of cells to 37°C for 1h, the proportion of pp150+ cells remained consistent
among all samples. However, by 4 hpi a sharp decrease was observed in the proportion of
pp150+ vim+ cells infected with AD169 relative to pp150+ vim- cells treated in the same
way. This trend was also observed 8 hpi, although the overall number of pp150+ cells
steadily decreased. TB40/E infection produced similar results, however the differences
between pp150+ vim+ and pp150+ vim- cells was less pronounced at 4 hpi (Fig. 2-7E).
Since pp150 remains associated with the capsid throughout entry, loss of signal is likely
to represent degradation subsequent to disassembly of the capsid after nuclear deposition
of the viral genome. Taken together, these results suggest that vimentin IFs increase the
efficiency of this process at a step subsequent to binding.
To more precisely determine the fate of viral particles in vim+ and vim- MEFs, we
monitored their localization 1 h after transfer to 37°C, at a time wherein the number of
pp150+ cells had been determined to be equal among all treatment groups (Fig. 2-7F).
Interestingly, we found that there was a general decrease in the proportion of particles
localized at the nucleus in vim- MEFs infected with either AD169 or TB40/E. In the case
of AD169, the was accompanied by a concomitant increase in the proportion of particles
maintained in the cytoplasm, while TB40/E particles appeared to be retained mainly at
the cell periphery (Fig. 2-7A-D). This again led us to conclude that an intact vimentin
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cytoskeleton is important for the efficient onset of CMV infection and that it is likely to
play a role subsequent to virus binding, potentially during trafficking of particles towards
the nucleus.
In summary, we have investigated a previously unappreciated aspect of CMV entry in
fibroblasts. We have shown that TB40/E exhibits a consistent delay in the onset of
infection in fibroblasts relative to AD169. Our results demonstrate that both the
fibroblast-adapted strain AD169, and the EC-tropic strain TB40/E rely on an intact
vimentin cytoskeleton during onset of infection in fibroblasts. The structure of vimentin
IFs remain unchanged during entry of both CMV strains in fibroblasts, akin to
microtubules. Disruption of the vimentin IF network using the chemical agent
acrylamide, vimentin bundling in fibroblasts harvested from patients with GAN, and the
absence of vimentin in vim- MEFs all had a negative effect on the efficiency of CMV
infection. TB40/E consistently exhibited a greater degree of reliance on vimentin IFs than
did AD169. Coupled with the delay in onset of infection observed for TB40/E and its
retention at the periphery of vim- MEFs, we speculate that TB40/E may enter fibroblasts
through a mechanism other than direct fusion at the plasma membrane. The presence of
the gH/gL/UL128-131A glycoprotein complex on TB40/E particles offers the possibility
that strains expressing this complex are also capable of entering fibroblasts through an
endocytic pathway, similar to that observed in endothelial and epithelial cells. Given
recent advances in dissecting the multitude of possible endocytic routes of entry exploited
by enveloped virus, careful future studies will be needed to understand the specific
cellular processes involved (22). The apparent defect in viral particle trafficking observed
during infection of vim- MEFs suggested that vimentin IFs are likely to play a role in the

208

trafficking of AD169 and TB40/E virions post-penetration. Again, retention of TB40/E
virions at the periphery of vim- cells may imply that vimentin is also important during
penetration of this strain. These dual roles for vimentin during TB40/E entry may account
for the greater degree of reliance on vimentin IFs displayed by TB40/E in the various
systems explored herein.
Future studies should focus on elucidating the processes through which TB40/E enters
fibroblasts. This is likely to be an important point especially as it relates to the
development of entry-inhibitor anti-viral therapeutics. In addition, dissecting the specific
role assumed by vimentin during the onset of CMV infection will be important in
enhancing our understanding of the IF network during CMV entry. It is possible, perhaps
even likely, that these same mechanisms are involved in the onset of infection with other
types of herpesviruses. Finally, it would be of particular interest to determine whether IF
types expressed by other cells function in a way that is analogous to vimentin during
CMV entry. Epidemiological data relating the susceptibility of patients with disorders
which affect IFs to CMV infection would be especially interesting in this regard.

5.3

A Transactivating and Growth-Promoting Role for 55R
E1A During HAdV Infection

It is amazing that despite over three decades of intense study, there remains much to be
learned about the many functions of E1A during HAdV infection. This speaks to the
amazing complexity and importance of regulating the expression of both viral and
cellular genes during the course of infection. While the majority of studies have focused
on the products of the 13S and 12S mRNA species, little to nothing is known about the
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specific functions of the the product of the 9S mRNA species. The 9S E1A mRNA
produced by species C HAdV encodes a 55R protein. Unlike the products of the 11S and
10S E1A which do not contain any novel sequences relative to the 13S product, splicing
of 9S E1A causes a frameshift which results in 27 unique C-terminal residues (12, 44,
59). This is not the only property that makes 55R E1A unique relative to all other
isoforms, it also accumulates preferentially at late times post-infection and seems to
require replication of viral DNA to do so efficiently (8, 55-56, 59, 65). A major barrier to
the direct study of 55R E1A function has been the lack of an Ab which specifically
recognizes this E1A isoform. Therefore, we set out to generate such and Ab and
subsequently perform an initial characterization of 55R E1A encoded by species C
HAdV.
Anti-55R E1A polyclonal Abs were generated in rabbits using a peptide immunogen
corresponding to residues 43-55 of 55R E1A from HAdV-2 coupled to keyhole limpet
hemocyanin. These Abs were affinity-purified and using purified recombinant protein
and we were able to show that they are exquisitely specific for the detection of 55R E1A
from HAdV-2 (Fig. 3-1C). The Abs could also be used to detect HAdV-2 55R E1A by
indirect immunofluorescence and to immunoprecipitate 55R E1A (Fig. 3-1D, E). We
were pleased that this new reagent could be used for all of the applications tested and are
confident that it will be a useful tool for future studies focused on elucidating the
functions of 55R E1A.
As mentioned previously, earlier studies have reported that the 9S E1A mRNA species is
expressed with late kinetics and seems to require viral DNA replication (8, 55-56, 59,
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65). However, the lack of an Ab which recognizes 55R E1A has precluded an analysis of
the kinetics of protein expression until now. In agreement with previous reports, we
found that 9S mRNA was expressed at late times post-infection in A549 cells (58-59).
Protein expression matched these results closely. The larger E1A isoforms could be
detected starting at 6 hpi and expression increased up to 24 hpi. In contrast, 55R E1A
could be detected only weakly at 24 hpi and expression increased up to 72 hpi (Fig. 3-2).
This was the first time that endogenous 55R E1A has ever been detected. Of particular
interest was the observation that during infection, 55R E1A appears to be located
predominantly in the nucleus of host cells (Fig. 3-2B). 55R E1A lacks the NLS present in
the larger E1A isoforms, however, at a predicted MW of only 6 kDa it falls well below
the approximately 40 kDa exclusion size mediated by the NPC (63). Once in the nucleus,
55R E1A may be retained through binding to other factors also present in the nucleus,
resulting in the apparent enrichment observed by immunofluorescence analysis.
The localization of 55R E1A in the nucleus led us to question whether 55R E1A played
any role in regulation of viral gene expression. Along with helping push host cells into
the S-phase of the cell division cycle, this is one of the major functions of E1A,
especially the 289R protein (3). We found that compared to dl312 (an E1A-null virus),
viruses expressing only the 55R E1A isoform from either cDNA (JM17-55R) or from
mutated genomic DNA (dl521), transactivated the expression of all viral genes tested to
at least a limited extent. As expected, the maximal level of transactivation achieved by
viruses expressing only 55R E1A was consistently lower than those observed during
dl309 infection (Fig. 3-3). 289R E1A, which is expressed during dl309 infection, contains
CR3, a potent transactivating domain. This activity is mediated through interactions with
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a variety of cellular proteins, including MED23 (a component of the mediator complex),
TBP, p300/CBP and S8 (1, 4, 16, 26, 29, 40-41, 43, 62). 55R E1A lacks this region as
well as all of the other CRs. In fact, it shares only it's first 29 amino acids with the other
E1A isoforms. Unlike HAdV-12, these 29 amino acids encoded by HAdV-2 do not seem
to possess a transactivation function (27). This would suggest that the transactivating
properties of 55R E1A are mediated, at least in part, by the novel C-terminal domain
found within this protein. Potential binding partners of this region remain completely
unexplored and represent an exciting new field of research. Identifying these putative
factors will help in elucidating the mechanism through which 55R E1A transactivates
viral gene expression and may uncover as yet undiscovered functions. Given the kinetics
of expression, it is tempting to speculate that 55R E1A may preferentially induce viral
and cellular genes that are important at the later stages of HAdV infection. In support of
this, hexon was one of the most strongly-induced transcripts by viruses which expressed
only the 55R E1A isoform (Fig. 3-3E). E4orf6/7 transcription was also potently
stimulated by viruses expressing 55R E1A. This protein is known to dimerize with free
E2Fs, which increases their affinity to stimulate transcription of the viral E2 promoter
(10, 31, 35). Since processing of the 9S transcript seems to rely on viral DNA replication,
this may serve as a positive feedback loop at late times post-infection to ensure that the
viral genome is replicated to appropriate levels and that 55R E1A is expressed efficiently.
While we have shown that 55R E1A is capable of transactivating the expression of viral
genes, it does not appear to be sufficient to transform primary rodent cells in cooperation
with E1B, nor does it share the pro-apoptotic properties of 289R E1A (18, 64). This led
us to question whether 55R E1A could, in addition to transactivating the expression of
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viral genes, promote productive replication of HAdV in contact-inhibited, primary IMR90 fibroblasts. To assess this, contact inhibited IMR-90 cells were infected with a variety
of viruses capable of expressing multiple combinations of E1A isoforms, including both
JM17-55R and dl521, which express only 55R E1A. Replication assays were performed
and titres for each virus were normalized to those gathered from infections with dl312, an
E1A-null virus. As expected, virus expressing wildtype E1A grew to the highest titres,
followed by a virus which expresses 289R, but not 243R E1A. Viruses expressing only
55R E1A consistently replicated to titres over one log-fold greater than E1A-null virus.
To our surprise, replication of JM17-55R at 48 hpi and dl521 and 120 hpi exceeded that
of dl520, a virus which expresses 243R E1A, but not the 289R protein (Fig. 3-4A). These
results demonstrate that the 55R E1A can not only stimulate expression of viral genes,
but can also promote productive viral replication to a substantial degree in an E1A-null
background.
Studying the effect of the 55R E1A isoform in isolation provided a controlled
environment through which we were able to dissect the functions of that particular E1A
isoform without confounding influences from the other E1A proteins. However, during
infection 55R E1A is expressed in the context of the other E1A isoforms, and therefore
determining the contribution of 55R E1A to HAdV replication in the context of the other
E1A isoforms was important. To do this, we performed co-infections experiments
whereby contact-inhibited IMR-90 cells were infected with either a 289R E1Aexpressing virus (pm975) or a 243R E1A-expressing virus (dl520) and either dl521 (55R
E1A only) or dl312 (E1A null). In combination with pm975, dl521 co-infection did not
increase viral titres above those observed during co-infection with dl312. In contrast,
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dl521 increased viral titres 1- and 2-log-fold at 48 and 120 hpi, respectively, in
combination with dl520 (Fig. 3-4B). Since both pm975 and dl520 are capable of
expressing 55R E1A on their own, these results indicate that endogenous levels of 55R
E1A are sufficient to maximize the replication potential of HAdV in combination with
289R E1A. However, when 289R E1A is not expressed, as is the case during dl520
infection, providing additional 55R E1A can further enhance viral replication. These
results agree well with our earlier observation that both JM17-55R and dl521 are capable
of replicating to titres greater than those of dl520 in contact-inhibited IMR-90 cells.
Given that 55R E1A shares its first 29 amino acids with the larger E1A proteins, we
hypothesized that cellular partners which interact with this region may also be important
for the function of 55R E1A. Based on our finding that 55R E1A was able to
transactivate expression of viral genes, we focused our attention on S4 and S8. These two
proteins are components of APIS, the regulatory component of the 26S proteasome. Both
have been shown to interact with E1A residues 4-25 (57). Later, S8 was also shown to
interact with CR3 and could be recruited to HAdV early gene promoters (43). Most
interesting in the context of our work, was the observation that inhibition of proteasome
activity had an inhibitory effect on the ability of E1A to transactivate viral genes (43).
However, the effect of proteasome inhibition on viral replication was not directly tested.
We found that 55R E1A interacted well with S8 in both GST pulldown and
immunoprecipitation assays. Surprisingly, we did not detect an interaction with S4 (Fig.
3-5A). These results would suggest that 55R E1A interacts with S8 selectively, and that
either the C-terminus of 55R E1A had an inhibitory effect on the S4 interaction, or that
regions present in the larger E1A isoforms but absent from the 55R isoform stabilize the
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interaction. We hypothesized that if the interaction of 55R E1A with S8 played an
important role in its ability to transactivate viral gene expression, knockdown of S8
should have an impact on the ability of a virus expressing only 55R E1A to replicate.
Indeed, we found that knockdown of S8 in A549 cells reduced viral titres by 2-fold 48
hpi (Fig. 3-5C). This strongly suggests that the interaction with S8 plays an important
role in the replication-promoting properties of 55R E1A. Not only does the S8 interaction
provide some insight into the mechanism through which 55R E1A accomplishes its
functions, it is also the first reported binding partner of 55R E1A.
In the future, it will be of great interest to determine additional binding partners of 55R
E1A, specifically those which bind the unique C-terminal region of the protein.
Identifying these interactions and elucidating their functional consequences will provide
additional insight into a severely understudied area of HAdV biology - the function of the
55R E1A protein.

5.4 RASCAL, a Potential New Member of the CMV NEC
The nuclear egress of CMV nucleocapsids is a complex process that requires the
formation of a multiprotein complex consisting of both viral and cellular factors. While
several members of this complex have recently been identified, it is highly likely that
additional factors are also involved. CMV, like other herpesviruses, contains a very large
genome by virus standards and thus, many ORFs have yet to be characterized. Several
studies in the past have demonstrated that serial passage of clinical isolates on HF leads
to the mutation or deletion of ORFs which are responsible for maintaining the broad cell
tropism exhibited during natural infection (7, 17, 60-61). While the loss of epithelial and
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endothelial cell tropism has been mapped to mutations in the UL128-131A gene locus,
AD169, a fibroblast-adapted CMV strain which contains a frameshift mutation leading to
a non-functional UL131A product, remains able to infect mature Langerhans cells (17,
20, 60-61). This suggests that other, as of yet uncharacterized ORFs, may help mediate
CMV tropism for specific cell types. In an attempt to identify these factors, we compared
each ORF present in TB40/E-BAC4 to the corresponding ORFs from five other common
CMV strains. A recently identified putative ORF, originally called c-ORF29, was of
particular interest as the putative protein encoded by CMV strains Towne and Toledo was
75 amino acids longer than the corresponding protein encoded by AD169 and TB40/E
(34). Thus, we set out to characterize the role of this putative protein during CMV
infection, and to compare the two variants of the protein to one another.
In silico analysis of both short and long RASCAL sequence revealed the presence of
putative transmembrane domains at the N- and C-termini of the short RASCAL isoform.
Two additional regions of high hydrophobicity were identified in the long RASCAL
isoform, but neither were reliably predicted to be a transmembrane domain. The protein
was also predicted to contain PKC and PKA phosphorylation sites (Fig. 4-1B, C). These
predictions were particularly insightful in light of the fact that RASCAL was found to
localize at the nuclear membrane and to interact with components of the CMV NEC,
which contains PKC and is known to rely on extensive phosphorylation events to
remodel the nuclear lamina. In the future it will be interesting to determine whether
RASCAL is indeed phosphorylated, and whether phosphorylation is important in
regulating its function.
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To ensure that c-ORF29 actually produced a transcript, we performed RT-PCR analysis
on HF that had been infected with either TB40/E or Towne/GFP-IE2. In each case we
observed a band corresponding to the predicted size of the respective c-ORF29 isoform.
Sequencing confirmed that a T-to-C transition had occurred at position 292 of
RASCALTowne that resulted in the conversion of a TAA stop codon into a CAA codon,
which codes for Gln. To determine the kinetics of c-ORF29 expression, HF were treated
with PFA, a compound that inhibits viral DNA replication by interfering with UL44 - the
viral DNA polymerase processivity subunit, or were left untreated. These cells were then
infected with TB40/E and samples were collected at multiple times post-infection for RTPCR analysis of c-ORF29 expression. PFA treatment diminished, but did not completely
abolish c-ORF29 expression, indicating that it is expressed with early-late kinetics (Fig.
4-2A, B). Interestingly, despite the incomplete inhibition of c-ORF29 mRNA expression,
PFA treatment of HF was subsequently found to reduce RASCAL protein levels below
detectable levels (Fig. 4-4). These experiments were performed using rabbit polyclonal
Abs generated using a peptide corresponding to residues 21 to 39 of RASCALTB40/E. This
antibody was able to recognize RASCAL isoforms encoded by both TB40/E and
Towne/GFP-IE2 (Fig. 4-2C, D).
In order to narrow down the potential function of RASCAL during infection, we sought
to determine its subcellular localization during infection. To this end, HF were infected
with either Towne/GFP-IE2 (Fig. 4-3), AD169 or TB40/E, and samples were collected
and stained at multiple times post-infection. RASCAL expression was clearly detectable
starting at 48 hpi, with punctate cytoplasmic staining and enrichment around the nucleus
(Fig. 4-3). As infection progressed, enrichment at the nuclear membrane continued and
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RASCAL could be found co-localizing with lamin B in deep intranuclear invaginations
(Fig. 4-3, 4-5). These structures were reminiscent of those previously reported during
immunofluorescence and ultrastructural studies of CMV infection. The invaginations
were subsequently found to occur at late times post-infection and to contain UL50, UL53
and UL97, central components of the CMV NEC (5-6, 11, 14, 30, 38, 45, 50). In these
regions, the nuclear lamina has been reported to be dissolved and the INM seems to
stretch down to areas which are dense with CMV nucleocapsids. Indeed, capsids can be
seen budding into these structures, and therefore, they are thought to be regions of
primary envelopment (5).
Strikingly, at late stages of infection RASCAL was also observed in lamin B-positive
vesicles that appeared to be derived from the nuclear envelope and stretched throughout
the body of the cell (Fig. 4-6). These structures were induced during infection by CMV
strains encoding either the large or small RASCAL isoforms. The size of these structures,
coupled with their distance from the nuclear envelope raises the intriguing possibility that
they may undergo active retrograde transport. Whether these structures contain CMV
virions or other viral components remains to be seen. Closer examination of the contents
contained within these structures will be of great interest in future studies, as will
examining their potential role in the CMV replication cycle.
Due to the kinetics of RASCAL accumulation at the nucleus, we questioned whether
other viral factors might be required to mediate its localization. Indeed, pUL50 and its
homologs are known to be required for the proper localization of pUL53 (and its
homologs) during assembly of the NEC (32-33). Exogenous expression of RASCAL in
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HEK293T cells revealed that when expressed alone, RASCAL does not become enriched
at the nuclear rim. However, co-expression of RASCAL with UL50-HA, but not UL53FLAG was sufficient to induce accumulation of RASCAL at the nuclear envelope (Fig.
4-7).

The

association

of

RASCAL

with

pUL50

was

also

confirmed

by

immunoprecipitation (Fig. 4-8). Interestingly, contrary to results obtained using COS7
cells, expression of RASCAL, UL50 and UL53 either alone or in combination with one
another were insufficient to induce the invaginations of the INM observed during
infection (6). This suggests that functioning of the NEC may, in some cases, be cell-type
dependent.
It was surprising that at no point in our study did we observe a functional difference
between the long and short RASCAL proteins. This leaves us to hypothesize that
differences in the function of these two isoforms might be quite subtle and/or contextdependent. We did not directly compare the two RASCAL isoforms in the context of
measuring efficiency of viral egress. Therefore, it is possible that differences may exist at
that level. It is also possible that the elongated RASCAL isoform may have additional
functions only in particular cell types, potentially by interacting with specific viral or
cellular NEC components required in only these cells.
In the future, it will be important to carefully map all of the binding partners of RASCAL
so that its relative contribution to the NEC can be determined. It will also be interesting
to determine whether, and in what contexts, the long and short isforms of RASCAL
function differently. The RASCAL- and lamin B-positive vesicles observed at late times
post-infection are especially intriguing, as they may constitute a previously unknown
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pathway that contributes to CMV egress. In conclusion, we have identified novel CMV
protein that exhibits interesting nuclear and vesicular localization at late times postinfection. This protein appears to exist in complex with pUL50, and requires pUL50 for
its enrichment at the nuclear rim. Together, these results suggests that RASCAL may be a
novel viral component of the CMV NEC.

5.5 Concluding Remarks
" Science is facts; just as houses are made of stone, so is science made of facts; but a pile
of stones is not a house, and a collection of facts is not necessarily science."
-Jules Henri Ponticaré (1854-1912) French Mathematician
This work has described studies concerned with exploring three processes essential in the
replication cycle of all viruses: entry, gene regulation and egress. Considered in isolation,
each chapter seems to focus on the investigation of a fixed process, applicable to one
particular virus. Even such stepwise contributions to our understanding of viral biology
should not be overlooked. We have, after all, not only described a function for two
previously unstudied viral proteins and identified a novel cellular factor important during
CMV entry, but in doing so, have also catalyzed new fields for future investigation. It is
this contextualization of observations and the spawning of new ideas that underlie the
very nature of science, and differentiate it from a collection of meaningless facts.
Considered together, the studies described herein tell a much more important story about
the very nature of infection and the many processes which even the simplest of viruses
must accomplish in order to replicate productively. It is in considering these broader
truths that we are able to extract the truly immeasurable contribution of scientific inquiry
to society. We should not forget the privilege that we experience being in a position to
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make such contributions, nor the responsibility that such a privilege entails. Each of
these studies has built on years of research describing either the importance of the
cytoskeleton during virus entry, the pleiotropic functions of E1A during HAdV infection,
or the mechanism of CMV nuclear egress and composition of the CMV NEC. Our
contributions to these areas have improved the current state of knowledge underlying
three fundamental viral processes. We are confident that this work will now serve as the
foundation of future studies that will continue to expand our understanding of the natural
world, and that directly or indirectly, they will play a key role in a much larger body of
biomedical knowledge that continually catalyzes the improvement of human health.
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